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Introduction
Introduction
Cardiovascular disease (CVD) is the leading cause of death in the Western 
industrialized world, and although the mortality has decreased almost 50% since 
1972, CVD still accounts for 36% of all deaths in the Netherlands in 1999 [1]. The 
principal cause of vascular disease is atherosclerosis, which is, in normal conditions, 
a protective response to endothelial and smooth muscle cell damage of the artery 
wall. The accumulation of lipids within the arterial wall has been thought to be the 
process of atherogenesis, but this process actually consists of the formation of 
lesions which result from an excessive inflammatory-fibroproliferative response to 
numerous different forms of insult [2]. These lesions can lead to ischemia of the 
heart, brain or extremities and, accordingly, three categories of CVD can be 
recognized: coronary heart disease, cerebrovascular disease and peripheral vascular 
disease. Multiple risk factors have been established, such as an unfavorable lipid 
profile (i.e. high LDL, low HDL cholesterol), hypertension, diabetes mellitus, smoking. 
However, these established risk factors cannot account for all CVD. The initial 
observation of vascular disease in two children with different inborn errors of 
homocysteine metabolism by McCully in 1969 [3], has resulted in an exponential rise 
in studies on elevated tHcy as a risk factor for CVD.
Homocysteine metabolism
Homocysteine is a sulfur amino acid that is formed by the demethylation of the 
essential amino acid methionine via S-adenosylmethionine (AdoMet) and S- 
adenosylhomocysteine (AdoHcy) (Figure 1). Methionine adenosyltransferase (MAT) 
catalyzes the formation of Adomet, which is the methyl donor in numerous reactions, 
e.g. methylation of DNA, RNA, hormones and lipids. The transmethylation reactions 
form AdoHcy, which is an inhibitor of many methyltransferases. Adenosine and 
homocysteine are formed upon hydrolysis of AdoHcy by SAH-hydrolase. 
Homocysteine can be further metabolized in two pathways; it may be irreversibly 
degraded to cystathionine and cysteine in the transsulfuration pathway or 
remethylated to methionine, the so-called remethylation pathway.
Transsulfuration
The first step in the transsulfuration pathway is the condensation of homocysteine 
with serine to cystathionine. Cystathionine ß-synthase (CBS) catalyzes this initial step 
and requires pyridoxal 5'-phosphate (PLP = active form of vitamin B6) for its activity. 
Cystathionine is subsequently hydrolyzed to cysteine and homoserine by another 
PLP-requiring enzyme, j-cystathionase. These enzymatic steps are limited to the liver 
and kidney.
Remethylation
Apart from transsulfuration, homocysteine can also be remethylated to methionine in 
two different reactions: (i) methionine synthase (MS) and (ii) betaine-homocysteine 
methyltransferase (BHMT) catalyzed reactions, with respectively, 5-methyltetrahydro-
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Figure 1. Homocysteine metabolism
Introduction
folate (5-methylTHF) and betaine (trimethylglycine) as methyl donors. MS is 
dependent on methylcobalamin (biologically active form of vitamin B12) as a cofactor 
for its enzymatic activity. 5-MethylTHF is formed upon the reduction of 5,10- 
methylenetetrahydrofolate, a reaction that is catalyzed by the enzyme 5,10- 
methylenetetrahydrofolate reductase (MTHFR). MTHFR uses FAD (flavin adenine 
dinucleotide; the active form of vitamin B2) as cofactor [4]. The reversible conversion 
of serine and tetrahydrofolate (THF) to glycine and 5,10-methyleneTHF is catalyzed 
by serine hydroxymethyltransferase (SHMT), another PLP-dependent enzyme in 
homocysteine metabolism. Methylenetetrahydrofolate dehydrogenase (MTHFD) 
exhibits several enzymatic properties and catalyzes three sequential reactions in the 
interconversion of one-carbon derivatives of THF. The remethylation by BHMT occurs 
primarily in the liver and kidney, while the folate and vitamin B12-dependent 
remethylation of homocysteine takes place in every cell of the human body, except 
the red blood cell.
B-vitamins as cofactors
Several B-vitamins serve as cofactors in the homocysteine metabolism: PLP (vitamin 
B6) as cofactor for CBS, j-cystathionase and SHMT, methylcobalamin (vitamin B12) 
for MS and FAD (vitamin B2) for MTHFR. In addition, 5-methylTHF, the active form of 
folate, is needed by MS as a co-substrate which is formed upon reduction of 5,10- 
methyleneTHF by MTHFR.
Vitamin B6
Vitamin B6 consists of different related forms: pyridoxine, pyridoxal and 
pyridoxamine, and their phosphate esters [5]. Vitamin B6 is absorbed in the upper 
small intestine by diffusion and transported to the liver where phosphorylation takes 
place [6]. PLP is the main circulating form which, bound by albumin, is exported from 
the liver [7] and is the only active form that can be used by enzymes. Uptake into 
tissue by extracullular dephosphorylation is followed by metabolic trapping 
intracellularly as PLP [8].
Vitamin B12
Dietary vitamin B12 is first released from food by pepsin. In the stomach it is bound 
to haptocorrin (HC). Vitamin B12 is released from HC by pancreatic proteases and is 
subsequently bound to intrinsic factor (IF) [9]. In the ileum, the IF-vitamin B12 
complex binds to its receptor cubulin [10] and is absorbed by receptor-mediated 
endocytosis. Vitamin B12 transport in the circulation is performed by the protein 
transcobalamin (TC), which also delivers vitamin B12 to the cells [11]. The vitamin 
B12-TC complex is taken up by receptor mediated endocytosis via the receptor TC-R 
[11], which is expressed on the cell surface of most tissues. Intracellularly, vitamin 
B12 is released and metabolized in different steps before it can function as a methyl 
carrier in the homocysteine metabolism. Different inborn errors of the metabolism 
involved in each of these necessary steps have been described. These have been
13
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subdivided into different groups (cbl. F-cbl. C/D-cbl. E-cbl. G) on the basis of 
complementation experiments.
Folate
Folate occurs naturally as a mixture of polyglutamate derivatives [12]. However, the 
dietary folate polyglutamates must be hydrolyzed to monoglutamates in the intestine 
prior to absorption. Folylpoly-j-glutamate carboxypeptidase (FGCP) which is 
anchored to the intestinal brush border membrane, hydrolyses these 
polyglutamylated folates into monoglutamyl folates, that can be actively transported 
across the membrane by the reduced folate carrier. Once inside the cell the 
monoglutamyl folates have to be converted back to polyglutamates by 
folylpolyglutamate synthetase (FPGS), since the enzymes that utilize folate as 
cofactor have higher affinities for polyglutamated folate species [13]. 
Folylpolyglutamates cannot pass or are only poorly transported across cell 
membranes and are important for intracellular retention of folates, while 
monoglutamates, in particular of methylTHF, are the transport form of the vitamin 
[13].
Homocysteine and vascular disease
The most common clinical features of classical homocystinuria are dislocation of the 
optic lens, osteoporosis, mental retardation and atherothrombosis. In 1969, McCully 
noted that the arterial lesions discovered in a child with an abnormality of cobalamin 
metabolism resembled many of the lesions found in CBS deficient patients [3]. Both 
disorders resulted in elevated plasma total homocysteine (tHcy) concentrations and 
this pointed towards homocysteine as a toxic compound for the arterial wall. This 
observation led to the hypothesis that a moderately elevated tHcy concentration 
could be a cardiovascular risk factor in the general population [14]. Shortly 
thereafter, Wilcken and Wilcken [15] published the first report that coronary artery 
disease patients frequently had an abnormal homocysteine metabolism. Since then, 
multiple studies reported on the relationship between tHcy concentration and 
coronary artery disease [16], cerebrovascular disease [17, 18], peripheral artery 
disease [18-20], and venous thrombosis [21, 22]. Most of the studies performed 
involved retrospective studies, while only a small part were of a prospective design. 
A disadvantage of retrospective studies is the cause-effect relationship: is an 
elevated tHcy concentration the cause or a consequence of the disease? This 
question also holds for prospective studies, since the onset of the disease, i.e. 
atherosclerosis, may have started long before the actual vascular incident. About 30 
studies were quantitatively summarized in a meta-analysis [23]; 17 concerned 
coronary disease of which 14 studies showed that elevated tHcy concentrations, 
either fasting or after methionine loading, are more frequently observed in patients 
with vascular disease than in controls subjects (Figure 2). Most studies, however, 
were of retrospective nature. Of the 19 additional studies described in Refsum et al.
[24], 15 found a positive association between tHcy concentrations and coronary
14
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disease, of which eight were of prospective design. In a meta-analysis of 22 studies 
a different association between tHcy concentrations and CVD was observed between 
retrospective studies and prospective studies [25]. The overall odds ratio (OR) per 5 
—mol/L increase in tHcy concentrations for retrospective studies was 1.6 (95% CI 
1.4-1.7), while for prospective studies a OR of 1.3 (95% CI 1.1-1.5) was observed
[25]. In a recent meta-analysis of 14 prospective studies an OR of 1.2 (95% CI 1.14­
1.25) was calculated for each 5 —mol/L increase in tHcy concentration [26]. Besides 
fasting tHcy concentrations, also post-methionine load tHcy concentrations were 
found to be associated with an increased risk for cardiovascular disease, 
independently from an elevated fasting level [27-30]. Furthermore, several studies 
have reported an association between low plasma folate and cardiovascular disease 
risk. Although this increased risk is generally ascribed to an increased tHcy 
concentration, several studies found this association to be independent of tHcy 
concentrations [31-33].
Boushey et al. [23] 
studies
Retro- + Prospective i------------■---------- 1
Danesh et al. [25] Retrospective studies 
Prospective studies
i—
i------------■--------
-------- ■— i
—i
Ueland et al. [26] Prospective studies i— l - i
O 1 1. 2
Figure 2. Odds ratios (95%  C I) per 5 —mol/L increase in tHcy concentration.
Determ inants of homocysteine concentration
Disturbances in the intracellular homocysteine metabolism may lead to elevated tHcy 
levels. These defects may have a genetic background, like an inherited enzyme 
deficiency or a variation in the genes encoding these enzymes leading to altered 
activity, or an environmental etiology (Table 1), such as diet and lifestyle factors, 
which could lead to depletion of important cofactors or substrates involved in 
homocysteine metabolism or even inhibited enzyme activity.
Environmental factors
Renal function
A strong determinant of tHcy concentrations is kidney function [34]. Patients with 
renal failure have evidently elevated tHcy concentrations, but the underlying
15
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pathophysiological mechanism is unknown. However, the extent to which 
homocysteine is excreted in the urine of these patients is as low as in normal 
persons. Probably, the homocysteine metabolism is influenced or even regulated by 
kidney function, or the kidney itself converts a major amount of homocysteine 
present in blood. Serum creatinine concentrations, as an indicator for altered renal 
function, have shown to be strongly positively correlated with tHcy concentrations 
[35].
Age and sex
Increasing age [36, 37] and male gender [37, 38] have found to be associated with 
an increased tHcy concentration, although the influence of gender was observed to 
be most pronounced in the lower range of the tHcy distribution [38]. The sex 
difference may be explained by vitamin status [39], muscle mass and hormonal 
factors [40].
Table 1. Environmental factors associated with hyperhomocysteinemia.
Determinants_________
Environmental 
Renal function 
Increasing age 
Male gender 
Dietary
Low folate status 
Low vitamin Bi2 status 
Low vitamin B6 status 
Lifestyle
Coffee consumption
Smoking
Alcohol
Lack of exercise 
High BMI 
Other
Drugs___________________
Dietary factors
Several dietary factors have been investigated as possible determinants of tHcy 
concentrations in the Hordaland Homocysteine Study [41], the Framingham Offspring 
cohort [35] and the MORGEN Study [42]. Obviously, folate status and of other B 
vitamins are important determinants of tHcy concentrations in the general population 
since they play an important role in the homocysteine metabolism as substrate or 
cofactors. Both folic acid supplementation as well as a high dietary folate intake [19, 
37, 39, 43, 44] have been shown to decrease tHcy concentrations and this 
relationship was found to be dose-responsive. However, folic acid in supplements 
appears to be more effective than natural food folate in improving folate status [37],
16
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presumably because the synthetic form of the vitamin is more stable and more 
bioavailable than the natural food folate [45]. Regular users of multivitamin 
preparations also have low tHcy concentrations [38], although the intake of 
supplements that contain only vitamin B6 and cobalamin, but not folic acid, was not 
related to tHcy concentrations [37]. In the Framingham Offspring Cohort, folate and 
vitamin B12 levels were associated with low tHcy concentrations, whereas dietary 
vitamin B12 intake was not [35]. In a Dutch population, folate was the only B-vitamin 
that was independently inversely associated with tHcy concentrations [42].
Lifestyle factors
Coffee consumption and smoking have been associated with increased tHcy 
concentrations [46-48] and, in combination with low folate intake greatly exceeded 
the effect of each factor alone [37]. The association between alcohol consumption 
and tHcy seems J-shaped [49]; alcoholics have high tHcy concentrations [50], 
whereas moderate alcohol users have lower tHcy concentrations compared with non­
drinkers [51]. The effect of alcohol consumption was also shown to be dependent on 
the type of alcoholic beverage [52].
Miscellaneous
Several drugs, like antiepileptics, methotrexate or lipid-lowering drugs, have been 
positively associated with tHcy concentrations [53]. Also, lack of exercise [54], body 
mass index [35] and cardiovascular risk factors like cholesterol [16, 54] and blood 
pressure [20] have been mentioned as a determinant of high tHcy concentrations.
Genetics
Homocystinuria
Severe hyperhomocysteinemia or homocystinuria is characterized by accumulation of 
homocysteine in blood with homocysteine excretion in the urine and was first 
described by Carson and Neill [55]. CBS deficiency is the most common cause of 
homocystinuria [56]. Predominant clinical features of CBS deficiency include 
dislocation of the optic lens, osteoporosis, marfanoid features, mental retardation 
and an early onset of vascular disease. Most CBS deficient patients have clearly 
reduced CBS enzyme activity in extracts of cultured fibroblasts. In addition to 
homocysteine, also methionine accumulates in the body and is excreted via the 
kidney. In the CBS gene, over 100 mutations have been described in CBS deficient 
patients, of which most of them have been found to significantly decrease the CBS 
enzyme activity [57]. The two most frequent mutations are the 833ToC (I278T), 
which accounts for about one-fourth of all homocystinuric alleles and is the major 
cause of homocystinuria in the Netherlands [58], and the 919GoA (G307S), which is 
the leading cause of homocystinuria in Ireland [59].
Reduced MS activity due to inborn errors of methylcobalamin transport or synthesis 
has been described to cause severe hyperhomocysteinemia, but these are very rare 
[60, 61].
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In MTHFR deficiency the clinical severity correlates with the degree of enzyme 
deficiency and the most common clinical manifestation of MTHFR deficiency is 
developmental delay [60]. In contrast to CBS deficiency the major biochemical 
findings are moderate homocystinuria and homocystinemia with low or relatively 
normal levels of plasma methionine and the excretion of homocysteine is much less 
than in homocystinuria due to CBS deficiency. Both CBS, MTHFR as well as MS 
deficiency show increased risk for vascular disease.
Hyperhomocysteinemia
tHcy concentrations in the normal population have found to be correlated in healthy 
twins without vascular disease [62, 63], but also among family members with 
vascular disease and moderately elevated tHcy levels [64-66]. So, it can be 
concluded that hyperhomocysteinemia is, at least partially, genetically based.
CBS
In 1985, Boers et al. [18] reported that heterozygosity for CBS deficiency accounted 
for the hyperhomocysteinemia in vascular patients. Later, also Clarke et al. [27] 
reported the same observation. However, results from Mudd et al. [67] showed no 
statistically significant increase in the incidence of heart attacks or strokes in parents 
and grandparents of homocystinuric CBS deficient children. Furthermore, the 
estimated frequency of heterozygosity for CBS deficiency is much lower than the 
frequency of mild hyperhomocysteinemia which is approximately 10-20% in the 
normal population and is therefore too low to account for the number of vascular 
patients with mild hyperhomocysteinemia [68]. The finding of decreased CBS 
activities in the heterozygous range in cultured fibroblasts from 
hyperhomocysteinemic vascular disease patients could not be reproduced [69, 70], 
and still needs clarification.
The isolation and characterization of the CBS cDNA by Kraus et al. [71] permitted the 
molecular genetic analysis of the CBS cDNA in patients with vascular disease. In 60 
Dutch patients with arterial occlusive disease, the 833ToC (I278T) mutation in the 
CBS gene, could not be detected, although the mutation is present in ~50% of 
alleles of Dutch homozygotes for CBS deficiency [70]. In a comparable study, 
Gallagher et al. [72] did not detect the 'Celtic' 919GoA (G307S) mutation in 100 
vascular disease patients, whereas this mutation is the predominant cause of 
homocystinuria in the Irish population [59]. These observations were supported by 
the results of Kozich et al. [73] who analyzed the CBS cDNA in four 
hyperhomocysteinemic patients with peripheral arterial occlusive disease and 
decreased CBS activities in extracts of cultured fibroblasts. Neither pathogenic 
mutations, nor a defective stimulation by AdoMet were noticed as a possible cause of 
decreased enzymatic activity. In summary, all genetic studies performed so far, failed 
to detect an involvement of heterozygosity for CBS deficiency in 
hyperhomocysteinemia and premature vascular disease.
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In the coding region of the CBS gene no polymorphism associated with mild 
hyperhomocysteinemia has been found. However, a 68 bp insertion at the intron 7- 
exon 8 boundary (844ins68) was described as a possible pathogenic variant and was 
postulated to introduce a premature termination codon, which would result in a 
nonfunctional CBS. Still, individuals carrying the insertion showed normal size mRNA 
[74, 75], normal CBS enzyme activity [75] and the presence of this variant was not 
associated with increased tHcy concentrations [75, 76].
MTHFR
In 1988, Kang et al. [77] detected a variant of the MTHFR enzyme which was 
associated with decreased enzyme activity, reduced stability after heating at 46°C 
and increased tHcy concentrations. A few years later they demonstrated that this 
thermolabile form of MTHFR was more common among CVD patients (17%) than 
among controls (5%) [78]. In 1995, Frosst et al. [79] identified the single base pair 
substitution of C to T at nucleotide 677 to be responsible for this thermolabile 
MTHFR. Since then, several studies have reported an association between this 
common 677CoT variant and increased tHcy concentrations, and decreased MTHFR 
enzyme activities [70, 80]. Thermolabile MTHFR accounts for 25% of the mild 
hyperhomocysteinemia in vascular disease patients [69], which indicates that 
additional mutations in the MTHFR gene or in other genes may also affect tHcy 
levels. Besides, it appears that the 677TT genotype is associated with increased tHcy 
concentrations only in individuals with low folate status [81, 82]. So possible gene­
environment interactions also play an important role in determining tHcy levels.
Given that tHcy concentration is a graded risk factor for CVD, the observation that 
the 677CoT variant is associated with increased tHcy concentrations leads to the 
prediction that this variant is also associated with an increased risk of CVD. Several 
studies have investigated this possible association of which some found an 
association while others did not [83]. Two meta-analyses have evaluated the results 
found and declared contrasting conclusions [84, 85]. Kluijtmans & Whitehead [85] 
concluded that 677CT heterozygotes had an elevated risk over 677CC homozygotes, 
while the conclusion of Brattstrom et al. [84] was that the MTHFR variant does not 
increase cardiovascular risk.
Besides all the positive associations observed between increased tHcy concentrations 
and CVD [23-26], several studies failed to find such an association [86, 87]. Taken 
together, these results do not give conclusive evidence for homocysteine as a causal 
risk factor for CVD.
Objectives and outline of this thesis
The main objective of this thesis was to provide more information on the genetic 
basis of hyperhomocysteinemia in vascular disease. tHcy concentrations are 
influenced by environmental, like diet and life-style, and genetic factors. At the start 
of this project, insight in the genetic basis of hyperhomocysteinemia was limited to 
the MTHFR 677CoT variant. Very little was known about variation in other genes
19
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involved in the homocysteine metabolism, and whether these variations contribute to 
hyperhomocysteinemia and risk of CVD. By examining genes, encoding for enzymes 
involved in homocysteine metabolism, on variations we intend to
- study genetic origins of hyperhomocysteinemia
- investigate whether genetic variation in genes involved in homocysteine 
metabolism increase the risk of CVD
The studies presented in this thesis can be subdivided into two parts, dealing with 
the genetic variation in genes concerning remethylation of homocysteine (Part 1, 
chapters 2-6), and with genetic variation in the CBS gene, the regulating enzyme in 
the transsulfuration pathway (Part 2, chapters 7-9).
Part 1
In chapter 2 we describe the association between the MTHFR 677CoT and 
1298AoC variants and MTHFR enzyme activity, tHcy concentrations and risk of CVD. 
The association between folate and tHcy concentrations and a polymorphism in the 
GCPII gene is discussed in chapter 3.
In chapter 4 we describe a polymorphism in the MS gene and its possible 
association with tHcy concentrations and risk of CVD.
Chapter 5 deals with several genetic variants in the TC gene.
The molecular genetic analysis of the BHMT gene and investigation of the influence 
of the three mutations discovered in this gene on tHcy concentrations and CVD risk is 
presented in chapter 6.
Part 2
A genetic variant of the CBS gene is described in chapter 7, where associations with 
CBS enzyme activity, tHcy concentrations and the probable occurrence of alternative 
splicing are studied.
The association between tHcy concentrations and this CBS variant was further 
examined in subjects from the Framingham Offspring Study, as described in chapter 
8.
A genetic association study was performed in which we investigated a potential 
involvement of variants in non-coding regions or of silent mutations in the CBS gene 
in hyperhomocysteinemia and vascular disease, as possible markers which may be in 
linkage disequilibrium with a functional polymorphism, as described in chapter 9.
In the last decade, several studies have been conducted to elucidate the genetic 
determinants of hyperhomocysteinemia in patients with cardiovascular disease. We 
discuss hyperhomocysteinemia in vascular disease and made a detailed overview of 
all the genetic determinants reported so far in chapter 10.
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Remethylation

Chapter 2
A second common variant in the methylenetetrahydrofolate 
reductase (MTHFR) gene and its relationship to MTHFR enzyme 
activity, homocysteine, and cardiovascular disease risk
Karin J.A. Lievers, Godfried H.J. Boers, Petra Verhoef, Martin den Heijer, Leo A.J. 
Kluijtmans, Nathalie M.J. van der Put, Frans J.M. Trijbels and Henk J. Blom
Department of Pediatrics, Department of Internal Medicine and Department of 
Internal Medicine; Division of Endocrinology, University Medical Center Nijmegen, 
Nijmegen, The Netherlands.
Wageningen Center for Food Sciences and Division of Human Nutrition & 
Epidemiology, Wageningen University, Wageningen, The Netherlands.
Journal of Molecular Medicine 2001; 79:522-528

Two MTHFR polymorphisms
Abstract
Molecular defects in genes encoding enzymes involved in homocysteine metabolism 
may account for mild hyperhomocysteinemia, an independent and graded risk factor 
for cardiovascular disease (CVD). We examined the relationship of two 
polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, the 
677CoT and 1298AoC variants, to MTHFR activity, tHcy concentrations and risk of 
CVD in a population of 190 vascular disease patients and in 601 apparently healthy 
controls. The mean specific and residual MTHFR activities were significantly lower in 
677CT and 677TT individuals (both 3<0.001). The 1298AoC mutation alone showed 
no effect on MTHFR activities. However, when the 677CoT genotype was taken into 
account, the 1298AoC mutation also caused a significant decrease in MTHFR 
activities, which was observed in both the homozygous 1298CC (3<0.001) and the 
heterozygous 1298AC states (3^0.005). Both the 677TT as the 677CT genotypes 
were associated with significantly higher fasting and postload tHcy levels than 677CC 
(3<0.001 and 3^0.003, respectively). The 1298AoC mutation had no effect on 
fasting or postload tHcy levels. Since tHcy itself is considered to be positively 
associated with the risk of CVD, these findings indicate that the 1298AoC mutation 
cannot be considered a major risk factor for CVD.
Introduction
Homocysteine is a sulfur amino acid that is degraded in the transsulfuration pathway 
to cystathionine, a step that is catalyzed by cystathionine ß-synthase (CBS). 
Alternatively, it can be remethylated to methionine via a pathway regulated by 5,10- 
methylenetetrahydrofolate reductase (MTHFR). MTHFR converts 5,10- 
methylenetetrahydrofolate to 5-methyltetrahydrofolate, the primary circulatory form 
of folate. In both pathways major genetic defects that cause enzyme deficiencies are 
associated with very high tHcy levels and excretion of homocystine into the urine. 
These forms of homocystinuria are characterized by neurological abnormalities and 
by the development of early arteriosclerotic and thrombotic vascular disease [88, 
89].
Wilcken et al. were the first to report an association between mildly elevated tHcy 
levels and cardiovascular disease (CVD) [15]. Later, numerous investigators have 
reported the occurrence of elevated tHcy levels in patients with cerebral, peripheral 
or coronary artery disease or venous thrombosis [18, 21, 90]. Today a mildly 
elevated tHcy concentration is generally [26, 91], although not universally [87, 92] 
accepted as an independent and graded risk factor for both arterial occlusive disease 
and venous thrombosis.
tHcy levels are influenced by various factors: genetic, dietary and life-style factors 
can interfere with transsulfuration and remethylation. tHcy concentrations have been 
found to be correlated in monozygotic and dizygotic healthy twins [62, 63] and to be 
strongly correlated among family members of patients with coronary vascular disease 
[64, 65] or with various forms of arterial occlusive disease [66].
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In 1988 Kang et al. [77] described a thermolabile variant of MTHFR that was 
associated with decreased enzyme activity and increased heat lability of the enzyme. 
Frosst et al. [79] reported the 677CoT mutation to be the genetic cause of 
thermolabile MTHFR. This 677CoT mutation leads to the exchange of an alanine 
with a valine amino acid and is associated with elevated tHcy concentrations, 
especially in those individuals with low folate status [81]. Thermolabile MTHFR, 
however, accounts for mild hyperhomocysteinemia in approximately 25% of vascular 
disease patients [69], which indicates that additional mutations in the MTHFR gene 
or other genes may also affect tHcy levels. In 1998 we [93] described an AoC 
change at base pair 1298 that results in the substitution of glutamate by an alanine 
residue. Subsequently its effect on homocysteine and folate metabolism and its 
potential role as a risk factor for neural-tube defects was investigated. That study 
found compound heterozygosity for the 677CoT and 1298AoC variants to be 
associated with reduced MTHFR specific activity, elevated tHcy, and decreased 
plasma folate levels [93].
In the present study we examined this 1298AoC mutation and its potential 
interaction with the 677CoT mutation as a possible cause of elevated tHcy 
concentration and as a possible genetic risk factor for CVD. We assess the effect of 
both variants on tHcy levels, MTHFR activity, and residual MTHFR activity in 190 
vascular disease patients and in 601 apparently healthy subjects.
Materials and Methods
Patients and Controls
We studied 190 patients with coronary, peripheral, or cerebral vascular disease. Of 
these, 130 were recruited from persons who underwent coronary angiography in the 
Zuiderziekenhuis Hospital in Rotterdam, The Netherlands [28], and 60 had 
documented premature CVD (10 myocardial infarction, 32 cerebral arterial occlusive 
disease, and 18 peripheral arterial occlusive disease [70]. The control group 
consisted of 601 controls, of whom 101 were included from the general population in 
Rotterdam [28] and 500 were recruited from a general practice in The Hague, The 
Netherlands [94].
The proportion of men was higher among patients (75.3%) than controls (47.1%; 
P<0.001). The mean age of patients was 49.0+10.2 years, and that of controls was 
50.6+12.7 years (n.s). Table 1 presents the major clinical characteristics of patients 
and controls. The patient group showed a significantly higher fasting tHcy levels 
(3=0.005), while the postload tHcy levels tended to be higher in patients (P=0.10). 
Specific and residual MTHFR activity did not differ between patients and controls, 
although the residual MTHFR activity expressed as a percentage of the specific 
activity tended to be lower in patients (3=0.06).
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Table 1. Clinical characteristics of study population. Age and MTHFR activities are expressed 
as mean ±SD; tHcy as geometric means (95%  C I) ; MTHFR activities as nanomoles of 
formaldehyde formed per milligram of protein per hour (n=129 for controls and n=42 for 
patients)
Patients (n=190) Controls (n=601) 3 a
Fasting tHcy (—mol/L) 14.4 (13.7-15.0) 13.1 (12.7-15.1) 0.005
Postload tHcy (—mol/L) 41.1 (39.7-43.2) 40.1 (39.1-41.1) 0.10
Specific MTHFR activity 17.5 ± 7.1 18.8 ± 6.8 0.74
Residual MTHFR activity 10.1 ± 5.9 11.9 ± 5.6 0.25
Residual MTHFR activity (%) 53.3 ± 15.9 59.4 ± 13.3 0.06
a 3  values are age- and sex-adjusted.
Mutation Detection
The 677CoT variant creates a H/nfI site, and was analyzed by restriction fragment 
length polymorphism polymerase chain reaction (PCR) as described elsewhere [79]. 
The 1298AoC variant changes a glutamate to an alanine residue and abolishes a 
MboII restriction site. Mutation analysis was performed by PCR and subsequent 
restriction enzyme analysis with MboII. The PCR was carried out in a total volume of 
50 —l containing 50 ng of the forward primer 5'-ATGTGGGGGGAGGAGCTGAC-3' and 
50 ng of the reverse primer 5'-CCCTCTTCCCATTCAACCCTCTG-3', 200 —M each dNTP, 
10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1 mM MgCl2 and 1 unit Taq polymerase (Life 
Technologies). PCR conditions were: an initial denaturation step of 3 minutes at 
92°C, followed by 35 cycles of 92°C/60 s (denaturation), 55°C/60 s (annealing), and 
72°C/60 s (extension), and a final extension of 7 minutes at 72°C. The amplified PCR 
fragment of 240 bp was digested with the restriction enzyme MboII, followed by gel 
electrophoresis analysis on a 2% agarose gel. After restriction enzyme analysis the 
1298AA genotype results in two fragments of 25 and 215 bp. The 1298CC genotype 
shows only one fragment of 240 bp [95].
MTHFR enzyme activityassay
Specific and residual MTHFR activities in isolated lymphocytes were determined 
radiochemically as described by Engbersen et al. [69]. Activities are expressed as 
nanomoles of formaldehyde formed per milligram of protein per hour. The residual 
MTHFR activity is the enzyme activity after heat incubation for 5 min at 46°C and is 
also expressed as a percentage of the specific MTHFR activity before incubation.
tHcy
All CVD patients and controls were subjected to a standardized oral methionine 
loading test (0.1 g L-methionine/kg body weight) [96]. tHcy was measured in plasma 
using a high-performance liquid chromatography procedure, with reverse phase 
separation and fluorescence detection, as described by Te Poele-Pothoff et al. [97]. 
All tHcy measurements were conducted in our laboratory at the University Medical 
Center Nijmegen, The Netherlands.
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Statistics
tHcy concentrations were logarithmically transformed prior to all statistical analyses. 
Differences between patient and control groups were assessed by Student's t test for 
continuous variables and Pearson's chi-square test for frequencies. 3  values were 
age- and sex-adjusted by linear regression analysis. Age- and sex-adjusted odds 
ratios and 95% confidence interval were calculated by logistic regression analysis to 
estimate the relative risk of CVD for the various genotype combinations. One-way 
analysis of variance was used to assess the differences in continuous variables 
between the different genotypes, followed by Bonferroni-corrected t tests. 3  values 
are two-tailed, and 3<0.05 was considered statistically significant.
Table 2. Prevalence and odds ratios (OR; adjusted for age and gender) and 95%  confidence 
intervals (95%  C I) for risk of CVD of the MTHFR polymorphisms in patients and controls
Genotype
677 1298
Number of 
Patients Controls
OR 95% CI
CC AA 23 79 1a
CC AC 48 146 1.22 0.68-2.21
CC CC 13 57 0.79 0.36-1.76
CT AA 42 119 1.43 0.77-2.65
CT AC 32 112 0.99 0.53-1.85
TT AA 20 52 1.42 0.69-2.93
a Reference category.
Results
MTHFR genotype distribution and CVD risk
Both 677CoT and 1298AoC genotype distributions were in Hardy-Weinberg 
equilibrium. We observed an allele frequency of the 1298C allele of 0.30 in patients 
and of 0.33 in controls (%2=1.45, 3=0.48). The allele frequency of the 677T allele in 
controls was 0.29, compared with 0.33 in patients (%2=1.57, 3=0.46); thus the 
frequency of the mutated alleles was similar in patients with CVD and in controls. 
Table 2 combines the 677CoT and 1298AoC genotypes to generate composite 
genotypes and presents calculated odds ratios for risk of CVD for each genotype 
relative to the 677CC/1298AA genotype. No increased risk for CVD was observed for 
any of the composite genotypes. The distribution of composite MTHFR genotypes is 
consistent with the hypothesis that both variants originated on different alleles.
MTHFRactivities
MTHFR activity was measured in isolated lymphocytes of 42 patients and 129 
controls. Part of the control group has been used in our previous study [93]. Because 
the relationship between the MTHFR genotypes and MTHFR enzyme activity was
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similar in cases and controls (data not shown), we combined the groups to increase 
statistical power in subsequent analyses.
Table 3. Relationship between MTHFR genotypes and MTHFR enzyme activity. Activities are 
expressed as nanomoles of formaldehyde formed per milligrams of protein per hour; 3  
values calculated by analysis of variance.
Genotype n MTHFR activity
Specific Residual Residual (%)
677a
CC 96 21.8 (±6.3) 14.5 (±5.1) 65.3 (±8.2)
CT 60 15.9 (±4.4) 8.7 (±3.2) 53.1 (±10.0)
TT 15 7.9 (±2.2) 2.4 (±1.7) 27.6 (±13.4)
3 <0.001 <0.001 <0.001
1298
AA 74 18.8 (±8.0) 11.4 (±6.6) 54.2 (±16.6)
AC 83 18.6 (±6.2) 11.7 (±5.3) 60.3 (±12.1)b
CC 13 15.8 (±3.2) 10.1 (±2.5) 62.8 (±5.4)
3 0.34 0.622 0.011
a P<0.001 677TT vs. 677CC, 677CT vs. 677CC, 677TT vs. 677CT (Bonferroni W-test) 
b 3 ^ .0 5  1298AC vs. 1298AA (Bonferroni W-test)
Table 3 shows the separate effects of the 677CoT and 1298AoC mutations on the 
MTHFR activity. The mean specific and residual MTHFR activities were significantly 
lower in individuals with the homozygous 677TT genotype and the heterozygous 
677CT genotype than in those observed in 677CC homozygotes (3<0.001, analysis of 
variance). The 1298AoC mutation by itself had no effect on specific and residual 
MTHFR enzyme activity, but the 1298AC and 1298CC showed higher residual (% ) 
activities than with the 1298AA genotype (3=0.011, analysis of variance; Table 3). 
Figure 1 shows the effects of the 1298AoC genotypes and MTHFR activity within 
each of the three 677CoT genotype groups. Among 677CC subjects those with the 
1298CC or 1298AC genotype had lower specific MTHFR activity than their 1298AA 
peers (both 3<0.005; Figure 1A). Among 677CT heterozygotes, those with the 
1298AC genotype also showed significantly lower activities than individuals with the 
677CT/1298AA genotype (3<0.001). The mean residual (% ) MTHFR activities of the 
composite genotypes show that within none of the MTHFR 677CoT genotype 
groups a significant effect of the 1298AoC mutation on residual (% ) MTHFR activity 
(Figure 1B) could be observed.
tHcylevels
Because separate analysis of the relationship between MTHFR genotype and tHcy in 
patients and controls showed the same results (data not shown), we combined the 
groups to increase statistical power. Table 4 shows the individual effects of the
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Figure 1. Relationship between composite MTHFR genotypes and specific (A) and residual 
(B) MTHFR activity. Figures in parentheses indicate number of individuals in each genotype 
group. MTHFR activities are expressed as nanomoles of formaldehyde formed per milligram 
of protein per hour. Residual MTHFR activity is expressed as a percentage of the MTHFR 
activity before heat incubation.
677CoT and the 1298AoC genotypes on the tHcy levels. Individuals with the 677TT 
or 677CT genotype had significantly higher fasting and postload tHcy levels than 
677CC homozygotes (3<0.001 and 3=0.003, respectively). The 1298AoC mutation 
alone showed no effect on fasting or postload tHcy levels.
Figure 2 shows the combined effects of the 677CoT and the 1298AoC genotypes 
on both fasting and postload tHcy levels. Individuals with the composite 
677CT/1298AC genotype had slightly higher geometric mean fasting (13.7 —mol/L, 
95% CI 13.0-14.6) and postload (42.4 —mol/L, 95% CI 40.1-44.8) tHcy levels than 
those with the 677CT/1298AA genotype (13.2 —mol/L, 95% CI 12.6-13.7; and 39.9 
—mol/L, 95% CI 38.0-41.8, respectively), but these differences were not statistically 
significant (3=0.18 and 3=0.08, respectively).
Discussion
As reported previously by us [70, 79, 98], the MTHFR 677CoT mutation has a 
significant effect on MTHFR activity. Both the heterozygous 677CT and the 
homozygous 677TT genotypes are associated with significantly lower MTHFR enzyme 
activities than the homozygous wild-type genotype. The 677TT genotype is the 
genetic basis of the so-called thermolabile MTHFR [79]. Some mutations may in 
particular affect the stability of the enzyme, which becomes manifest at studying 
thermolability [69, 79].
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Table 4. Relationship between MTHFR genotypes and fasting and postload tHcy 
concentrations, expressed as geometric means (with 95%  confidence intervals); 3  values 
calculated by analysis of variance
Genotype n tHcy (—mol/L)
Fasting Postload
677
CC 378 12.7 (12.4-13.1) 38.9 (37.8-40.1)
CT 317 13.5 (13.1-14.0)a 41.2 (39.8-42.7)a
TT 74 15.6 (14.0-17.4)b' c 46.0 (42.1-50.4)b, d
3 <0.001 <0.001
1298
AA 337 13.5 (13.0-14.0) 40.6 (39.3-42.1)
AC 340 13.1 (12.7-13.6) 40.5 (39.0-41.9)
CC 70 12.9 (12.2-13.7) 38.7 (36.6-41.1)
3 n.s. n.s.
a P<0.05 677CT vs. 677CC, b P<0.001 677TT vs. 677CC, c P<0.005 677TT vs. 677CT, d P<0.05 677TT vs. 677CT (Bonferroni W- 
test)
Although the 1298AoC polymorphism does have a significant effect on the MTHFR 
activity (Figure 1A), neither the 1298AC genotype nor 1298CC genotype results in 
elevated tHcy levels. Earlier studies [99, 100] have shown similar findings of the 
effect of the 1298AoC polymorphism on MTHFR activity; the 677CC/1298AC and 
677CC/1298CC genotypes show MTHFR activities of 60-92% and 52-66% compared 
with the 677CC/1298AA genotypes. The combined heterozygotes (677CT/1298AC) 
show MTHFR activities between 36 and 62% of the activity associated with the 
677CC/1298AA genotype. In these two studies no effect of the 1298AoC 
polymorphism on tHcy concentrations was observed. Friedman et al. [101] however, 
did find a lower tHcy concentration of the 677CC/1298CC genotype than the 
677CC/1298AA genotype, suggesting that the 1298AoC variant affects tHcy 
concentrations. Furthermore, in our earlier study [93] compound heterozygotes had 
a higher tHcy concentration than 677CT/1298AA individuals. Jacques et al. [82] 
reported that subjects who were homozygous for the 677CoT polymorphism had 
elevated tHcy concentrations only in the presence of low folate status (< 15.4 
nmol/L). Girelli et al. [102] showed that in individuals with folate levels below the 
median (< 11.5 nmol/L) fasting tHcy was significantly higher not only in 677TT but 
also in 677CT individuals than in 677CC homozygotes. Therefore folate status may 
explain the discrepancy in the results of the above studies. Other environmental 
factors, such as nutritional intake, ethnic differences, and body mass index, have 
also been reported to affect tHcy concentrations [24]. A meta-analysis by Jee et al. 
[103] revealed an association of the 677CoT polymorphism with increased risk of 
CVD in Japan but not in other populations.
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Figure 2. Relationship between composite MTHFR genotypes and fasting (A) and postload 
(B) tHcy concentrations. Figures in parentheses indicate number of individuals in each 
genotype group
Another plausible explanation is that the decreased MTHFR enzyme activity must 
reach a certain threshold level before it results in increased tHcy concentrations. If 
this threshold level is between 12.61 and 7.89 nmol of formaldehyde formed per 
milligram of protein per hour, i.e. between the level of the combined heterozygotes 
and the level of the 677TT/1298AA genotype (Figure 1A), this could explain the 
different effects of these two genotypes on tHcy concentrations in this study.
The genotype distributions were similar in patients and controls, indicating that no 
particular MTHFR genotype is associated with increased CVD risk. The effect of the 
1298AoC polymorphism in the MTHFR gene is reflected in the enzyme activity, but a 
significant effect on tHcy levels was not found. Since tHcy itself is considered to be 
positively associated with the risk of CVD, the results of this study indicate that the 
1298AoC mutation cannot be considered a major risk factor for CVD.
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Influence of a GCPII polymorphism
Abstract
Elevated levels of tHcy and low folate in blood are independent and graded risk 
factors for arterial occlusive disease. An impairment of folate distribution can be an 
important cause of hyperhomocysteinemia. Glutamate carboxypeptidase II (GCPII) 
regulates the absorption of dietary folates. In the present study, we examined the 
relationship of a 1561CoT variant in the GCPII gene with fasting, post-methionine 
load tHcy, folate and vitamin B12 levels and the risk of cardiovascular disease (CVD) 
in 190 vascular disease patients and in 601 apparently healthy controls.
Fasting as well as postload tHcy concentrations associated with the 1561TT genotype 
tended to be lower, whereas the tHcy concentrations of the 1561CT individuals were 
not different from their 1561CC peers. The 1561CoT polymorphism significantly 
increased both red blood cell folate and plasma folate concentrations (ANOVA 
3^0.013; test for linear trend 3^0.03, respectively), but had no effect on vitamin B12 
levels (ANOVA 3^0.35). Since not only tHcy itself is considered to be positively 
associated with the risk of CVD, but also a decreased folate status, the results of this 
study indicate that the 1561CoT polymorphism may affect the predisposition to 
CVD.
Introduction
A mildly elevated level of tHcy in blood, or hyperhomocysteinemia, is an independent 
and graded risk factor for arterial occlusive disease [23, 30]. Furthermore, several 
studies also found an association between decreased folate levels and cardiovascular 
disease (CVD) risk [31-33]. Hyperhomocysteinemia is attributed to commonly 
occurring genetic causes, like the 677CoT polymorphism [69, 81, 104], and 
environmental factors, such as folate and vitamin B12 deficiencies [37, 105]. An 
impairment of folate uptake can therefore be an important cause of 
hyperhomocysteinemia. Dietary folates are a mixture of polyglutamylated folates. 
Folylpoly-j-glutamate carboxypeptidase (FGCP), which is anchored to the intestinal 
brush border membrane, hydrolyses these polyglutamylated folates into 
monoglutamyl folates that are actively transported across the membrane by the 
reduced folate carrier. The folylpoly-j-glutamate carboxypeptidase enzyme is 
expressed by the glutamate carboxypeptidase II (GCPII) gene. Genetic variation in 
GCPII could therefore affect the efficiency of absorption of dietary folate. In 2000, 
Devlin et al. [106] reported a C oT  substitution at nucleotide 1561 (H475Y) of the 
GCPII gene. They found that transfected COS-7 cells expressing the H475Y 
mutagenized GCPII cDNA showed 53% less FGCP enzyme activity compared to cells 
expressing the wild-type GCPII enzyme. The heterozygous genotype of this GCPII 
variant was associated with lower folate and higher tHcy concentrations in a 
population of 75 healthy Caucasians.
In the present study, we examined this GCPII 1561CoT variant in 190 patients with 
arterial occlusive disease and in 601 population-based controls. We report the allele 
frequencies and genotype distributions of this polymorphic variant in both cases and
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controls, and describe its association with fasting, post-methionine load tHcy, folate 
and vitamin B12 levels.
Materials and Methods
Pat¡ents and controls
We studied 190 patients with coronary, peripheral or cerebral vascular disease; a 
total of 130 patients were recruited from persons who underwent coronary 
angiography in the Zuiderziekenhuis Hospital in Rotterdam, The Netherlands [28]. 
The other 60 patients had documented premature cardiovascular disease of which 10 
patients had suffered from myocardial infarction, 32 from cerebral arterial occlusive 
disease and 18 from peripheral arterial occlusive disease [70].
The control group consisted of 601 controls, of which 101 were included from the 
general population in Rotterdam [28] and 500 were recruited from a general practice 
in The Hague, The Netherlands [94].
Mutation Detection
The 1561CoT transition creates an AccI site, and was analyzed by PCR-RFLP as 
described elsewhere [106].
Biochemicalparameters
Cardiovascular patients and controls were subjected to a standardized oral 
methionine loading test (0.1 g L-methionine/kg body weight) [18]. tHcy was 
measured in plasma using a high-performance liquid chromatography (HPLC) 
procedure, with reverse phase separation and fluorescence detection, as described 
by Te Poele-Pothoff et al. [97]. All tHcy measurements were conducted in our 
laboratory at the University Medical Center Nijmegen, the Netherlands. Vitamin B12 
and folic acid concentrations were measured in serum samples stored at -70°C with 
the Dualcount SPNB (solid phase no boil) Radioassay (Diagnostic Product 
Corporation, Los Angeles, USA). Folate and vitamin B12 levels were only available of a 
part of the control group (n=500).
Statistics
tHcy, folate and vitamin B12 concentrations were logarithmically transformed prior to 
all statistical analyses. Differences between patient and control groups were assessed 
with Student's t test for continuous variables and Pearson's chi-square test for 
frequencies. 3  values were age- and sex-adjusted by linear regression analysis. Odds 
ratios (OR) and 95% confidence interval (95% CI) were calculated by logistic 
regression analysis to estimate the relative risk of CVD for the different genotypes. 
One-way analysis of variance (ANOVA) was used to assess the differences of 
continuous variables between different genotypes, followed by Bonferroni-corrected t 
tests. 3  values are two-tailed, and 3<0.05 was considered statistically significant.
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Results
Table 1 shows the main characteristics of the patient and the control group. The 
percentage of males was higher among patients than controls (3<0.001). Mean age 
did not differ between patients and controls. The patient group showed a 
significantly higher fasting tHcy level (3=0.005), whereas the postload tHcy level 
tended to be higher in cases (3=0.10).
Table 1. Characteristics of study population
Cases
(n=190)
Controls
(n=601)
3 Odds ratio (95% CI)
Age (years) 49.0 ± 10.2 50.6 ± 12.7 0.11
Gender (%  male) 75.3 47.1 <0.001
Fasting tHcy (—mol/L) 14.4 (13.7-15.0) 13.1 (12.7-15.1) 0.005a
Postload tHcy (—mol/L) 41.1 (39.7-43.2) 40.1 (39.1-41.1) 0.10a
1561CC (n) 168 479 1b
1561CT (n) 17 55 x2=1 .23 3=0.54 0.88 (0.50-1.56)
1561TT (n) 0 3 -
Age is expressed as mean ± SD; tHcy concentrations are expressed as geometric means (95% CI). 
a 3  values are age- and sex-adjusted. 
b Reference category
The genotype distribution of the 1561CoT polymorphism was in Hardy-Weinberg 
equilibrium. We observed an allele frequency of the 1561T allele of 4.6% in patients 
and of 5.7% in controls (%2=1.23, 3=0.54). Thus, we observed no difference in 
frequency of the mutated allele in the CVD patients compared with controls (Table 
1). We calculated odds ratios (OR) for risk of CVD for the 1561CT genotype relative 
to the 1561CC genotype. No increased risk for CVD was observed for the 1561CT 
genotype (OR: 0.88 (95%CI 0.50-1.56); OR adjusted for age, gender and tHcy 
concentrations: 0.70 (95%CI 0.37-1.34), Table 1). No OR could be calculated for the 
1561TT genotype relative to the 1561CC genotype since no 1561TT individuals were 
observed among cases.
Because the relationship between the GCPII genotypes and tHcy concentrations was 
similar in cases and controls (data not shown), we combined both groups to increase 
statistical power in subsequent analyses.
Table 2 shows the associations of the 1561CoT genotype with tHcy, folate and 
vitamin B12 concentrations. The fasting as well as the postload tHcy concentrations 
in the 3 subjects with the 1561TT genotype tended to be lower, though these 
differences were not statistically significant. The 1561CT individuals had similar tHcy 
concentrations compared with their 1561CC peers. Folate and vitamin B12 levels were 
only available from a part of the control group (n=500). In this group, the 1561CoT 
polymorphism was associated with increased red blood cell folate (ANOVA 3=0.013) 
and plasma folate concentrations (ANOVA 3=0.013; test for linear trend 3=0.03), but 
had no effect on vitamin B12 levels (ANOVA 3=0.35). The association of the
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1561CoT polymorphism with both fasting and postload tHcy concentrations in this 
control group is similar compared with the association in the total study group; the 
1561CC genotype showed a fasting tHcy concentration of 12.7 (95% CI : 12.3-13.1) 
and postload concentration of 40.1 (95% CI:38.9-41.4); 1561CT: 12.7 (95% CI:11.7- 
13.7) and 41.5 (95% CI:38.3-45.0) respectively; the three 1561TT individuals were 
part of this control group.
Table 2. Relationship between GCPII genotypes and tHcy, folate and vitamin Bi 2 
concentrationsa
Genotype 1561CC 1561CT 1561TT ANOVA 3
Fasting tHcy 13.3 (13.0-13.6) 13.2 (12.5-14.1) 9.1 (6.2-13.2) 0.11
(—mol/L) n=634 n=70 n=3
Postload tHcy 40.5 (39.5-41.5) 41.1 (38.3-44.1) 31.1 (24.0-40.3) 0.32
(—mol/L) n=610 n=67 n=3
RBC folate 390.6 (373.5-408.4) 466.8 (401.5-542.6)b 599.3 (324.4-1107.2) 0.013
(nmol/L) n=370 n=42 n=3
Plasma folatec 12.8 (12.2-13.4) 14.3 (12.4-16.5) 21.4 (10.5-43.2) 0.07
(nmol/L) n=397 n=42 n=3
Vitamin Bi2 219.9 (210.6-229.7) 233.0 (206.9-262.3) 163.7 (147.6-181.5) 0.35
(pmol/L) n=397 n=42 n=3
a Concentrations are expressed as geometric means (95% CI) 
b Bonferroni W-test 3=0.04 vs.1561CC 
c Test for linear trend 3=0.03
Since the 1561TT group consisted of only three individuals, we combined these with 
the heterozygous 1561CT group; results are shown in Figure 1. After adjustment for 
age, gender and MTHFR 677CoT genotype, the 1561CoT variant had no statistically 
significant effect on fasting tHcy concentrations (3=0.27; Figure 1A) or postload tHcy 
concentrations (3=0.86; data not shown), but significantly increased both plasma 
folate (3=0.048; Figure 1B) and red blood cell folate levels (3=0.010; Figure 1C).
Discussion
In the present study, we examined a 1561CoT variant in the GCPII gene in 190 
patients with arterial occlusive disease and in 601 population-based controls. The 
genotype distributions were similar in cases and controls, indicating that no particular 
GCPII genotype is associated with increased CVD risk. However, we did find a 
positive association between the GCPII 1561CoT genotype and folate levels, both in 
plasma and in red blood cells, but this did not lead to significantly decreased tHcy 
concentrations in this study group.
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Our results conflict with the data recently published by Devlin et al. [106] who 
reported decreased plasma folate and increased tHcy levels in 6 heterozygotes for 
the 1561CoT variant. Their results were substantiated by in vitro experiments, in 
which the mutated GCPII H475Y enzyme had only 47% of the activity of wildtype 
FGCP. They studied 75 healthy subjects among whom only 6 heterozygotes and no 
homozygotes for the GCPII 1561CoT variant were observed, whereas the results 
presented here included 72 heterozygous and 3 homozygous individuals. 
Furthermore, they did not adjust their analyses for potential confounding by age, 
gender and MTHFR 677CoT genotype status.
Data presented by from Brancaccio et al. [107] showed a decreased prevalence of 
the heterozygous genotype for the 1561CoT polymorphism in neural tube defects 
(NTD) patients compared with controls; OR=0.34 (95%CI 0.12-0.86). The latter 
suggests a protective effect of the 1561CoT polymorphism on the risk of NTD, 
which is in line with our results of increased folate status in individuals with the 
1561CoT polymorphism.
Numerous studies have reported an association between increased tHcy, low plasma 
folate and cardiovascular disease [23, 108]. The increased cardiovascular risk of low 
folate status is generally ascribed to an increased tHcy concentrations. However, 
several studies found this association to be independent of tHcy concentrations [31­
33]. Therefore, this 1561CoT variant, which leads to elevated folate levels, but has 
no effect on tHcy concentrations, may even reduce CVD risk.
In conclusion, our results do not corroborate with the results published by Devlin et 
al. [106] who described decreased plasma folate and increased tHcy concentrations 
in heterozygotes for the 1561CoT variant and found decreased enzyme activities of 
mutated GCPII cDNA in COS-7 cells. In the present study however, the 1561C o T  
polymorphism was associated with increased red blood cell and plasma folate 
concentrations. Hence, this 1561CoT variant in the GCPII gene may affect the 
predisposition to CVD.
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The MS 2756AoG variant
Abstract
Elevated tHcy levels have been associated with an increased risk of cardiovascular 
disease. A 2756AoG polymorphism has been found in the gene conding for 
methionine synthase (MS), an enzyme catalyzing remethylation of homocysteine to 
methionine. In a Dutch case-control study comprising 123 cases with coronary heart 
disease (CHD) and 540 healthy controls, we evaluated whether the 2756AoG 
polymorphism was associated with tHcy, folate and vitamin B12 concentrations and 
CHD risk. The polymorphism was not associated with fasting or post-methionine load 
tHcy concentrations. Individuals with the GG genotype had 30% lower vitamin B12 
concentrations than individuals with the AA or AG genotype (3<0.05). After 
adjustment for CHD risk factors, the odds ratio (OR) of CHD compared with the AA 
genotype was 4.00 (95% CI 1.38-11.57) for the GG genotype and 0.71 (95% CI 
0.43-1.17) for the AG genotype. In a meta-analysis of five case-control studies, 
including the present one, the combined OR of CHD for the GG genotype was 0.99 
(95% CI 0.60-1.65) and for the AG genotype 1.01 (95% CI 0.84-1.21), compared 
with the AA genotype. Despite the absence of an association with plasma 
homocysteine, the GG genotype showed a four-fold increased CHD risk. However, 
this was not confirmed by the meta-analysis. Additional studies are needed to assess 
whether any association is modified by vitamin B12 or folate status or other 
cardiovascular risk factors.
Introduction
Homocysteine is a sulphur-containing amino acid, formed at demethylation of the 
essential amino acid methionine. Homocysteine can either be degraded by 
transsulfuration, involving the vitamin B6-dependent enzyme cystathionine ß- 
synthase (CBS), or remethylated to methionine, involving the vitamin B12-dependent 
enzyme methionine synthase (MS). The latter enzyme requires 5- 
methylenetetrahydrofolate as methyl donor which is formed upon reduction of 5,10- 
methylenetetrahydrofolate by the enzyme methylenetetrahydrofolate reductase 
(MTHFR) [109]. Many epidemiological studies have shown that elevated tHcy 
concentrations are associated with increased risk of atherosclerosis and thrombosis 
[22, 26]. Hyperhomocysteinemia can be caused by suboptimal intake of vitamins 
involved in the homocysteine metabolism, like folic acid, vitamin B12 and B6. It may 
also be due to reduced function of one or more key-enzymes of its metabolism, as a 
result of variations in the genes encoding these enzymes.
The most extensively studied polymorphism in the homocysteine metabolism is the 
677CoT polymorphism in the MTHFR gene. The MTHFR 677TT genotype is 
associated with a ~25% increase in tHcy concentrations [84], and a 16% increase in 
coronary heart disease (CHD) risk (Klerk et al, unpublished results). Only recently, 
the role of polymorphisms of methionine synthase in hyperhomocysteinemia has 
attracted interest. In 1996, the human MS gene was cloned using cell lines from cbIG 
patients who have an inborn error resulting in MS deficiency [110] and sequencing 
analysis revealed a 2756AoG variant. Due to this transition, aspartic acid is
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substituted by glycine. Subsequent reports confirmed that this was a common 
variant, with allele frequencies ranging from 0.15-0.20 [111, 112]. Although it is not 
known whether the variant changes enzymatic activity or levels of MS, it was 
hypothesized that the MS 2756AoG variant might increase tHcy levels and hence 
increase risk of CVD [110].
In the present case-control study we evaluated whether the MS 2756AoG 
polymorphism is associated with tHcy concentrations and CHD risk in a Dutch 
population. Furthermore, the association between the polymorphism and serum 
vitamin B12 and folate concentration was studied in a subgroup of the controls. To 
summarize the available case-control data with respect to the MS 2756AoG 
polymorphism and CHD risk so far, we performed a meta-analysis of 5 international 
case-control studies, including the present one.
Methods
Studypopulation
A total of 130 cases were selected from patients who underwent coronary 
angiography in the Zuiderziekenhuis Hospital in Rotterdam between 1992 and 1994. 
Reasons for angiography were myocardial infarction or angina pectoris. Cases were 
only selected if they met certain criteria for coronary stenosis: >90% occlusion in one 
and >40% occlusion in one additional major coronary vessel. The control group 
consisted of 101 healthy subjects who were recruited from the general population in 
Rotterdam [104]. Exclusion criteria for both groups were diabetic, renal, hepatic, 
thyroid or gastro-intestinal disease, cancer, alcohol or drug abuse, and psychiatric 
illness. To increase statistical power the control group was expanded with data of 
440 healthy subjects who were recruited from a general practice in the Hague to 
take part in a health survey [94].
Blood sampling and analyses
Venous blood samples were obtained from all subjects after an overnight fast. In 
addition, subjects were subjected to a standardized oral methionine loading test (0.1 
g L-methionine/kg body weight). tHcy was measured in plasma using a high­
performance liquid chromatography (HPLC) procedure, with reverse phase separation 
and fluorescence detection as described by Te Poele-Pothoff et al. [97]. In serum 
samples from the control subjects from the Hague, vitamin B12 and folate 
concentrations were analyzed by radioimmunoassay (Dualcount SPNB; Diagnostic 
Product Corporation, Los Angeles, USA).
2756AoG genotyping
DNA was obtained from buffy coats by a standard method [113]. DNA for the 
analysis of the MS 2756AoG genotype (see below) was available for 123 cases and 
540 controls. The polymorphism involves an A to G substitution (D919G) at basepair
44
The MS 2756AoG variant
2756. The transition creates a HaeIII site, which was used for mutation analysis by 
PCR and restriction fragment length polymorphisms analysis. The PCR was carried 
out in a total volume of 50 —l containing 50 ng of the forward primer 5'- 
GGTGTGTTCCCAGCTGTTAGATG-3' and 50 ng of the reverse primer 5'- 
GACACTGAAGACCTCTGATTTGAAC-3', 200 —M each dNTP, 10 mM Tris-HCl (pH 8.3), 
50 mM KCl, 2 mM MgCl2 and 1 unit Taq polymerase (Life Technologies). PCR 
conditions were an initial denaturation step of 3 minutes at 92°C, followed by 35 
cycles of 92°C/60 s (denaturation), 54°C/60 s (annealing), and 72°C/60 s 
(extension), and a final extension of 7 minutes at 72°C. The PCR amplification 
resulted in a fragment of 265 bp which was digested with the restriction enzyme 
HaeIII, followed by gel electrophoresis analysis on a 2% agarose gel. After 
restriction enzyme analysis the 2756A allele shows one fragment of 265 bp, while the 
2756G allele results in two fragments of 180 and 85 bp, respectively.
Table 1. Baseline characteristics of patients and controls (mean ± SD or 95% CI)
Patients (n=123) Controls (n=540)
Age (years) 52.4 ± 7.6 50.4 ± 12.5a
Body mass index (kg/m2) 26.7 ± 3.0 25.9 ± 4.3a
Total cholesterol 6.9 ± 1.4 6.1 ± 1.2b
Systolic blood pressure 135 ± 14 133 ± 21
Diastolic blood pressure 81 ± 8 83 ± 11a
Sex (%  male) 85 46b
Smoking (%  yes) 24 33
Alcohol (%  yes) 84 75
Fasting tHcy (—mol/L)c 14.3 (13.5-15.2) 13.1 (12.7-13.4)b
Postload tHcy (—mol/L)c 41.5 (39.0-44.1) 40.1 (39.0-41.2)
a P<0.05' b 3 ^ .0 1
c age and sex adjusted geometric mean (95%CI)
Statistics
Fasting and post methionine load tHcy, vitamin B12 and serum and erythrocyte folate 
concentrations were log-transformed prior to all statistical analyses to obtain 
normally distributed data. Geometric mean concentrations of fasting and postload 
tHcy, vitamin B12 and folate were compared among genotypes. Vitamin B12 and folate 
values were available only for the subgroup of controls from the Hague. Since age 
and sex are important determinants of tHcy and B-vitamin levels, mean 
concentrations were adjusted for age and sex using generalized linear models. Tests 
for trend were performed using linear regression analysis. All reported 3-values are 
for two-tailed tests, with a = 0.05.
Pearson's chi-square test was used to determine whether the study population was 
in Hardy-Weinberg equilibrium and to study whether the frequency of the MS 
2756AoG genotypes differed between cases and controls. We used logistic 
regression analysis to calculate odds ratios and 95% confidence intervals for subjects
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with the GG or the AG genotype, taking subjects with the AA genotype as a 
reference group.
For a summary quantitative risk assessment of the MS 2756AoG polymorphism in 
CHD, we evaluated 4 international case-control studies [114-117], plus the present 
one. We confined the analysis to case-controls studies on coronary artery disease or 
myocardial infarction, in which the MS 2756AoG genotype distributions among both 
CHD cases and controls were either given, or could be calculated from the data. We 
calculated the MS 2756AoG genotype distribution and ORs of CHD for the GG and 
AG genotype compared with the AA genotype in each study separately, and for all 
studies combined with adjustment for study.
All data-analyses were performed with SAS for PC, version 6.12 (SAS institute Inc., 
Cary, North Carolina, USA).
Results
Characteristics of cases and controls are shown in Table 1. In the case group, mean 
age, body mass index, total cholesterol, and fasting tHcy were significantly higher, 
and diastolic blood pressure lower compared with the control group. Among cases 
there were also significantly more males compared with controls.
Table 2. tHcy concentrations within MS 2756A oG  genotypes in cases and controls 
combined
____________________________ 2756AoG genotype____________________________  3
AA (n=457)____________ AG (n=185)_____________ GG (n=21) trend
Fasting tHcy (—mol/L)a 13.4 (13.0-13.8) 13.1 (12.5-13.7) 14.1 (12.4-16.0) 0.84 
Postload tHcy (—mol/L)a 40.4 (39.3-41.6) 40.3 (38.4-42.2) 42.4 (37.0-48.7) 0.78
a age and sex adjusted geometric means (95%CI)
Table 2 shows age- and sex-adjusted geometric mean fasting and post methionine 
load tHcy concentrations in the three MS 2756AoG genotype groups. Since there 
were no differences in associations between cases and controls (data not shown) we 
combined both groups to increase statistical power. There were no significant 
differences in fasting or postload tHcy concentrations between genotypes; a trend 
test was also not significant (3=0.84 and 3=0.78, respectively).
Table 3 shows vitamin B12 and folate concentrations for the subgroup of controls for 
which these data were available. Individuals with the GG genotype had ~30% lower 
serum vitamin B12 levels than individuals with the AA or AG genotype. This was also 
reflected by a trend of decreasing vitamin B12 concentrations with increasing number 
of G alleles (3=0.06). Mean concentrations of serum folate were not statistically 
significantly different between MS 2756AoG genotypes, although there was a trend 
of increasing folate concentrations with increasing number of G alleles (3=0.08).
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Table 3. B-vitamin concentrations within 2756A oG  genotypes in a subgroup of controls
2756AoG genotype 3  trend
AA (n=318) AG (n=113) GG (n=9)
Serum vitamin Bi2 (pmol/L)a 
Serum folate (nmol/L)a 
Erythrocyte folate (nmol/L)a
225 (214-236) 
12.7 (12.0-13.4) 
904 (859-951)
217 (201-236) 
13.6 (12.4-14.9) 
922 (847-1004)
152 (114-201)b 
15.6 (11.3-21.6) 
759 (568-1015)
0.06
0.08
0.80
a age and sex adjusted geometric means (95%CI) 
b GG versus AA and AG, P<0.05
Mean concentrations of erythrocyte folate were not significantly different between 
genotypes, nor showed a trend over the genotypes (3=0.80). Adjusting these 
analyses for CHD risk factors did not change the results (data not shown).
The distribution of the MS 2756AoG genotypes among cases and controls is shown 
in the left part of in Table 4. The genotype distribution was in Hardy Weinberg 
equilibrium in controls (%2=0.55, 3=0.46), but not in cases (%2=4.2, 3=0.04). The 
genotype distribution was significantly different between cases and controls (%2=8.5, 
3=0.014). Crude analysis of the data showed that the GG genotype was associated 
with a 3.5-fold increase in risk of CHD compared with the AA genotype, whereas the 
AG genotype was not associated with CHD risk (Table 4, right part). Although 
confounding is not to be expected in this type of analyses, there can be a 
coincidental uneven distribution of CVD risk factors over the MS 2756AoG 
genotypes. Therefore, we adjusted our analyses for confounding by age, sex and 
other CHD risk factors. After adjustment for these factors, the OR for those with the 
GG genotype was 4.0 (95%CI 1.38-11.57), and there was a non-significant lower risk 
for those with the AG genotype (Table 4).
Table 4. Frequencies of MS 2756A o G  genotypes and ORs (9 5% C I) for CHD
Genotype Cases Controls ____________________________OR (95%CI)____________________________
n (% ) n (% ) Crude adjusted for adjusted for age, sex,
____________________________________________________________ age and sex and CHD risk factors3
2756AA 81 (65.9) 376 (69.6) 1 1 1
2756AG 33 (26.8) 152 (28.2) 1.0 (0.6-1.6) 0.8 (0.5-1.3) 0.7 (0.4-1.2)
2756GG__________ 9 (7.3) 12 (2.2) 3.5 (1.4-8.5) 3.3 (1.3-8.9) 4.0 (1.4-11.6)
a total cholesterol, systolic and diastolic blood pressure, current smoking and alcohol use
To summarize the available case-control data with respect to the MS 2756AoG 
polymorphism and CHD risk so far, we combined data of 5 studies, including our own 
data, in a meta-analysis. Study specific risk estimates are shown in Figure 1. There 
was significant heterogeneity between the results of individual studies for the risk 
associated with the GG genotype (%2=10.1, 3=0.04), but not for the risk associated 
with the AG genotype (%2=0.25, 3=0.99) The combination of all studies yielded a 
case group of 1174 individuals (789 AA, 352 AG and 33 GG) and a control group of
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1746 individuals (1196 AA, 501 AG, 49 GG). After adjustment for study, the 
combined odds ratio of CHD for the GG genotype was 0.99 (95%CI 0.60-1.65) and 
for the AG genotype 1.01 (95%CI 0.84-1.21), compared with the AA genotype.
Klerk et al. (present) 
Zhang et al. [117] 
Tsai et al. [114] 
Morita et al. [115] 
Chen et al. [116] 
Overall
1.01 3.48
1 11 1
1.16 1.41
1------- -■-------- 1
0.94 0.63
1 I 1
0.98 0.89
1 11 1
1.0 0.56
H ■—1 
1.01
1 ■ “ I
0.99
H H
0.1 10 0.1 10
OR for AG vs. AA OR for GG vs. AA
Figure 1. Meta-analysis with available case-control data with respect to the MS 2756A oG  
polymorphism and CHD risk, including overall result.
Discussion
In this Dutch case-control study with 123 cases and 540 controls, the MS 2756AoG 
polymorphism was not associated with fasting or post methionine load tHcy 
concentrations. However, individuals with the GG genotype had significantly lower 
vitamin B12 levels than individuals with the AA or AG genotype. The MS 2756GG 
genotype was significantly associated with a 4-fold increase in CHD risk, whereas the 
AG genotype was not associated with CHD risk.
Just like our study, several other studies did not show an association between the MS 
2756AoG polymorphism and tHcy concentrations [111, 115, 118-121]. Some 
studies, however, found that both fasting and post-methionine load tHcy 
concentration decreased with increasing number of G alleles [114, 116, 122-124]. In 
the present study, subjects with the GG genotype had significantly lower vitamin B12 
concentrations. This is striking, because it is not expected that a polymorphism of an 
enzyme would affect the level of its cofactor. Two other studies did not find any 
association between the MS 2756AoG polymorphism and vitamin B12 concentration
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[118] or methylmalonic acid, which is an indicator of vitamin B12 status [121]. But 
even if the low vitamin B12 concentrations found in GG subjects are just a 
coincidence, then vitamin B12 status could have confounded the association between 
the GG genotype and CHD risk, provided that low B12 status is related to increased 
CHD risk. We could not control for confounding by B12 status, as we had only 
information on vitamin B12 status in controls subjects. However, counfounding of this 
type is not likely since an inverse association between vitamin B12 and CHD risk was 
observed in only one observatinal study [125]. Other observational studies observed 
no association or even a positive association between plasma vitamin B12 and CHD 
risk [87, 126-129].
Mean levels of serum or erythrocyte folate were not significantly different among MS 
2756AoG genotypes. However, serum folate levels showed a slight positive trend 
with increasing G alleles. Two other studies showed that plasma folate 
concentrations increased with increasing G alleles [116, 130]. These results indicate 
that the MS 2756 AoG variant might cause some methyl-trapping, hence resulting in 
higher plasma folate concentrations.
The overall result of our meta-analysis indicated that neither the GG nor the AG 
genotype is associated with CHD risk. However, the overall OR for the GG genotype 
seems to be strongly influenced by the quite discrepant positive association that was 
found in our own study. The majority of the case-controls studies suggests that the 
MS 2756GG genotype has a protective rather than an adverse effect on CHD [114­
116].
The heterogeneity between studies might be explained by interaction between the 
MS 2756AoG polymorphism and vitamin B12, folate or other cardiovascular risk 
factors. Wang et al. [131] found that the MS 2756AoG variant enhanced the 
elevation in CHD risk related to smoking. A few other studies addressed possible 
interaction between the MS 2756AoG polymorphism and the polymorphisms of 
MTHFR on tHcy concentration and homocysteine-related diseases. None of these 
studies showed a clear interaction between these polymorphisms [115, 119, 123, 
124, 130]. Unfortunately, case-control studies in general are much to small to 
investigate possible effect modification.
In conclusion, in the present case-control study a strong positive association was 
found between the MS 2756GG genotype and CHD risk. In contrast, the majority of 
the other observational studies suggests that the MS 2756GG genotype has a 
protective rather than an adverse effect on CHD. Combining the results of available 
studies in a meta-analysis revealed that neither the AG and GG genotype are 
important risk factors for CHD. Therefore, we feel that larger case-control studies in 
different populations are needed to further elucidate the association between the MS 
2756GoG polymorphism and tHcy or CHD risk and to assess whether any 
association is modified by vitamin B12, folate status or other cardiovascular risk 
factors.
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Polymorphisms in the TC gene
Abstract
Background Hyperhomocysteinemia is an independent risk factor for cardiovascular 
disease (CVD). Intracellular vitamin B12 deficiency may lead to increased tHcy 
concentrations (tHcy) and because transcobalamin (TC) is the plasma transporter 
that delivers vitamin B12 to cells, genetic variation in the TC gene may affect 
intracellular vitamin B12 availability and, consequently, tHcy concentrations.
Methods We examined five sequence variants, i.e., I23V, G94S, P259R, S348F and 
R399Q, in the TC gene as possible determinants of tHcy and, concordantly, as 
possible risk factors for CVD in 190 vascular disease patients and 601 controls. We 
also studied potential effect-modification of vitamin B12 by genotype.
Results In individuals with high vitamin B12, 259PP individuals had lower tHcy 
concentrations than 259PR and 259RR individuals. Homozygous 23VV individuals had 
lower fasting tHcy concentrations than their 23IV and 23II peers. None of the 
genotypes defined by the three other sequence variants showed an association with 
tHcy concentrations, nor was any TC genotype associated with an increased CVD 
risk.
Conclusions In individuals in the highest quartile of the vitamin B12 distribution (>299 
pmol/L), tHcy concentrations are lower in 259PP homozygotes than in 259PR and 
259RR individuals. Therefore, 259PP individuals, who represent >25% of the general 
population, may be more susceptible to reduction of plasma tHcy concentrations by 
increasing the vitamin B12 status.
Introduction
Molecular defects in genes encoding enzymes involved in homocysteine metabolism 
may account for hyperhomocysteinemia, an independent and graded risk factor for 
cardiovascular disease (CVD) [26, 91]. Homocysteine can either be catabolized in the 
transsulfuration pathway to cysteine or be remethylated to methionine by methionine 
synthase (MS). MS requires vitamin B12 as a cofactor to transfer the methyl group of 
5-methyltetrahydrofolate via vitamin B12 to homocysteine. Intracellular vitamin B12 
availability may therefore influence plasma total homocysteine (tHcy) concentrations. 
Low vitamin B12 concentrations in the cell can be the result of a low vitamin B12 
intake, but they can also be attributable to a disturbance in the absorption, transport 
or cellular uptake of this vitamin. Transcobalamin (TC) is the transporter of vitamin 
B12 in the circulation and delivers vitamin B12 to the cells [11]. After binding by 
haptocorrin (HC) in the stomach and intrinsic factor (IF) in the duodenum, vitamin 
B12 is transferred to TC within the enterocyte and released into the blood. 
Subsequently, the vitamin B12-TC complex is taken up by receptor mediated 
endocytosis via the receptor TC-R [11]. Variations in the TC protein could affect the 
binding characteristics of vitamin B12 to TC or recognition of the vitamin B12-TC 
complex by TC-R, with possible repercussions on vitamin B12 availability in the cells. 
Therefore, genetic variation in the TC gene may produce altered plasma tHcy 
concentrations and CVD risk.
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The TC gene has been mapped to chromosome 22, between bands 22q12 and 22q13 
[132], and encodes a polypeptide of 43-45 kDa [133]. The TC gene spans ~20 kb 
and contains nine exons and eight introns [132], and shows considerable 
heterogeneity [132, 134-137]. Li et al. [134] described four sequence variants of the 
human TC gene: M198T, I219L, P259R, and S376L. In 1994 Li et al. [135] published 
an additional polymorphic site at position 234 (QoR). Subsequently, a substitution of 
isoleucine by valine at codon 23 was reported [132]. Both mammalian IF and TC I 
(one of the forms of HC), two other vitamin B12 transporting proteins, are highly 
homologous in their amino acid sequence to TC (33% overall and up to 80% in 
certain, mostly hydrophobic, regions) [134].
Very recently, Namour et al. [138] reported that the blood apo-TC (the proportion of 
TC that does not contain vitamin B12) concentration of 259PP homozygotes was 
significantly higher than that of homozygous 259RR and heterozygous individuals. In 
addition, heterozygotes had higher tHcy concentrations compared with both 
homozygous genotypes.
In the present study, we examined five sequence variants in the TC gene, which 
were found by sequencing analyses [139], as possible genetic determinants of 
plasma tHcy concentration and, concordantly, as possible genetic risk factors for CVD 
in 190 vascular disease patients and in 601 apparently healthy subjects.
Materials and Methods
Patients and Controls
We studied 190 patients with coronary, peripheral or cerebral vascular disease, of 
whom 130 cases were recruited from a cohort of patients who underwent coronary 
angiography in the Zuiderziekenhuis Hospital in Rotterdam, The Netherlands [28]. 
The other 60 patients had documented premature CVD: 10 had experienced a 
myocardial infarction, 32 had been diagnosed with cerebral arterial occlusive disease, 
and 18 had been diagnosed with peripheral arterial occlusive disease [70]. The 
control group consisted of 601 controls, of whom 101 were included from the general 
population in Rotterdam [28] and 500 were recruited from a general practice in The 
Hague, The Netherlands [94]. The protocol was approved by the local ethics 
committee, and written informed consent was obtained from each individual.
tHcy and vitamin B12 analyses
All cardiovascular disease patients and controls underwent a standardized oral 
methionine loading test (0.1 g L-methionine/kg of body weight) [96]. Plasma tHcy 
was measured by reversed-phase separation HPLC with fluorescence detection, as 
described by Te Poele-Pothoff et al. [97]. All tHcy measurements were conducted in 
our laboratory at the University Medical Center Nijmegen, The Netherlands. Fasting 
and postload plasma tHcy concentrations were obtained from 675 and 650 
individuals, respectively. Vitamin B12 concentrations were measured with the
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Dualcount SPNB (solid-phase, no boil) radioassay (Diagnostic Product Corporation) in 
samples stored at -700C. Vitamin B12 concentrations were available for some of the 
control group (n=500).
Statistics
The distributions of plasma tHcy and vitamin B12 concentrations showed positive 
skewness; therefore, natural log-transformed tHcy and vitamin B12 values were used 
in all statistical analyses. Differences between patient and control groups were tested 
with the Student's t test for continuous variables and the Pearson's chi-square test 
for dichotomous frequency measures. P values were derived from age- and sex- 
adjusted linear regression models. Age- and sex-adjusted odds ratios (ORs) and 95% 
confidence intervals (95% CIs) were calculated by logistic regression analysis to 
estimate the relative risk of CVD associated with the different genotypes. One-way 
ANOVA was used to assess the differences in continuous variables between different 
genotypes, followed by Bonferroni-corrected W-tests. In addition, we calculated 
Pearson correlation coefficients for the correlation between vitamin B12 and plasma 
tHcy. All reported P values are two-tailed, and P<0.05 was considered statistically 
significant.
The haplotype frequencies and linkage disequilibrium were estimated by the EH 
program [140]. The extent of the linkage disequilibrium (D') is reported as the ratio 
between the actual value of D, and the maximum value it could have for the given 
allele frequencies, where D is the departure from linkage disequilibrium. The sign in 
front of the coefficients indicates whether the rare alleles are associated (+) or 
whether the rare allele at locus one is associated with the most common allele at the 
other locus (-).
Mutation detection
In our ongoing effort to dissect the molecular basis of hyperhomocysteinemia, we 
analyzed the coding region of the TC gene in 12 females [139]. Of those 12 females, 
8 were selected on the basis of their low holo-TC concentrations and low holo- 
TC/total-TC ratio: 7 were mothers who had given birth to a child with a neural tube 
defect and 1 was a control. The remaining four females included one mother who 
had a child with a neural tube defect and three female controls, all with high holo-TC 
concentrations. Using DNA sequencing analyses with intron-based oligonucleotides 
we found five variants: I23V (67AoG; exon 2), G94S (280GoA; exon 3), P259R 
(776CoG; exon 6), S348F (1043CoT; exon 7), and R399Q (1196GoA; exon 8; 
Table 1). We also examined whether the Q234R variant [135] was present in a 
portion of our study population (161 cases and 100 controls; Table 1). Restriction 
fragment length polymorphism (RFLP) analyses were used to determine the 
genotypes defined by these six TC variants; PCR primers and conditions are 
described in Afman et al. [139]. We obtained a complete set of genetic data for 596 
individuals.
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Table 1. Sequence variants in the transcobalamin gene
DNA variant Amino acid 
Substitution
Location Screening Method Allele frequency 
mutant allele (% )a
67AoG
_o>
3
ÍNI-H Exon 2 RFLP +RsäI 12.6%
280GoA G94S Exon 3 RFLP +A/ZNI 0.8%
701AoG Q234Rc Exon 5 RFLP +Mspl not found
776CoG P259Rc Exon 6 RFLP -BstNl 46.9%
1043CoT S348F Exon 7 RFLP-PIRA'i -EspI 11.1%
1196GoA R399Q Exon 8 RFLP -BsmAl 2.0%
a patients and controls combined 
b Li et al. [132] 
c Li et al. [135]
d PIRA, primer-introduced restriction analysis
Results
The main characteristics of the patient and the control group are shown in Table 2. 
The percentage of males was higher among patients than controls (P<0.001). Mean 
age did not differ between both groups. The patient group had a significantly higher 
geometric mean fasting tHcy level (3=0.005); postload tHcy also tended to be higher 
in patients (3=0.10). Unfortunately, creatinine and folate concentrations were not 
available; therefore, we could not adjust for them.
Table 2. Characteristicsa of cardiovascular disease patients and controls
Cases
(n=190)
Controls
(n=601)
P
Age (years) 49.0 ± 10.2 50.6 ± 12.7 0.11b
Sex (%  male) 75.3 47.1 <0.001c
Fasting tHcy (—mol/L) 14.4 (13.7-15.0) 13.1 (12.7-15.1) 0.005d
Post-load tHcy (—mol/L) 41.1 (39.7-43.2) 40.1 (39.1-41.1) 0. o Q
.
a Age is expressed as mean ± SD and tHcy is expressed as geometric mean (95% CI) 
b Student's t test 
c Pearson %2 test 
d Adjusted for age and sex
We examined the coding region of the TC gene for possible genetic variation by 
sequencing analysis [139] and found five possibly functional variants (Table 1). 
These five variants all led to an amino acid substitution, with possible impact on TC 
function. To assess the effects on plasma tHcy and vitamin B12 levels and their 
potential contribution to CVD risk, we analyzed samples from 191 CVD patients and 
601 controls. We also examined a portion of our study population (161 cases and
100 controls) for the Q234R variant [135], but did not find it. Genotype distributions 
for all sequence variations were in Hardy-Weinberg equilibrium in both controls and 
patients. The allele frequencies for the five genetic variants were very divergent, 
varying from 0.8% to 46.9% (Table 1). Allele frequencies and genotype distributions 
for all five variants did not differ between cases and controls (Table 3). Thus, none
56
Polymorphisms in the TC gene
of the genotypes defined by the sequence variants was associated with an increased 
risk for CVD.
Because separate analysis of the relationships between TC genotypes and tHcy in 
patients and in controls produced the same results (data not shown), we combined 
both groups to increase statistical power. Homozygous 23VV individuals (n=6) had 
lower fasting tHcy concentrations than their 23IV (n=153) and 23II (n=507) peers 
(3=0.05 and 3=0.07 respectively; Figure 1). None of the genotypes defined by the 
other variants showed an association with fasting or postload tHcy or vitamin B12 
concentrations.
Table 3. Prevalence and ORs (95%  CI) for CVD risk according to TC  polymorphisms in 
patients and controls
Genotype Controls, n (%) Patients, n (%) ORa 95% CI 3 b
23II 388 (75.3) 127 (77.0) 1b 0.37
23IV 121 (23.5) 38 (23.0) 0.87 0.57-1.34
23VV 6(1-2) NOd
94GG 498 (98.4) 179 (98.4) 1b 0.95
94GS 8 (1.6) 3 (1.6) 0.85 0.22-3.33
94SS NO NO
259PP 141 (27.0) 49 (27.1) 1b 0.77
259PR 276 (52.8) 91 (50.3) 0.94 0.62-1.42
259RR 106 (20.2) 41 (22.6) 1.04 0.81-1.33
348SS 409 (78.8) 134 (77.5) 1b 0.36
348SF 105 (20.2) 39 (22.5) 1.03 0.67-1.58
348FF 5(1.0) NO
399RR 497 (96.1) 164 (95.3) 1b 0.65
399RQ 20 (3.9) 8 (4.7) 1.12 0.47-2.64
399QQ NO NO -
a ORs are adjusted for age and sex 
b x2 test
c reference category 
d NO,not observed
To examine the effect of having more than one variation in the TC gene, we 
combined different genotypes to generate composite genotypes. As described above, 
it appeared that individuals homozygous for the I23V variant had low plasma tHcy 
concentrations. Individuals who were also heterozygous for the P259R variant had 
even lower tHcy concentrations; the three individuals with the 23VV/259PR genotype 
had a geometric mean tHcy concentration of 7.4 (95% CI 3.4-15.8) —mol/L (Table 
4)-
We also assessed potential gene-environment interactions by subdividing a portion of 
the control group (n=500; see Materials and Methods) into quartiles according to 
vitamin B12 status. This stratification showed a significantly lower tHcy concentration
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in 259PP homozygotes (geometric mean, 10.9 —mol/L; n=49) compared with 259PR 
(12.7 —mol/L; n=82) and 259RR (12.6 —mol/L; n=36) individuals (ANOVA, 3=0.010; 
Bonferroni corrected W-test, 3=0.012 and 3=0.063, respectively; Figure 2) in the 
fourth quartile of the serum vitamin B12 distribution (>299 pmol/L). We subsequently 
calculated the correlation coefficients between vitamin B12 and plasma tHcy for each 
259PoR genotype. In both the 259PP homozygotes and the 259PR heterozygotes, 
we observed a clear negative correlation between vitamin B12 and tHcy (r = -0.39 
and -0.30, respectively; both 3<0.001), whereas this correlation was absent in 
259RR individuals (r = -0.07; 3=0.5).
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Figure 1. Relationship between TC  genotypes and fasting tHcy in the entire study 
population. Values in parentheses indicate the number of individuals in each genotype 
group.
On the basis of the three most frequent polymorphisms, i.e., I23V, P259R and 
S348F, we constructed TC haplotypes and calculated their relative frequencies with 
the EH program [140] (Table 5). The allele frequencies of the other two TC variants 
were very low and were therefore omitted. The two most common haplotypes, A and 
C, accounted for >80% of all the chromosomes defined by these three 
polymorphisms (Table 5). We found no differences in haplotype frequencies between 
cases and controls (data not shown).
In addition, we calculated linkage disequilibrium coefficients (D') between these 
variants. A high degree of linkage disequilibrium was observed between the three
ANOVA 3=0.054
(6)
(507) 
§
(153)
<>
ANOVA 3=0.69
(11)
(663)
* <>
ANOVA 3=0.98
( 187) (358) ( 144) 
1  * \
ANOVA 3=0.95
(553) (14 0) 
!
(5)
ANOVA 3=0.81
(27)
(648)
§
V  V V  GG G S PP PR RR S S  S F  FF RR RQ
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most common polymorphisms; D' were -0.42 between the I23V and P259R variants, 
-0.97 between the P259R and S348F variants, and 0.97 between the I23V and S348F 
variants (all 3<0.001).
Table 4. Relationshipa between I23V and P259R TC  composite genotypes and fasting tHcyb
Genotype 23II 23IV 23VV
259PP 13.3 (12.5-14.0) 13.2 (12.0-14.4) 11.8 (2.8-395)
(n=120) (n=57) (n=2)
259PR 13.3 (12.8-13.7) 13.4 (12.3-14.6) 7.4 (3.4-15.8)c
(n=260) (n=74) (n=3)
259RR 13.1 (12.4-13.8) 13.6 (11.8-15.7) not observed
(n=116) (n=19)
a Overall ANOVA, 3=0.016 
b expressed as geometric mean (95%CI) in —mol/L
c 3<0.05 vs 23II/259PP, 23IV/259PP, 23II/259PR, 23IV/259PR, 23II/259RR, 23IV/259RR (Bonferroni corrected W-test)
Discussion
Using an exon-based DNA sequencing stategy we examined the TC gene for possible 
genetic variants and found five [139]: I23V (67AoG; exon 2), G94S (280GoA; exon 
3), P259R (776CoG; exon 6), S348F (1043CoT; exon 7), and R399Q (1196GoA; 
exon 8; Table 1). We also loooked for the Q234R variant, reported previously by Li et 
al. [135], but did not find this TC variant in our study population. None of the five 
variants affected vitamin B12 concentrations, nor was one of the five sequence 
variants associated with CVD risk. The six 23VV individuals had lower tHcy 
concentrations compared with those with the 23IV and 23II genotypes; 23VV 
subjects who were also heterozygous for the P259R substitution had even lower tHcy 
concentrations (Table 4); but this subset consisted of only three individuals. The 
259PP homozygotes had decreased tHcy concentrations compared with 259PR and 
259RR individuals when vitamin B12 concentrations were in the highest quartile of the 
distribution (>299 pmol/L; Figure 2).
Genetic variations in the TC gene may influence the transport of vitamin B12 to the 
cells by altering the vitamin B12 binding site or impairing recognition by TC-R. 
Because vitamin B12 is crucial in the transfer of the methyl group of 5- 
methyltetrahydrofolate to homocysteine, decreased intracellular concentrations could 
lead to an increase in plasma tHcy. Unfortunately, holo-TC and total-TC 
concentrations were not measured in the current study population; we could 
therefore not assess the potential influence of TC variants on vitamin B12 binding. 
When we stratified a portion of the control group (n=500) into quartiles according to 
their vitamin B12 status, we found that 259 PP homozygotes in the fourth quartile for 
serum vitamin B12 (>299 pmol/L) had a lower tHcy concentration than 259PR and 
259RR individuals. These data indicate that 259PP individuals in particular benefit 
from high vitamin B12 concentrations with respect to tHcy lowering, in contrast to 
their 259PR and 259RR peers, and suggest a gene-environment interaction between
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<174.9 (Q1) 174.9-229.2 (Q2) 229.2-299.0 (Q3) >299.0 (Q4)
Figure 2. Association between the P259R genotype and fasting tHcy after stratification for 
vitamin Bi2 concentrations (quartiles, Q1-Q4). Vitamin Bi2 concentrations are in pmol/L. 
Values in parentheses indicate the number of individuals in each genotype group. Values 
above brackets in Q4 are P  values; * indicates statistical significance.
this TC variant and vitamin B12. We therefore also investigated whether the P259R 
genotype influences the slope of the curve relating plasma tHcy and vitamin B12 by 
calculating the correlation coefficient between these two variables for each P259R 
genotype group separately. We observed a clear negative correlation between 
vitamin B12 and plasma tHcy in 259PP individuals as well as in 259PR heterozygotes, 
whereas individuals with the 259RR genotype demonstrated no such association. The 
259P allele thus may affect TC transcription or the binding and transport of vitamin 
B12 by TC, with positive repercussions on availability of vitamin B12 in the cell. This 
raises the interesting hypothesis that more than one fourth of the general population 
has a TC genotype that significantly increases susceptibility to tHcy-lowering 
intervention by vitamin B12.
Our results correspond well with the data of Namour and coworkers [137, 138], who 
were the first to report an association between the P259R variant and vitamin B12 
and apo-TC concentrations in a small group of 39 healthy Caucasians [137]. They 
reported that the P259R variant affects the serum concentrations of both apo-TC and
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vitamin B12; compared with the 259RR homozygotes, 259PP homozygotes showed 
1.7- and 1.4-fold higher serum apo-TC and vitamin B12 serum concentrations, 
respectively. This group was unable to reproduce their results showing an association 
between the 259PP genotype and increased vitamin B12 in a somewhat larger study 
that included 159 healthy Caucasions, but they did find, similar to their previous 
results, a 1.4-fold higher apo-TC concentration in 259PP homozygotes compared with 
259RR homozygotes [138].
Table 5. Main haplotype frequencies of the TC  gene and their relative frequencies
Haplotype I23V
Polymorphism
P259R S348F Relative frequency
A I P S 0.416
B I P F 0.029
C I R S 0.433
D I R F <0.001
E V P S 0.005
F V P F 0.082
G V R S 0.033
H V R F 0.001
Very recently, we measured the plasma concentrations of total vitamin B12, tHcy, and 
the apo and holo forms of TC and HC in 46 mothers who had delivered a child with a 
neural tube defect and in 73 female controls [141]. We observed that tHcy 
concentrations were significantly higher among individuals with low holo-TC and total 
vitamin B12 concentrations and low holo-TC/total-TC ratios. It appears that these low 
holo-TC concentrations were not attributable to low plasma vitamin B12, but were 
likely the result of reduced binding of vitamin B12 to TC because we observed no 
correlation between holo-TC and vitamin B12 concentrations when the holo-TC 
concentration was below the 50th percentile [141]. These low holo-TC/total-TC ratios 
may be explained by the reduced affinity of TC for vitamin B12, possibly attributable 
to allelic heterogeneity in the TC gene. In another study, we found both lower holo- 
TC and a lower holo-TC/total-TC ratio in 259PR and 259RR individuals compared with 
259PP individuals [139]. This suggests that the 259P protein has an increased affinity 
for vitamin B12 and consequently can influence tHcy.
In conclusion, in individuals in the highest quartile of vitamin B12 distribution (>299 
pmol/L), the tHcy concentration was lower in 259PP homozygotes compared with 
259PR and 259RR individuals. We plan to elucidate the exact mechanism for this 
observation in future studies. The 259P allele probably is associated with increased 
vitamin B12 binding or transport ability of TC, which is in line with other of our data 
[139, 141]. Therefore, individuals with the 259PP genotype, a group that constitutes 
>25% of the general population, may be more susceptible to reduction of plasma 
tHcy concentrations by increasing the vitamin B12 status.
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Genomic sequencing of BHMT
Abstract
Elevated tHcy levels have been associated with arteriosclerosis and thrombosis. 
Hyperhomocysteinemia is caused by altered functioning of enzymes of its metabolism 
due to either inherited or acquired factors. Betaine-homocysteine methyltransferase 
(BHMT) serves, next to methionine synthase, as a facilitator of methyl group 
donation for remethylation of homocysteine into methionine, and reduced 
functioning of BHMT could theoretically result in elevated tHcy levels. Recently, the 
genomic sequence of the BHMT gene was published. Mutation analysis may reveal 
mutations of the BHMT gene that could lead to hyperhomocysteinemia. In the 
present study we performed genomic sequencing of the BHMT gene of 16 vascular 
patients with hyperhomocysteinemia and detected three mutations in the coding 
region of this gene. The first was an amino acid substitution of glycine to serine 
(G199S), which was found only in the heterozygous state. The second mutation was 
a substitution of glutamine to arginine (Q239R), and the last mutation was an amino 
acid substitution of glutamine to histidine (Q406H). The latter was also found only in 
the heterozygous state. The relevance of these mutations was tested in a study 
group, which consists of 190 cases with vascular disease and 601 controls. The 
influence of these three mutations on tHcy levels was investigated. None of the three 
mutations led to significantly changed tHcy levels. In addition, no differences in 
genotype distribution between cases and controls were found. So far, our results 
provide no evidence for a role of defective BHMT functioning in 
hyperhomocysteinemia or subsequently in vascular disease.
Introduction
Hyperhomocysteinemia is caused by a combination of genetic and nutritional 
disturbances. Homocysteine may accumulate due to altered functioning of the 
remethylation pathways, but also from a defect in the transsulphuration pathway due 
to defective functioning of cystathionine ß-synthase (CBS) (Figure 1). 
Hyperhomocysteinemia can be classified into two forms, severe and mild 
hyperhomocysteinemia. Patients with severe hyperhomocysteinemia (tHcy >50 
—mol/L) due to deficiency of methylenetetrahydrofolate reductase (MTHFR), 
methionine synthase (MS) or CBS (Figure 1) often suffer from vascular disease. Mild 
hyperhomocysteinemia has also been associated with vascular disease [21, 30]. 
Recently, a common mutation in the MTHFR gene (677CoT) has been found, 
leading to mildly elevated tHcy levels. This mutation, however, can only explain the 
observed increased tHcy levels in some cases [69, 79]. Therefore, deficiencies of 
other enzymes of methionine/homocysteine metabolism are expected to contribute 
to hyperhomocysteinemia. Genes coding for CBS and methionine synthase (MS) have 
been investigated, but whether mutations in these genes lead to mild 
hyperhomocysteinemia remains questionable [18, 27, 111, 123].
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Methylated product Methylacceptor
Cysteine
Choline --------->- Betaine aldehyde Sarcosine ---------► Glycine
Figure 1. Simplified scheme of methionine/homocysteine metabolism. Main regulating 
enzymes are depicted and cofactors are encircled; BHMT, betaine-homocystine 
methyltransferase; CBS, cystathionine ß-synthase; MTHFR, methylenetetrahydrofolate 
reductase; MS, methionine synthase; MTRR, methionine synthase reductase; SAM, S- 
adenosylmethionine and SAH, S-adenosylhomocysteine; 1, transsulfuration; 2, 
remethylation.
Betaine-homocysteine methyltransferase (BHMT; EC 2.1.1.5) is the enzyme, along 
with methionine synthase, which remethylates homocysteine to methionine. Altered 
functioning of BHMT may result in elevated tHcy levels and could therefore 
contribute to the risk for vascular disease. BHMT is also involved in choline 
metabolism, where it converts betaine into dimethylglycine, which is then transferred 
to sarcosine to form glycine (Figure 1) [142]. BHMT is primarily expressed in liver 
and kidney. In liver, BHMT is responsible for 50% of homocysteine remethylation. 
Oral betaine supplementation lowers tHcy concentrations in severe 
hyperhomocysteinemic patients, but this effect is poorly studied in other forms of 
hyperhomocysteinemia [143]. This tHcy lowering effect of betaine is accomplished 
via two pathways [144]. First, via donation of methyl groups for direct remethylation 
of homocysteine to methionine by BHMT. Secondly, the oxidation of dimethylglycine 
to glycine introduces one-carbon units into the folate pool that will stimulate the 
folate-dependent homocysteine remethylation, resulting in decreased tHcy levels. 
Recently, it was indicated that BHMT is a zinc metalloenzyme [145, 146]. Cysteine 
residues of BHMT protein function as zinc-binding domains, which in turn are
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required for the binding of homocysteine to BHMT. Replacement of three highly 
conserved cysteine residues with either alanine or serine resulted in complete loss of 
activity [145]. These results suggest that mutated BHMT may lead to decreased 
binding of homocysteine to BHMT, resulting in accumulated tHcy levels.
Enzymatic measurement of BHMT activity cannot be performed in fibroblasts or 
lymphocytes, which explains in part why defects of BHMT have not been observed 
previously. Molecular analysis enables screening for BHMT defects and could answer 
the question; is mutated BHMT involved in hyperhomocysteinemia and subsequently 
in vascular disease? Recently, the gene coding for betaine-homocysteine 
methyltransferase has been cloned [144, 147, 148]. The BHMT gene has been 
localized to chromosome 5q13.1-q15 and consists of 8 exons and 7 introns. In the 
present study, we report the molecular genetic analysis of the BHMT gene and 
investigate the influence of the three mutations discovered in this gene on 
homocysteine metabolism in a study group of 190 vascular cases and 601 controls.
Table 1. Characteristics o f study group
Cases (n=190) 
Mean (95% CI)
Controls (n=601) 
mean (95% CI)
P value
Age (years) 49.0 (47.5-50.4) 50.6 (49.5-51.6) 0.08
Gender (% male) 75.3 47.1 < 0.001
Fasting tHcy (—mol/l)a 14.3 (13.7-15.0) 13.1 (12.7-13.4) 0.005b
Post-load tHcy (—mol/l)a 41.3 (39.1-43.2) 40.0 (39.1-41.1) 0.10b
a geometric mean
b adjusted for age and gender differences
Materials and Methods
Patientmaterial
A patient group, with diagnosed vascular disease and mildly elevated tHcy levels, 
was preselected according to availability of fibroblasts. This enabled the use of this 
patient group for different strategies of mutation analysis. In total 16 patients were 
selected and their material was used for genomic sequencing. Fibroblasts were 
cultured according to standard procedures and DNA was isolated with the Puregene 
DNA extraction kit (Biozym, The Netherlands), essentially as indicated by the 
manufacturer. To investigate whether mutations of the BHMT gene lead to elevated 
tHcy levels and may therefore contribute to the risk for vascular disease, we used a 
second group of cases and a large group of controls, which we will call the study 
group (Table 1). One part consists of 130 cases with severe coronary occlusions and
101 population-based controls as described by Verhoef et al. [104]. Another group of 
60 cases with documented premature cardiovascular disease as described by 
Kluijtmans et al., was also used [70]. Furthermore, we used 500 additional controls, 
which were recruited from a general practice in The Hague, The Netherlands [94].
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Finally, 13 patients with severe hyperhomocysteinemia (tHcy >100 —mol/L) were also 
screened for the three mutations.
tHcymeasurements
tHcy concentrations were measured in EDTA plasma after an overnight fast and 6 
hours after a methionine load [97]. The tHcy values of cases and controls described 
by Verhoef et al. [104] were remeasured at our laboratory in order to make a proper 
comparison with other tHcy values of the study group.
Table 2. Primer sequences used for molecular analysis of the BHMT gene
Primer Sequence (5' o  3')a Tm (°C) Product size (bp)
1 for gggctcgcctagtcggtc 58 1 CO CO
1 rev cggcagggtccgagggc
2 for cctccctcatctgtaattttag 51 226
2 rev gctgggattacaggcatgag
3 for tcctgcttgtttatctgagagcc 58 304
3 rev caaactctgaagaggttgaaccc
4 for tagatgtgaatgtttgaataataat 55 300
4 rev tttatctttcaccacatctttc
5 for agtactctaaccttaactgattccag 47 235
5 rev ggcactagtgtgttcttttaag
6 for tgccctgctggtttctgg 50 313
6 rev ggtatagatttacttgagtttatatg
7 for ctacttgtagctacttatcttg 50 347
7 rev ctaatcataaattagtttggg
8 for gagtctgttgtctggtgtcatg 47 270
8 rev gtgacccaaacacctagaattc
MB-PCRb for CTTGACCCCACCATTAG 59 011
MB-PCRb rev CAGGAGT GT GGTAAGCC
MB-WTc GCGACGGCT GCCGACTGAGTCGC 59
MB-MUTc GCGACAGGCT GCCAACTGAGTCGC
8 revd PIRA CATCAAAAATAGCTTCTAT CGAGGGT 58 248
a Exonic sequences are indicated by uppercase and intronic sequences are indicated by lowercase 
b Used for PCR in molecular beacon analysis to screen for the 716GoA polymorphism 
c Molecular beacons which hybridize to wildtype (WT) or mutant (MUT) alleles, 716 G or A is indicated in bold 
d Used for screening of the 1218GoT mutation with PCR-PIRA, altered nucleotide is depicted in bold
Molecularanalysis
Molecular analysis was performed by genomic sequencing of the different exons. 
Intronic primers were developed based on the published genomic sequence 
(Genbank accession number AF118371, Table 2 and Figure 2).
PCR of the different exons was carried out in a total volume of 50 —l on a Perkin- 
Elmer 9600 thermocycler (PE Biosystems, The Netherlands), containing 50 ng of the 
forward and reverse primers (Table 2), 200 —M dNTPs, 10 mM Tris-HCl buffer (pH 
8.3), 1.0 mM MgCl2 and 0.5 unit Taq polymerase (all from Life Technologies, The 
Netherlands). PCR parameters were as follows: 92°C/120s (initial denaturation)
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followed by 35 cycles of 92°C/30s (denaturation), 47-58°C/30s (annealing), 
72°C/30s (elongation) followed by a final elongation step of 7 minutes at 72°C. The 
obtained PCR products were separated on a 2% agarose gel and subsequently 
sequenced on the ABI Prism 377 automated sequencer using the ABI Prism BigDye 
Terminator cycle sequencing kit according to the instructions of the manufacturer 
(PE Biosystems, The Netherlands).
To determine whether mutations of the BHMT gene lead to elevated tHcy levels and 
therefore are possible risk factors for vascular disease, a detection method was 
developed to screen for these mutations in the total study group. The first mutation 
in the BHMT gene, the 595GoA mutation was screened using restriction enzyme 
analysis. This mutation, which is present in exon 5 of the BHMT gene, resulted in an 
abolishment of a NcH restriction site. A 235 bp region containing exon 5 was 
amplified using PCR with exon 5 for en rev primers (Table 2). NciI digestion of wild­
type sequence (595 AA) then leads to two fragments of 143 and 92 bp, respectively. 
The products were analyzed on a 2% agarose gel. The second mutation, which was 
found in exon 6 of the BHMT gene did not lead to a formation or abolishment of a 
restriction site. To screen for this mutation we first tried primer-introduced restriction 
analysis (PCR-PIRA) but the results were not satisfactory. Subsequently, we decided 
to use molecular beacons for the detection of this mutation [149, 150]. Two new 
primers were developed, which created 110 bp PCR products (Table 2). Two 
molecular beacons were designed, one to detect the G allele (MB-WT) and one that 
detects the A allele (MB-MUT). PCR was carried out in a total volume of 50 —l 
containing 50 ng of the forward and reverse primers, 150 ng of the wild-type TET 
beacon and 250 ng of the mutant HEX beacon, 200 —m dNTPs, 10 mM Taq gold 
amplification buffer, 4 mM MgCl2 and 1.5 unit of AmpliTaq Gold (PE Biosystems ,The 
Netherlands). PCR conditions were as follows: cycling was preceded by 10 min. 95°C 
(activation AmpliTaq Gold) followed by 40 cycles of 95°C/30s (denaturation), 
59°C/30s (annealing) and 72°C/30s (elongation). PCR was performed on the ABI- 
Prism 7700 (PE Biosystems, The Netherlands) and fluorescence was measured during 
the second step of stage 2 (annealing). Results were analyzed by Sequence 
Detection System software (PE Biosystems, The Netherlands). The third mutation 
found in exon 8 of the BHMT gene, namely the 1218GoT substitution does not 
result into an abolishment or formation of a restriction site. Therefore, PCR-PIRA was 
used to induce an alternative restriction site. For the 1218GoT substitution, guanine 
at position 1221 was substituted with cytosine by the reverse PIRA primer, thereby 
creating a restriction site for RsaI (Table 2) This allows RsaI to cut the PCR-PIRA 
fragment of 248 bp into two fragments of 222 bp and 26 bp in the case of the wild­
type sequence (1218GG). These fragments were analyzed on a 3% agarose gel.
Statistics
Differences between cases and controls were calculated using Student's t test for 
continuous variables and Pearson chi-square for frequencies. P values were age- and 
sex adjusted by linear regression analysis. To determine if mutated BHMT contributes 
to elevated tHcy levels, means, confidence intervals and P values were calculated. 
tHcy showed positive skewness, and therefore in all cases geometric means were 
calculated instead of means. Statistical significance between geometric means of
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different genotypes was estimated by one-way analysis of variance (ANOVA) and 
Student's t test, Pvalues were age and sex- adjusted by linear regression analysis. In 
addition, P  values were adjusted for MTHFR 677CoT mutation, which is evidently 
associated with increased tHcy levels [69, 70, 79, 104]. P<0.05 was considered 
statistically different; all P  values were two tailed. To estimate the possible risk of 
different genotypes on vascular disease, odds ratios (OR) and 95% confidence 
intervals (95% CI) were calculated.
3 4 6 7 8
DNA 5'
mRNA
position 0 33 166 285
★ ★ *
477 625 808 1037 1221I I  I
595GoA 716GoA 1218GoT 
(G199S) (Q239R) (Q406H)
Figure 2. Location of human BHMT mutations. Gene structure o f BHMT gene shows 
schematically the different exons and corresponding intronic primers used for sequencing 
analysis. Exons are indicated by shaded areas. The mutations are depicted (*) with their 
position on mRNA level and corresponding amino acid substitution.
Results
The relevance of BHMT in hyperhomocysteinemia and vascular disease was tested by 
genomic sequencing of the BHMT gene. Sixteen preselected patients with mildly 
elevated tHcy levels were subjected to mutation analysis. Genomic sequencing of all 
8 exons of the BHMT gene revealed three mutations, which were located in different 
exons (Figure 2). The first mutation detected, was the 595GoA transition in exon 5 
of the BHMT gene, which leads to a substitution of glycine to serine at amino acid 
position 199 (G199S). This mutation was found in one patient in a heterozygous 
state. A second mutation was found in exon 6 of the BHMT gene at nucleotide 
position 716, which was already reported by Park and Garrow [147]. This 716GoA  
mutation leads to a substitution of glutamine to arginine at amino acid position 239 
(Q239R). Two of the 16 patients were homozygous mutant (716AA) and 4 patients 
were heterozygous (716GA) for this mutation. A third mutation was found in exon 8 
of the BHMT gene at nucleotide position 1218 (1218GoT). This mutation leads to an
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amino acid substitution of glutamine to histidine at position 406 (Q406H). Only one 
patient was heterozygous for this mutation. The relevance of these mutations to 
hyperhomocysteinemia and subsequently to vascular disease was tested in a study 
group. The characteristics of this study group are depicted in Table 1. Screening of 
the total study group revealed the presence of the 595GoA mutation only in a 
heterozygous state in 2.8% of the cases and in 1.9% of the controls, which did not 
lead to an increased risk for vascular disease (OR 1.5, 95% CI 0.5-4.5) (Table 3). 
Moreover, the effect of this mutation on tHcy levels was investigated (Table 4). 
Among cases as well as controls, tHcy levels for those with GA genotype did not 
differ from those with GG genotype (Table 4). Additionally, 13 vascular patients with 
severe hyperhomocysteinemia (fasting tHcy >100 —mol/L) were screened for the 
595GoA mutation (data not shown), in order to find a possible 595AA allele. The 
mutation was not detected in any of these patients.
Table 3. Prevalence of the 5 95 G o A  and 7 1 6 G o A  mutations among cases and controls.
Mutation Cases Controls Odds ratio 
(95% CI)
595 G o A
GG 97.2 % (n=171) 98.1% (n=461) 1.0a
GA 2.8% (n=5) 1.9% (n=9) 1.5 (0.5-4.5)
AA - -
716 G o A
GG 52.6% (n=90) 47.7% (n=248) 1.0a
GA 40.4% (n=69) 42.5% (n=221) 0.9 (0.6-1.2)
AA 7.0% (n=12) 9.8% (n=51) 0.6 (0.3-1.3)
a Reference category; - not observed
The second mutation, the 716GoA mutation was found homozygously mutant (AA) 
in 7 %  of the cases compared to 9.8% of the controls (Table 3), which was not 
significantly different. In addition, the effect of this mutation on tHcy levels was 
tested. This mutation did not lead to significant divergent tHcy levels neither fasting 
nor postload (Table 4).
Three individuals were heterozygous for both the 595GoA and the 716GoA  
mutation and also had increased tHcy levels (fasting tHcy 18.7 —mol/l and postload 
tHcy 50.4 —mol/l) when compared to the wild-type (Table 5). However, after 
statistical analysis by ANOVA and after adjustment for confounders this increase in 
tHcy was not significant (3=0.09 for fasting tHcy and 3=0.19 for postload tHcy). 
Although, one genotype combination did result in significantly elevated postload tHcy 
levels (Table 5, 595GA/716GA vs 595GA/716GG; P=0.03).
Screening of the total study group for the 1218GoT mutation resulted in the 
detection of one heterozygous control. The presence of this heterozygous mutation 
did not lead to higher tHcy levels (data not shown).
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Table 4. Geometric means of tHcy levels of BHMT 595G oA  and 7 16 G o A  genotypes among 
study group
Cases meana (95% CI) Controls meana (95% CI) All subjects meana 
(95% CI)
595GoA
Fasting tHcy (—mol/l)
GG 14.2 (13.6-14.9)n=164 13.1 (12.7-13.4)n=454 13.4 (13.0-13.7)n=618
GA 11.3 (7.1-18.0)n=4 16.01 (12.1-21.3)n=9 14.42 (11.5-18.1)n=13
AA -b - -
Postload tHcy (—mol/l)
GG 40.5 (38.4-42.6)n=153 39.8 (38.7-40.9)n=438 40.0 (39.0-41.0)n=591
GA 37.1 (24.1-57.1)n=5 43.33 (33.4-56.3)n=8 40.84 (33.6-49.6)n=13
AA - - -
716GoA
Fasting tHcy (—mol/l)
GG 14.3 (13.4-15.4)n=86 12.8 (12.3-13.3)n=247 13.2 (12.7-13.6)n=333
GA 13.8 (12.9-14.8)n=66 13.3 (12.7-13.8)n=215 13.4 (12.9-13.9)n=281
AA 15.65 (12.8-19.1)n=11 13.2 (12.1-14.4)n=60 13.6 (12.6-14.7)n=61
Postload tHcy (—mol/l)
GG 41.7 (38.9-45.2)n=81 40.1 (38.6-43.3)n=240 40.5 (39.1-41.9)n=321
GA 39.7 (37.1-42.5)n=63 41.4 (39.6-43.3)n=206 41.0 (39.5-42.6)n=269
AA 43.36 (34.0-55.2)n=11 39.5 (36.7-42.5)n=47 40.2 (37.4-43.2)n=58
a geometric mean; no significant differences were observed before and after adjustment for confounders. 
b not observed
1 3=0.42, 2 3=0.79, 3 3=0.83; 4 3=0.60; 5 3=0.83; 6 3=0.60 (after adjustment for age, sex and MTHFR 677 genotype)
BHMT protein sequence of various species was compared to determine if amino acid 
substitutions of the BHMT gene can be found in a conserved region between 
different species. Only the 595GoA mutation (G199S) is conserved between 
different species (human, mouse, rat and pig). The other two mutations are not in 
any conserved region of the gene (data not shown). Furthermore, possible secondary 
structure influences due to different mutations were studied by Chou & Fasman 
analysis (Omiga 2.0, Oxford Molecular Ltd, England). Only the G199S substitution 
was predicted to result in a different secondary structure (data not shown).
Discussion
Deficiency of BHMT can theoretically result in elevated tHcy levels and may therefore 
contribute to the risk for vascular disease. Until now, no defects of BHMT have been 
described. Recently, the gene coding for BHMT has been published enabling 
molecular analysis, which facilitates the detection of mutants with possible BHMT 
deficiency in patients. In this study, 16 vascular patients with hyperhomocysteinemia 
were subjected to genomic sequencing of the BHMT gene and three mutations were 
detected in the coding region of the BHMT gene.
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Table 5. Geometric means of fasting and postload tHcy values for combinations of BHMT 
595 G o A  and 7 1 6 G o A  genotypes
716GoA genotype
595GoA genotype
595 GG 
meana (95% CI)
595 GA 
meana (95% CI)
595 AA 
meana (95% 
CI)
Fasting tHcy (—mol/l)
716GG 13.2 (12.7-13.7) 13.8 (11.4-16.7) -b
(n=283) (n=9)
716GA 13.3 (12.8-13.8) 18.71'2 (3.8-91.7) -
(n=244) (n=3)
716AA 13.3 (12.2-13.6) - -
(n=52)
Postload tHcy (—mol/l)
716GG 40.0 (38.5-41.5) 39.1 (30.5-50.2) -
(n=272) (n=8)
716GA 40.5 (38.9-42.2) 50.43'4 (34.2-74.2) -
(n=252) (n=4)
716AA 39.7 (36.7-43.1) - -
(n=50)
a geometric mean 
b not observed
13=0.09 595GA/716GA vs. 595GG/716GG , 23=0.06 595GA/716GA vs. 595GG/716GA, 33=0.19 595GA/716GA vs. 595GG/716GG 
and 43=0.03 595GA/716GA vs. 595GA/716GG
The first mutation is a 595GoA transition, which results in an amino acid substitution 
of glycine to serine at position 199 of the BHMT protein (G199S). This mutation 
seems to be a rare polymorphism with no relevance to hyperhomocysteinemia or 
vascular disease, at least in heterozygous state. As indicated in Table 4, tHcy levels 
(fasting as well as postload) of cases and controls are slightly elevated when both 
the 595G and 595A allele was present, although this increase is not significant. 
Presence of the homozygous mutated allele (595A) may theoretically result in 
significant elevated tHcy levels. Screening of 170 cases and 460 controls did not 
reveal any homozygous mutated alleles. Thus, 595A alleles seem rare and will hardly 
contribute to mild hyperhomocysteinemia or subsequently to the risk for vascular 
disease. Additionally, 13 patients with severe hyperhomocysteinemia (fasting tHcy 
>100 —mol/L) were screened for this mutation. None of them carried the possible 
595A allele (data not shown). Comparison of the BHMT amino acid sequence of 
different species indicated that glycine at position 199 is conserved between human, 
mouse, rat and pig (data not shown). Recently, Breska et al. [145] showed that 
replacement of conserved cysteine residues (Cys217, Cys299 and Cys300) in human, 
mouse, rat and pig BHMT already resulted in complete loss of activity, which 
suggested that glycine at position 199 could also be a functional amino acid. 
Secondary structure prediction by Chou & Fasman analysis indicated that the protein, 
which normally has a turn structure, changes into a coil structure when serine is 
introduced. Furthermore, the substitution at amino acid position 199 (G199S)
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converts the nonpolar amino acid glycine, which is commonly present on the surface 
of proteins, into the polar amino acid serine, which is frequently located in the 
interior part of the protein. Therefore, this substitution could result in secondary 
structure changes, which supports the findings by Chou & Fasman analysis. Based on 
these findings we hypothesize that the G199S mutation may result in altered 
functioning of BHMT, although further studies are required to confirm this 
hypothesis.
The second mutation found in the BHMT gene (716GoA transition) results in a 
substitution of glutamine to arginine at position 239 (Q239R). Screening of 171 cases 
and 520 controls did not show a significant difference on allele frequencies between 
cases and controls. Neither did the mutation influence tHcy concentrations, fasting 
nor postload (Table 4). This polymorphism was also noted by Park and Garrow [147], 
which suggests that this polymorphism is not unique to the Dutch population. 
Comparing the BHMT protein of different species (human, mouse, rat and pig) 
indicated presence of either glutamine or arginine at position 239, suggesting that 
this polymorphism is also present in species other than humans. Therefore, the 
presence of arginine instead of glutamine at position 239 probably does not seem to 
have major impact on folding of the protein and subsequently on protein functioning. 
Furthermore, secondary structure prediction by Chou & Fasman analysis does not 
lead to divergent structures. In summary, we have no evidence that this common 
716GoA mutation influences homocysteine metabolism and therefore we consider 
this as a benign polymorphism.
The third mutation found in exon 8 of the BHMT gene, the 1218GoT (Q406H), was 
only found in the heterozygous state in one of the preselected patients and one of 
the controls of the study group. Therefore, this mutation seems to be a very rare 
polymorphism, which is not assumed to be a risk factor for hyperhomocysteinemia or 
vascular disease. Glutamine at position 406 is not conserved, assuming no effect of 
this mutation on protein functioning. Presence of this mutation on both alleles 
(1218TT) is therefore not expected to have a major impact on protein functioning.
A combination of two mutations of the BHMT gene may have an additive effect on 
the phenotype. Therefore, we examined the combined effect of the 595GoA  
mutation and the 716GoA mutation on tHcy levels. This combination does not lead 
to significantly elevated tHcy levels, when compared to the wild-type. However, 
elevated postload tHcy levels were observed in one other genotype combination 
(3=0.03, 595GA/716GA vs 595GA/716GG). To exclude a possible role of genotype 
combinations on omocysteine levels, extension of the study group is necessary. In 
addition, a combination of mutated BHMT with mutated genes coding for other 
enzymes (MS, MTHFR, CBS, methionine synthase reductase (MTRR)) of the 
homocysteine metabolism also could influence tHcy concentrations (Figure 1).
Choline is the precursor of betaine (Figure 1). When choline intake is low, less 
betaine is formed and subsequently less homocysteine is remethylated to 
methionine, which may result in elevated tHcy concentrations. Choline is present in 
both animal and vegetable fats, but predominates in animal fats [151]. Thus, when
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mutations are present in the BHMT gene, we hypothesize that the availability of 
betaine may become limiting, and therefore a stronger effect of mutations could be 
expected in populations with low choline intake. Based on fat-intake, the Dutch 
population is presumed to have normal to high choline levels, therefore mutations of 
the BHMT gene may have less effect on tHcy in this population. An increased effect 
of these mutations could be expected in populations with less animal fat intake, e.g. 
the Chinese population.
Mutated BHMT may contribute to other disorders related to a disturbed 
homocysteine or folate metabolism such as neural tube defects or habitual abortions, 
due to different interaction of genetic and nutritional factors [152, 153]. Therefore, it 
would be interesting to investigate the role of mutated BHMT in relation to these 
disorders.
In this study three mutations were found in the BHMT gene, one of these three 
mutations (G199S) is conserved and could probably have an effect on BHMT protein 
functioning. To investigate whether mutations of the BHMT gene are pathogenic, 
mutations could be expressed in a bacterial expression system [145]. Using such a 
system would evaluate any possible effects of the homozygous mutated allele 
(595AA). Mutations in the BHMT gene could result in altered functioning of this gene 
and could therefore lead to hyperhomocysteinemia. This is the first study in which 
molecular genetic analysis of the BHMT gene is performed in relation to 
hyperhomocysteinemia and vascular disease. The results of this study indicate that 
mutated BHMT is not a major cause of mild hyperhomocysteinemia or vascular 
disease. Further molecular genetic and enzymatic studies on BHMT are required to 
answer the question if defective BHMT functioning contributes to 
hyperhomocysteinemia and vascular disease.
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31 bp VNTR in the CBS gene
Abstract
Molecular defects in genes encoding enzymes involved in homocysteine metabolism 
may account for mild hyperhomocysteinemia, an independent and graded risk factor 
for cardiovascular disease (CVD). Although heterozygosity for cystathionine ß- 
synthase (CBS) deficiency has been excluded as a major genetic cause of mild 
hyperhomocysteinemia in vascular disease, mutations in (non-)coding DNA 
sequences may lead to a mildly decreased CBS expression and, consequently, to 
elevated tHcy levels. We assessed the association between a 31 bp VNTR, that spans 
the exon 13-intron 13 boundary of the CBS gene, and fasting, post-methionine load 
and increase upon methionine load tHcy levels in 190 patients with arterial occlusive 
disease, and in 381 controls. The 31 bp VNTR consists of 16, 17, 18, 19 or 21 repeat 
units and shows a significant increase in tHcy concentrations with an increasing 
number of repeat elements, in particular after methionine loading. In 26 vascular 
disease patients the relationship between this 31 bp VNTR and CBS enzyme activity 
in cultured fibroblasts was studied. The CBS enzyme activity decreased with 
increasing number of repeat units of the 31 bp VNTR. RT-PCR experiments showed 
evidence of alternative splicing at the exon 13-intron 13 splice junction site. The 31 
bp VNTR in the CBS gene is associated with post-methionine load 
hyperhomocysteinemia that may predispose individuals to an increased risk of 
cardiovascular diseases.
Introduction
Cardiovascular disease is a complex multi-factorial trait, and is the leading cause of 
death in the industrialized world [2, 154]. Multi-factorial diseases are originating from 
interactions of genes and environmental factors that create a gradient of genetic 
susceptibility to disease. Established risk factors for cardiovascular disease include 
elevated blood cholesterol, hypertension, diabetes mellitus and tobacco smoking. A 
mildly elevated tHcy concentration is generally [21, 90, 91], but not universally [87] 
accepted as an independent and graded risk factor for both arterial occlusive disease 
and venous thrombosis.
Homocysteine is a branch-point intermediate of methionine metabolism, and can be 
irreversibly committed to transsulphuration by the vitamin B6-dependent enzyme, 
cystathionine ß-synthase (CBS). Alternatively, homocysteine can be remethylated to 
methionine in a reaction catalyzed by the vitamin B12-dependent enzyme methionine 
synthase (MS). The latter enzyme requires 5-methyltetrahydrofolate as a co­
substrate, which is formed upon reduction of 5,10-methylenetetrahydrofolate by 
methylenetetrahydrofolate reductase (MTHFR). Genetic defects in genes encoding 
these enzymes, or depletion of important cofactors or (co)substrates for those 
enzymes, including folate, vitamin B12 and vitamin B6 may result in elevated tHcy 
[39, 79].
In the last decade, several studies have been conducted to elucidate the genetic 
determinants of mild hyperhomocysteinemia in patients with premature
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cardiovascular disease. Hereditary defects in homocysteine metabolism have been 
investigated by enzymatic and molecular genetic techniques. In 1985, Boers et al. 
[18] reported decreased CBS activities in extracts of cultured fibroblasts of 
hyperhomocysteinemic vascular disease patients, which were comparable to those 
observed in obligate heterozygotes for CBS deficiency; similar results were described 
by Clarke et al. [27] in 80% of their hyperhomocysteinemic patients. Both studies 
concluded that vascular disease patients with hyperhomocysteinemia were 
presumably heterozygotes for CBS deficiency [18, 27], a finding hard to reconcile 
with an earlier observation by Mudd et al. [67] The finding of decreased CBS 
activities in cultured fibroblasts from hyperhomocysteinemic vascular disease patients 
in the range of obligate heterozygotes, however, could not be reproduced [69, 70], 
and still needs clarification.
The isolation and characterization of the CBS cDNA [71] permitted the molecular 
genetic analysis of the CBS cDNA in patients with vascular disease. All genetic studies 
reported so far, failed to detect an involvement of heterozygosity for CBS deficiency 
in hyperhomocysteinemia and premature vascular disease [70, 72, 73]. These 
studies, however, do not exclude an involvement of mildly impaired CBS function in 
hyperhomocysteinemia and vascular disease. Most genetic studies performed thus 
far, only explored the CBS coding region, and did not examine the non-coding 
regions of the CBS gene, for functional polymorphisms. As reported recently, genetic 
variation in these non-coding sequences may affect enzyme expression, transcript 
stability or splicing [155, 156].
In the present study, we analyzed a variable number of tandem repeats (VNTR) of 
31 bp which spans the exon 13-intron 13 boundary of the CBS gene in 190 patients 
with arterial occlusive disease and in 381 population-based controls. This VNTR was 
first described by Kraus et al. [157]. Each repeat unit contains a consensus splice 
donor site and this VNTR may therefore affect homocysteine metabolism. We report 
the allele frequencies and genotype distributions of this polymorphic variant in both 
cases and controls, and describe the association with fasting, post-methionine load 
and delta (i.e. increase upon methionine loading) tHcy concentrations.
Materials and Methods
Study population
The study population consisted of a group of 130 cases with severe coronary 
occlusions and 101 population based controls [28]. We extended our patient group 
with 60 patients with documented premature cardiovascular disease [70]. To 
equalize the male-female ratio between the patient and control group, all 280 male 
controls from a second population-based control group [94] were included.
Over the last ten years, fibroblasts had been collected from 26 cardiovascular 
patients with mild hyperhomocysteinemia. These selected patients are not included 
in the study group described above but we used the CBS activity measurements in
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these fibroblasts to assess a possible association between the different 31 bp VNTR 
genotypes and CBS enzyme activity.
Biochemical parameters
Cases and controls were subjected to an oral methionine loading test as described by 
Boers et al. [96]. tHcy was measured in plasma using high-performance liquid 
chromatography (HPLC), with reverse phase separation and fluorescence detection, 
as described by Te Poele-Pothoff et al. [97] All tHcy measurements were conducted 
at the University Medical Center Nijmegen, The Netherlands. Fasting and postload 
tHcy levels were obtained from 555 and 525 individuals, respectively.
CBS activities in extracts of cultured skin fibroblasts were determined in the absence 
and presence of 1 mM pyridoxal 5'-phosphate (PLP), essentially according to 
Engbersen et al. [69] Activities are expressed in nmol cystathionine formed per mg 
protein per hour at 37°C.
Detection of the CBS 31 bp VNTR
Genomic DNA was isolated from buffy coats by a standard method [113], and stored 
at 4°C until analysis. Genomic DNA was available of 561 individuals.
After PCR amplification in standard PCR buffer, containing 100 ng forward primer (5'- 
TGCAGCCGTCAGACCAAG -3') and 100 ng reverse primer (5'- 
TTAAGTCCCCAAAACACGG -3'), 200 —M each dNTP, 1.5 mM MgCh and using an 
annealing temperature of 52°C, the 784-908 bp DNA fragments were analyzed on a 
2% agarose gel. PCR products were sequenced on both strands using an ABI 377 
automated DNA sequencer to analyze the exact DNA sequence of each allele.
RT-PCR
Total RNA was isolated from cultured fibroblasts using an established method [158], 
and reverse transcribed using Superscript II reverse transcriptase according to the 
manufacturer's recommendations (Life Technologies). The CBS cDNA was 
subsequently analyzed for the inclusion of a part of intron 13 by PCR amplification 
using 100 ng forward primer (5'-GCACACCATCGAGATCCT-3'; cDNA # 1296-1313) 
and 100 ng reverse primer (5'-GCCTGTAGGTGACTGGGT-3'), located in intron 13 
(Figure 2). PCR was performed in standard PCR buffer including 200 —M each dNTP 
and 3 mM MgCl2 using the following profile: 3'/92°C, 35 cycles of 1'/92°C, 1'/55°C, 
1'/72°C, and a final extension of 7' at 72°C. Amplification of alternatively spliced 
mRNA, in which at least the first repeat of intron 13 is retained, results in a 192 bp 
fragment, whereas amplification of any residual DNA in the RNA isolate will result in 
a 772 bp fragment (Figure 1). The 100 bp DNA ladder of Life Technologies was used 
as a marker.
Statistical analysis
Differences in genotype distributions were assessed by Pearson's chi-square analysis. 
Differences in tHcy concentrations between cases and controls were assessed by
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Student's t-test, adjusted for age and gender by means of linear regression analysis. 
tHcy concentrations showed positive skewness and were therefore log-transformed 
prior to all analyses. The differences in tHcy concentrations between genotype 
subgroups were assessed by one-way analysis of variance (ANOVA) followed by 
Bonferroni corrected t-tests. Odds ratios (OR) and 95% confidence intervals (95%  
CI) for arterial occlusive disease, associated with elevated tHcy levels and with the 
different CBS genotypes, were calculated with logistic regression analysis. Tests for 
trend were performed with linear regression analysis. All P values reported are two­
tailed, and statistical significance was accepted at P<0.05.
Table 1. Characteristics and tHcy concentrations in cases and controls and 31 bp VNTR 
genotype distribution in cases and controls.
Cases
(n=190)
Controls
(n=381)
P a
Age (years) 49.0 ± 10.2 50.8 ± 11.9 0.11
Sex (% male) 75.3 74.3 0.80b
Fasting tHcy (—mol/L) 14.4 (13.7-15.1) 13.4 (13.0-13.9) 0.011c
Postload tHcy (—mol/L) 41.3 (39.4-43.3) 39.1 (38.0-40.3) 0.045c
Postload increase (—mol/L) 26.1 (24.6-27.7) 24.7 (23.6-25.9) 0.13c
Genotype 31 bp VNTR: n (%)
16-17 0 1 (0.3)
17-17 5 (2.8) 7 (2.1)
17-18 21 (11.7) 43 (12.9)
17-19 3 (1.7) 3 (0.9)
17-21 1 (0.6) 1 (0.3)
18-18 103 (57.5) 211 (63.2)
18-19 31 (17.3) 51 (15.3)
18-21 11 (6.1) 7 (2.1)
19-19 2 (1.1) 6 (1.8)
19-21 0 4 (1.1)
21-21 2 (1.1) 0
x2=13.86; 3=0.18
Age is expressed as mean ± SD and tHcy concentrations as geometric means (95% CI) 
a Student's t test 
b Pearson x2 test 
c Adjusted for age and sex
Results
Characteristics of study groups
Age, sex, and tHcy concentrations (i.e. fasting, post methionine load, and net 
increase upon methionine loading or delta) of cases and controls are shown in Table 
1. The geometric mean age and the percentage males did not differ between cases 
and controls. Cases had a higher fasting tHcy (+5.7%; 3=0.011) and a higher tHcy 
concentration after methionine loading (+5.1%; 3=0.045). The net increase upon
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methionine loading (i.e. postload minus fasting tHcy concentration) was slightly, but 
not significantly higher in cases compared with controls (+5.7% ; 3=0.13).
63 bp
r S
Exon 12 Intron 12 
(580 bp)
129 bp 
_ _ A _
Exon 13
R
Intron 13
GCAAA GTCATCTACAAGCAGTTCAAACAGgtaccca A (68.4 %)
gtcacctacaggcagctcaaacagatgcgca B (61.1 %)
gtcacctacaggcagctcaaacaggtgcccg C (65.1 %)
gtcacctacacgcagctcaaacaggtgcgcg D (79.3 %)
gtcacctacaggcagctcaaacaggtgagcg E (90.8 %)
gtcacctacaggcagctcaaacaggtacccg F (68.4 %)
gtcacctacaggcagctcaaacaggtgcgcg G (79.3 %)
gtcagctacaggcagctcaagcgggtgcgcg H (71.5 %)
gtcacctacaggcagctcaaacgggtgcccg I (57.2 %)
gtcacctacaggcagctcaaacgggtgcgcg J (71.5 %)
gtcacctacaggcagctcaaacgggtgccca K (57.2 %)
gtcacctacaggcagctcaaacaggtgcgcg L (79.3 %)
gtcacctacaggcagctcaaacaggtgcccg C (65.1 %)
gtcagctacacgcagctcaaacaggtgcccg M (65.1 %)
gtcagctacaggcagctcaaacaggtgcgcg N (79.3 %)
gtcacctacacgcagttcaaacaggtgcgca 0 (79.3 %)
gtcacctacacgcggctcaaacaggtactca P (68.2 %)
Allele types:
17: A-L,C, M-P
18: A-H, K, I, I, J, K, L, C, N-P 
19: A-H, I, I, K, J, K, L, C, M-P 
21: A-H, I, I, I, J, I, J, I, J, C, M-P
Figure 2. VNTR in exon 13/intron 13 of the CBS gene. F and R indicate the forward and 
reverse primer used in RT-PCR. The sequence of allele 17 is shown. The exonic sequence is 
indicated in capital letters; the underlined sequence indicates the localization of the reverse 
primer. The percentages indicate the weight estimates for splice donor sites according to 
Shapiro and Senapathy [162].
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VNTR genotype distributions and risk of arterial occlusive disease 
The 31 bp VNTR in intron 13 specifies five different alleles, with a variable number of 
tandem repeats, i.e. with 16, 17, 18, 19 or 21 repeat elements. The 31 bp VNTR 
consists of 16 heterogeneous repeat units. The four alleles that were sequenced are 
combinations of these sixteen different units (Figure 1). The first eight repeat units 
(A-H) as well as the last three (N-P) are present in all four alleles. The alleles were 
named according to the number of repeat units. The most frequent allele with an 
allele frequency of 77.2 %  (patients and controls combined) contained 18 repeats, 
whereas the alleles that contained 16, 17, 19 or 21 repeat units were less frequent 
with allele frequencies of 0.1%, 9.5%, 10.5% and 2.7% respectively.
The VNTR genotype distributions in the two constituent case groups were similar, as 
were those in the two constituent control groups (data not shown). Genotype 
distributions for the VNTR were compared between cases and controls (Table 2). 
VNTR genotypes were investigated as risk genotypes in arterial occlusive disease. 
The differences in VNTR genotype frequencies between the combined cases and 
controls groups were not statistically significant (Table 2).
Table 2. The relationship between tHcy and CBS genotypes.
31 bp VNTR Fasting Postload Postload
genotype tHcy tHcy increase
—mol/L —mol/L —mol/L
16-17 15.6 1{ 1{.09. 33.4 {1}
17-17 13.9 (10.8-17.9) {11} 37.5 (32.1-43.7) {11} 22.6 (18.6-27.5) {11}
17-18 12.8 (11.8-13.8) {63} 35.2 (32.7-37.9) {60} 21.9 (19.9-24.0) {60}
17-19 14.0 (11.1-17.6) {7} 35.4 (27.6-45.4) {7} 21.3 (16.0-28.2) {7}
17-21 11.7 (2.3-59.1) {2} 36.8 (2.6-515.7) {2} 25.0 (1.1-565.8) {2}
18-18 13.8 (13.3-14.3) {305} 41.1 (39.7-42.5)a {289} 26.7 (25.6-27.8) {288}
18-19 13.6 (12.6-14.6) {78} 37.8 (35.1-40.6) {73} 24.3 (22.4-26.3) {72}
18-21 14.2 (12.2-16.4) {18} 40.6 (36.6-45.0) {18} 25.2 (21.2-30.1) {18}
19-19 16.8 (10.6-26.8) {8} 46.8 (33.7-65.0) {7} 26.8 (16.9-42.5) {7}
19-21 13.8 (7.3-26.2) {4} 51.3 (39.0-67.5) {3} 37.3 (29.1-47.7) {3}
21-21 17.6 (13.2-23.4) {2} 65.0 (44.2-95.7) {2} 47.4 (31.0-72.4) {2}
P =0.286b P=0.002b P=0.003b
For the association between genotype and tHcy concentrations (expressed as geometric means (95% CI) {n }) , cases and controls were 
combined
a P=0.011 vs 17-18 (Bonferroni-corrected t test) 
b ANOVA on log transformed data
Association VNTR genotypes and tHcy
Fasting, postload and delta tHcy concentrations were determined, and their 
association with the VNTR genotypes was studied (Table 2). Because associations 
between VNTR genotypes and tHcy were similar in cases and controls (data not 
shown), we combined cases and controls to increase statistical power.
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ANOVA 3=0.067 
linear trend 3=0.013
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n=11 n=305
Homozygotes 31 bp VNTR
Figure 2.
Relationship 
between fasting 
(A), post-load (B) 
and increase upon 
methionine load 
(C) homocysteine 
concentrations and 
homozygous 
genotypes defined 
by the 31 bp 
VNTR.
ANOVA 3=0.05 
linear trend 3=0.02
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B. Homozygotes 31 bp VNTR
ANOVA 3=0.05 
linear trend 3=0.02
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The different genotypes defined by the 31 bp VNTR significantly influenced postload as 
well as delta tHcy concentrations (ANOVA 3=0.002 and 3=0.003 respectively; Table 2). 
When the homozygous genotypes were considered separately, individuals with the 17-17 
genotype had the lowest geometric mean postload tHcy concentration (37.5 —mol/L). The 
two homozygotes for the 21-21 genotype had a postload tHcy concentration of 63.0 and
65.0 —mol/L respectively, while those with the 18-18 and 19-19 genotypes showed 
intermediate geometric mean tHcy concentrations of 41.1 and 46.8 —mol/L, respectively 
(ANOVA 3=0.067; test for linear trend 3=0.013; Figure 2). This clearly demonstrates the 
positive association between the number of repeat units and postload tHcy concentrations. 
To elucidate the exact DNA sequence of every allele defined by this 31 bp VNTR, and to 
find a potential explanation for the increasing tHcy concentrations, we sequenced the 
VNTR in homozygotes for each of the alleles (Figure 1). Each repeat unit contains the 
splice donor site between exon 13 and its following intron. Therefore, the published exon- 
intron boundary is followed by at least 15 repeat units that differ only slightly in nucleotide 
sequence and carry all a potential splice donor site (Figure 1, A-P). RT-PCR experiments 
were performed to determine whether the first part of intron 13 was retained in at least 
some of the CBS mRNAs. PCR on cDNA with a reverse primer in intron 13 (primer In13R, 
Figure 1) indeed showed a fragment of 192 bp, indicating that alternative splicing does 
occur and that intron 13 is not completely spliced out (Figure 3). This could lead to 
abnormal CBS protein, and therefore decreased CBS enzyme activity.
Figure 3. Results of 
the RT-PCR. 18-19 
and 18-21 denote 
VNTR genotype. The 
presence of the 192 
fragment indicates 
alternatively spliced 
CBS mRNA.
We determined the 31 bp VNTR genotype in 26 individuals, from whom CBS activities had 
been measured in cultured fibroblasts, and found a clear negative association between 
CBS enzyme activity and the number of repeat units (-PLP: ANOVA 3=0.035; +PLP: 
ANOVA 3=0.021; Figure 4).
18-19 18-21
200 bp _ 
192 bp-
100 bp-
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Figure 4. Relationship 
between CBS enzyme 
activity and the 31 bp 
VNTR. *CBS enzyme 
activities in extracts of 
cultured fibroblasts are 
expressed in nmol 
cystathionine formed per 
mg protein per hour at 
37°C.
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Discussion
A mildly elevated tHcy concentration has been shown to be an independent risk factor for 
cardiovascular disease in both prospective [90, 159] and retrospective [18, 21, 27, 28] 
case-control studies. Although most studies only assessed the relationship between fasting 
hyperhomocysteinemia and the risk of CVD, several studies also report on the association 
between elevated post methionine load tHcy concentrations as a risk factor for 
cardiovascular disease, independently from an elevated fasting level [18, 27-29, 160]. As 
methionine loading has been postulated to provocate in particular the transsulfuration 
pathway [161], in which CBS is the regulating enzyme, these data suggest the 
involvement of suboptimal CBS function in hyperhomocysteinemia after methionine 
loading and, consequently, increased cardiovascular risk.
In the present study, we analyzed a 31 bp VNTR in exon 13-intron 13 of the CBS gene, as 
a potential contributor to the risk of arterial occlusive disease. No differences in genotype 
distributions or allele frequencies were found between cases and controls, indicating that 
no particular VNTR genotype is over-represented in arterial occlusive disease patients 
compared with controls.
We also investigated the associations between the VNTR genotypes and fasting and 
postload tHcy concentrations. Postload tHcy concentrations and net increase upon 
methionine loading were positively associated with the 31 bp VNTR; tHcy concentrations 
increased with the number of repeats (Table 2 and Figure 2).
Four alleles of the VNTR (i.e. with 17, 18, 19 and 21 repeat units) were sequenced to 
elucidate (i) the exact sequence of each allele, and (ii) a possible mechanism by which this 
31 bp VNTR may affect tHcy concentrations. In each allele, the first repeat unit 
(designated A) contains the postulated splice donor site between exon 13 and intron 13
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[157]. Every following repeat unit also contains a functional splice donor site according to 
the consensus sequence for splice signals [162] (Figure 1). Using appropriate weights, we 
calculated the weight estimate for each possible splice site in each repeat unit (Figure 1). 
The presence of multiple potential splice sites at the local DNA sequence environment 
increases the likelihood of their utilization as an alternative splice site [163]. Therefore, it 
is not unlikely that with every extra repeat unit an additional potential splice donor site is 
added, which increases the probability that these alternative splice sites are used in 
addition to the actual splice site in the first repeat unit of 31 bp. This hypothesis is 
supported by studies on Saccharomyces pombe and Drosophila melanogaster that show 
that expanding small introns in these organisms inhibits splicing of the intron or activates 
cryptic sites within the expanded introns [164]. The smallest size of intron 13 of the CBS 
gene is 1196 bp (allele 16) and the longer alleles defined by the 31 bp VNTR lead to 
relatively large increases in the intron size. The length of intron 13 with 17, 18, 19 and 21 
repeat units are respectively, 1227, 1258 bp, 1289 bp and 1351 bp, adding an additional 
2.6%, 5.2%, 7.8% and 13.0%, respectively. It can be postulated that with increasing 
length of intron 13 due to an increased number of the repeat elements, the more likely it 
is that an alternative splice donor site is used.
We used RT-PCR techniques to analyze whether any alternative splicing actually occurs, 
and obtained evidence that the first part of intron 13 is still present in a significant 
proportion of the CBS mRNA population (Figure 3). This demonstrates that either the 
entire intron 13 is retained in some mRNAs, leading to a premature stop codon, or that 
alternative splice donor sites downstream of this repeat are also used, which cause frame 
shifts. The observation of a modified splicing pattern by a VNTR has also been described 
for the human interferon-inducible gene 6-16 [165]. In this gene, a partially expressed 
minisatellite was detected, that consisted of 26 tandemly repeated dodecanucleotides. The 
splice donor site of exon 2 is a component of the most upstream element of the tandem 
repeat. It was shown that the two neighboring repeat units also provide functional splice 
donor sites [165].
The association between the number of repeat elements and elevated postload tHcy 
levels, potentially caused by aberrant splicing, is further substantiated by the observation 
of decreased CBS activities in fibroblasts of individuals with genotypes that include a high 
number of repeat elements. CBS enzyme activity decreased with increasing number of 
repeat elements (Figure 4). This association also underlines the existence of abnormal CBS 
protein leading to suboptimal CBS function.
Very recently, Yang et al. [166] reported new findings on this VNTR, in 398 coronary 
artery disease patients and in 137 apparently healthy controls. While they report a similar 
association between the 31 bp VNTR and postload tHcy levels, their study does not 
include an examination of CBS enzyme activities nor a detailed analysis on potential 
causes of this association. The present study clearly demonstrates that the length of the
31 bp VNTR is negatively associated with CBS enzyme activity for which a plausible 
explanation, i.e. the occurrence of alternative splicing at the exon 13-intron 13 boundary, 
is presented. The increased tHcy concentrations, associated with the increasing number of 
repeat elements, may predispose individuals to an increased risk of cardiovascular disease.
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CBS VNTR in the Framingham Offspring Study
Abstract
Elevated tHcy concentrations, both fasting and post-methionine load, have been 
established as risk factors for vascular disease. Recently, we described the 
association of a 31 bp variable number of tandem repeats (VNTR) in the CBS gene 
with both CBS enzyme activity and tHcy concentrations. In the present study, we 
determined the 31 bp VNTR genotypes in 2598 individuals of the Framingham 
Offspring Study and studied the association between this genotype and fasting, 2- 
hour post-methionine load and delta (i.e. increase upon methionine loading) tHcy 
concentrations in 1416 subjects. We observed a positive association between the 
number of repeat units of the CBS 31 bp VNTR and both postload and delta tHcy 
concentrations. Adjustment for effect modifying factors like age, sex and vitamin (B6, 
B12 and folate) status did not change this observation. We hereby confirm the results 
of our earlier study, in which we found that this 31 bp VNTR is a genetic determinant 
of post-methionine load tHcy concentrations. Since also post-methionine load tHcy 
concentrations are found to be associated with an increased risk for CVD, this 31 bp 
VNTR may be considered a risk factor for CVD.
Introduction
In addition to the well known risk factors for cardiovascular disease (CVD) like an 
unfavorable lipid profile (i.e., high LDL, low HDL cholesterol), hypertension, diabetes 
mellitus and smoking, an elevated tHcy has been identified as a risk factor for 
vascular disease in a number of studies [24, 26]. Besides fasting tHcy 
concentrations, also post-methionine load tHcy concentrations have been reported as 
a risk factor for CVD [28, 29, 160].
Homocysteine is formed by demethylation of methionine via S-adenosylmethionine 
and S-adenosylhomocysteine. Homocysteine can be further metabolized in two 
directions; it can be reconverted to methionine by methionine synthase (MS) via a 
remethylation pathway, or catabolized by the transsulphuration pathway in which 
cystathionine ß-synthase (CBS) irreversibly condensates homocysteine into 
cystathionine. tHcy levels are influenced by both dietary and life-style factors, but 
also genetic factors can interfere with transsulfuration and remethylation.
Although CBS deficiency is the most common cause of severe hyperhomocysteinemia 
[56], no genetic variants in the CBS gene have been described so far that are 
associated with mild hyperhomocysteinemia. However, very recently, we and others 
described the association of a 31 bp variable number of tandem repeats (VNTR) in 
the CBS gene with tHcy concentrations [166, 167]. In our study, we assessed the 
relationship between the CBS 31 bp VNTR genotype and both fasting and post­
methionine load tHcy concentrations in 190 CVD patients and 381 population based 
controls and found a positive association between postload tHcy concentration and 
increasing number of repeat units of the 31 bp VNTR. Furthermore, a negative 
association was observed between the number of repeat units and CBS enzyme 
activity. The first repeat unit contains the postulated splice donor site between exon
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13 and intron 13 [157], but since this 31 bp VNTR spans the exon-intron 13 
boundary of the CBS gene, each following repeat unit contains a consensus splice 
donor site which could lead to alternative splicing of the CBS gene. Indeed, we 
demonstrated with RT-PCR experiments on RNA isolated from fibroblasts, that the 
first part of intron 13 is still present in a significant proportion of the CBS mRNA 
population [167].
In the present study, we determined the CBS 31 bp VNTR genotype in more than 
2500 samples of the Framingham Offspring Study and studied the association 
between this genotype and fasting, post-methionine load and delta (i.e. increase 
upon methionine loading) tHcy concentrations in 1416 subjects. Since vitamin B6 
concentrations in blood were available of this population, we were also able to study 
possible effect modification by vitamin B6.
Materials and Methods
Subjects were participants in the Framingham Offspring Study; details of the design 
and methods have been described elsewhere [168]. Starting in 1948, 5209 subjects 
between the ages of 28 and 62 were enrolled in the cohort study, and beginning of 
1971, a total of 5124 of their children and the children's spouses were enrolled 
[169]. Between 1987 and 1991, blood samples for DNA were collected and DNA was 
available of 4144 subjects. In the Framingham Offspring Study, fasting and 2-hour 
post-methionine load tHcy concentrations were available of a part of the study 
group.
Detection of the CBS 31 bp VNTR
Genomic DNA was isolated from peripheral blood leukocytes by standard methods [113]. 
CBS 31 bp VNTR genotype analyses was performed by PCR amplification in standard 
PCR buffer, containing 100 ng forward primer (5'-TGCAGCCGTCAGACCAAG -3') and 
100 ng reverse primer (5'-TTAAGTCCCCAAAACACGG -3'), 0.2 mmol/L dNTPs, 1.5 mM 
MgCl2 and using an annealing temperature of 60 °C in the first 10 cycles, followed by 
an annealing temperature of 56°C in the next 30 cycles. The DNA fragments with 
sizes ranging from 784-908 bp were analyzed on a 2% agarose gel.
We were able to assess the 31 bp VNTR genotype of 2598 individuals and a 
complete set of genotype data and 2-hour post-methionine load tHcy concentrations 
was available of 1416 individuals.
Statistics
tHcy, folate, vitamin B6, vitamin B12 and creatinine concentrations were 
logarithmically transformed prior to all statistical analyses. One-way analysis of 
variance (ANOVA) was used to assess the differences of continuous variables 
between different genotypes, followed by Bonferroni-corrected t tests. Adjustment 
for confounding variables (i.e. age, sex, creatinine and vitamin status) was
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performed by general linear model analysis. Statistical significance refers to a two­
tailed analysis, where 3<0.05.
Table 1. Characteristics of study population
n=2598
Age (years) 59.0 ± 9.8
Gender (% male) 49.4
Fasting tHcy (—mol/L) 9.4 (9.3-9.6)
Post-load tHcy (—mol/L) 23.5 (23.2-23.9)
Vitamin B6 (pm/ml) 62.6 (60.5-64.7)
Vitamin Bi2 (pg/ml) 382.8 (375.3-390.5)
Folate (ng/ml) 8.2 (7.9-8.5)
Creatinine (mg/dl) 1.14 (1.13-1.15)
VNTR genotype [n (%)]
15-18 4 (0.2)
16-18 1 (0.04)
16-21 1 (0.04)
17-17 90 (3.5)
17-18 280 (10.8)
17-19 58 (2.2)
17-21 5 (0.2)
18-18 1730 (66.6)
18-19 270 (10.4)
18-21 47 (1.8)
19-19 106 (4.1)
19-21 3 (0.1)
21-21 3 (°.:Q
Age is expressed as mean ± SD; homocysteine (tHcy), 
vitamin B6, Bi2, folate and creatinine concentrations 
are expressed as geometric means (95% CI).
Results
The main characteristics of the study population are depicted in Table 1. A complete 
set of genotype data and post-methionine load tHcy concentrations was available of 
1416 individuals. There was an equal amount of men and woman in the study 
population and the mean age was 59 years. Besides fasting and post-methionine 
load tHcy concentrations, also data about vitamin B6, B12, folate and creatinine were 
available. The number of individuals in each genotype group are shown in Table 1. 
We detected six different alleles ranging from 15 to 21 repeat units. The allele 
frequencies of alleles 17, 18, 19 and 21 were 10.1%, 78.2%, 10.5% and 1.2%, 
respectively, while the frequencies of the alleles 15 and 16 were less than 0.1%. The 
genotype distribution of the 31 bp VNTR was in Hardy-Weinberg equilibrium.
Table 2 shows the associations of the 31 bp VNTR genotypes with tHcy 
concentrations (fasting, 2- hour post-methionine load and increase upon methionine 
loading), vitamin B6, folate, vitamin B12 and creatinine concentrations. Fasting tHcy 
concentrations (Figure 1) as well as vitamin B6, folate, vitamin B12 and creatinine 
concentrations did not differ between genotype groups. Post-methionine load tHcy
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Table 2. Association between CBS 31 bp VNTR genotypes and tHcy, vitamin B6, vitamin Bi2, folate, creatinine and age (expressed as 
geometric means (95%CI))
VNTR Fasting tHcy Postload tHcy tHcy increase Vitamin B6 Folate Vitamin Bi2 Creatinine Age
genotype (umol/L) (umol/L) (umol/L) (pm/ml) (nq/ml) (pg/ml) (mq/dl) (years)
15/18 9.7 (5.4-17.4) 16.1 (10.5-24.8) 6.4 (5.3-7.8) 43.3 (0.3-5594) 13.2 400 (81-1977) 0.82 (0.24-2.82) 63.5 (31.7-95.3)
16/18 10.1 - 84.3 10.4 423 - 61.0
16/21 7.0 17.4 10.4 74.0 12.2 754 1.11 64.0
17/17 8.8 (8.2-9.4) 20.7 (19.4-22.2) 11.6 (10.5-12.7) 61.2 (51.0-73.6) 7.4 (6.2-8.9) 385 (348-427) 1.10 (1.05-1.16) 59.1 (56.8-61.4)
17/18 9.2 (8.8-9.7) 22.1 (21.1-23.2) 12.7 (11.9-13.5) 59.5 (53.9-65.7) 8.1 (7.2-9.1) 373 (350-398) 1.13 (1.09-1.16) 59.3 (57.8-60.8)
17/19 9.0 (7.8-10.3) 19.3 (17.3-21.6) 9.8 (8.6-11.3) 62.9 (48.7-81.2) 7.8 (5.9-10.2) 389 (330-458) 1.09 (0.99-1.19) 55.0 (51.2-58.7)
17/21 11.6 (8.0-16.8) 24.5 (23.5-25.6) 12.6 (10.0-15.9) 56.1 (31.8-99.0) 5.5 (1.7-17.9) 433 (344-545) 1.28 (1.08-1.50) 66.8 (56.1-77.4)
18/18 9.4 (9.2-9.6) 24.1 (23.6-24.6) 14.1 (13.8-14.5) 63.1 (60.6-65.7) 8.2 (7.9-8.6) 384 (375-393) 1.13 (1.12-1.15) 58.9 (58.4-59.5)
18/19 9.4 (9.0-9.9) 22.6 (21.6-23.7) 12.8 (12.0-13.7) 64.0 (57.4-71.5) 8.6 (7.7-9.6) 383 (361-406) 1.16 (1.12-1.20) 58.7 (57.2-60.3)
18/21 8.4 (7.4-9.6) 25.8 (23.1-28.8) 17.2 (14.8-19.9) 92.7 (64.9-132) 8.9 (6.2-12.8) 428 (360-509) 1.12 (1.04-1.21) 59.3 (55.6-63.0)
19/19 9.4 (8.9-10.0) 22.3 (20.9-23.8) 12.3 (11.2-13.6) 59.5 (50.7-69.9) 8.5 (7.2-10.2) 382 (350-416) 1.14 (1.10-1.19) 60.3 (58.0-62.6)
19/21 8.3 (3.8-17.8) 18.9 (2.9-120.6) 9.8 (6.7-14.1) 85.5 (43.6-167) 14.8 (5.0-43.7) 424 (170-1053) 1.16 (0.87-1.54) 60.7 (46.3-75.0)
21/21 10.7 (0.4-253) 25.1 (13.9-45.4) 18.0 82.1 (2.2-3000) 4.5 (0.5-39.0) 420 (177-997) 1.01 (0.82-1.23) 53.7 (37.7-69.6)
Total 9.4 (9.3-9.6) 23.5 (23.1-23.9) 13.5 (13.2-13.8) 62.9 (60.8-65.1) 8.2 (7.9-8.5) 384 (376-391) 1.13 (1.12-1.14) 59.0 (58.5-59.4)
Total (n) 1617 1416 1414 1618 1612 1618 1612 1640
/’ ANOVA 0.624 <0.001* <0.001 0.512 0.701 0.898 0.297 0.497
/’ trend 0.250 <0.001 <0.001 0.177 0.335 0.591 0.054 0.877
* /’ adjusted for folate, vitamin B6 and B12, and creatinine <0.001
CBS VNTR in the Framingham Offspring Study
concentrations however, did show an association with the genotypes of the 31 bp 
VNTR as did the increase upon methionine loading (for both associations ANOVA and 
test for linear trend: 3<0.001; Table 2 and Figure 1). Adjustment for effect modifying 
factors like age, sex and vitamin (B6, B12 and folate) status did not change the 
association found between the 31 bp VNTR and both postload and increase upon 
methionine loading tHcy concentrations. The observed association between the 
genotypes of the 31 bp VNTR and post-methionine load tHcy concentrations was 
similar in men and women (data not shown).
Discussion
In this study, we investigated whether the 31 bp VNTR in the CBS gene is associated 
with tHcy concentrations in a population of over 1400 subjects of the Framingham 
Offspring Study. We found a significant positive association between the number of 
repeat units of this 31 bp VNTR with both 2-hour postload and increase upon 
methionine loading tHcy concentrations, while no association with fasting tHcy 
concentrations was observed. This significant association with postload as well as 
increase upon methionine loading tHcy concentrations was not affected by possible 
effect modifying factors like age, sex and vitamin (B6, B12 and folate) status.
Besides mildly elevated fasting tHcy concentrations, also elevated post-methionine 
load tHcy concentrations have been shown to be an independent risk factor for 
cardiovascular diseases [27-29]. Although CBS deficiency is the most common cause 
of severe hyperhomocysteinemia [56], heterozygosity for CBS deficiency is not a 
major determinant of mildly elevated tHcy concentrations [69, 70]. However, an 
involvement of mildly impaired CBS function in hyperhomocysteinemia and vascular 
disease is not excluded. A 68 bp insertion (844ins68) in the CBS gene was thought to 
be a possible pathogenic variant, but individuals carrying the insertion showed 
normal CBS enzyme activity [75] and normal tHcy concentrations [75, 76], although 
there is also a report on lower post-methionine load increase of tHcy in carriers of 
the 844ins68 insertion [170]. Very recently, we described the association of a 31 bp 
VNTR in the CBS gene with post-methionine load tHcy concentrations [167]. In a 
Dutch population, of 190 vascular patients and 381 population-based controls, we 
distinguished five different alleles, i.e. consisting of 16, 17, 18, 19 or 21 repeat units 
of 31 bp and observed higher 6-hour postload tHcy concentrations with increasing 
number of repeat units. This observation was further substantiated by the 
observation of decreased CBS activities in fibroblasts of individuals with genotypes 
that include a high number of repeat elements. We postulated that, by the presence 
of multiple potential splice donor sites, alternative splicing occurs, which was 
demonstrated by RT-PCR experiments.
Alternative splicing as a result of the presence of multiple alternate splice sites, had 
been refuted earlier by Yang et al. [166] who studied this CBS variant
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in relation to fasting and post-methionine load tHcy concentrations. They named 
their alleles according to the number of repeat units observed in each allele, with 
allele 17 being the most common. However, we observed that this most common 
allele in fact consist of 18 repeat units, resulting in a different numbering in which 
our allele 18 is the most common [167]. They reported that the genotypes 17-18 and 
18-19 had lower delta (i.e. increase upon methionine loading) tHcy concentrations 
that the most common 18-18 genotype and that this observation is probably caused 
by linkage disequilibrium with upstream transcriptional regulatory elements. They 
argued that the occurrence of alternative splicing is prevented by a G to A 
substitution at the exon-intron border of the second repeat unit. Although this G to A 
substitution is absent from all subsequent repeat units, they assumed that alternative 
splicing does not occur at those distal sites due to the lack of exon 13 sequences not 
contained in the repeat elements but needed for the binding of spliceosomes. We 
however, provided evidence that alternative splicing does occur, since the first part 
of intron 13 is still present in a significant proportion of the CBS mRNA population 
[167]. Still, we do not know whether the entire intron 13 is retained in some mRNAs, 
which would lead to a premature stop codon, or that alternative splice donor sites 
downstream of this repeat are also used, which will cause frame shifts.
In the present study we observed six different alleles, of which alleles 16 to 21 
showed similar allele frequencies compared with those in our previous report of a 
Dutch population [167] and those of earlier reports [157, 166]. Allele 15 was not 
observed before.
In the present study, 2-hour post-methionine load concentrations were available, 
while in our previous study an association between genotype and 6-hour post­
methionine load was reported [167]. We were able to confirm the observed positive 
association between the number of repeat units and 6-hour post-methionine load 
tHcy concentrations in the present study with 2-hour post-methionine load 
concentrations.
In conclusion, the results of this study confirm our earlier results that the 31 bp 
VNTR is a genetic determinant of post-methionine load tHcy concentrations and 
show that this association is not influenced by vitamin B6 concentrations. Since also 
post-methionine load tHcy concentrations are found to be associated with an 
increased risk for CVD [27-30], this 31 bp VNTR may be considered a risk factor for 
CVD. Since it is not known whether intron 13 is partially or completely spliced out 
further studies are warranted to elucidate the influence of the number of repeat 
elements on splicing of the CBS mRNA and subsequently CBS enzyme activity and 
tHcy concentrations.
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CBS association study
Abstract
Hyperhomocysteinemia is generally accepted as an independent and graded risk 
factor for both arterial occlusive disease and venous thrombosis. The only way of 
homocysteine degradation is conversion to cysteine in the transsulfuration pathway 
in which the regulating step is catalyzed by cystathionine ß-synthase (CBS). Mild 
impairment of CBS function could therefore affect homocysteine concentration, in 
particular after methionine loading, and consequently cardiovascular disease (CVD) 
risk. We analyzed two silent polymorphisms and one short tandem repeat in the CBS 
gene (i.e. 699CoT, 1080CoT and -5697 (GT) STR) as genetic markers potentially in 
linkage disequilibrium with a functional polymorphism. We assessed their association 
with fasting and post-methionine load tHcy in 190 patients with arterial occlusive 
disease, and in 381 controls. No differences in CBS genotype frequencies between 
cases and controls were found, nor was a particular CBS genotype associated with an 
elevated risk of arterial occlusive disease. Although we did find a high rate of linkage 
disequilibrium between the two single nucleotide polymorphisms and the GT STR, 
none of the genotypes defined by the three CBS variants studied showed an 
association with elevated fasting, post-load or increase upon methionine loading tHcy 
concentrations. In conclusion, we did not find any indication that genetic variation in 
the CBS gene is associated with increased tHcy concentrations.
Introduction
Established risk factors for cardiovascular disease (CVD) include elevated blood 
cholesterol, hypertension, diabetes mellitus and tobacco smoking. A modest elevation 
of plasma tHcy concentration, commonly referred to as hyperhomocysteinemia, is 
generally [26, 91], though not universally [87, 92] accepted as an independent and 
graded risk factor for both arterial occlusive diseases and venous thrombosis [21, 
22]. Homocysteine, an intermediate sulfur amino acid in methionine metabolism, 
may either be irreversibly degraded to cysteine via cystathionine in the 
transsulfuration pathway or remethylated to methionine. The remethylation by 
methionine synthase requires 5-methyltetrahydrofolate for methyl donation and 
vitamin Bi2 for methyl transport, while the remethylation by betaine-homocysteine- 
methyltransferase requires betaine as methyl donor. The regulating step in the 
transsulfuration pathway is catalyzed by cystathionine ß-synthase (CBS), a pyridoxal 
5'-phosphate-dependent enzyme. The inherited metabolic disorder CBS deficiency is 
acknowledged to be the most frequent cause of homocystinuria in humans [56] .
In 1985, Boers et al. [18] postulated heterozygosity for CBS deficiency as a major 
cause of hyperhomocysteinemia in CVD patients. This was based on the decreased 
CBS activities they found in extracts of cultured fibroblasts of hyperhomocysteinemic 
vascular disease patients and their increased post-methionine loading tHcy 
concentrations, both resembling those of obligate heterozygotes for CBS deficiency. 
Similar results were described by Clarke et al. [27]. Both studies however, do not 
reconcile with an earlier observation by Mudd et al. [67], who described a similar
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incidence of heart attacks or strokes in parents and grandparents of homocystinuric 
children compared with relatives of children with either new-mutation 
achondroplastic dwarfism or with impaired phenylalanine metabolism. Furthermore, 
the finding of decreased CBS activities in cultured fibroblasts from 
hyperhomocysteinemic vascular disease patients in the range of obligate 
heterozygotes could not be reproduced by us [69, 70], and still needs clarification. In 
addition to fasting tHcy concentrations, also post-methionine load tHcy 
concentrations were found to be correlated among family members of patients with 
hyperhomocysteinemia and vascular disease [64-66]. So, it can be concluded that 
hyperhomocysteinemia is, at least partially, genetically based. Still, elevated post­
methionine load tHcy concentrations are associated with increased CVD risk [28, 29, 
160], but its genetic determinants remain obscure.
Over 100 mutations have been described in the CBS gene in classical homocystinuria 
patients [57]. A 68 bp insertion in exon 8, first reported as a causal mutation in an 
Italian patient, was found to be polymorphic and not to be associated with plasma 
tHcy concentrations [75, 76]. No other potentially functional polymorphisms 
associated with elevated tHcy levels were detected in the CBS gene in the analyses 
of the genetic basis of homocystinuria. However, most studies performed thus far, 
only examined the coding region of the CBS gene, leaving the non-coding regions 
unexplored.
Very recently, we described an inverse correlation between the number of tandem 
repeats defined by a 31bp VNTR (variable number of tandem repeats) [157], and 
CBS enzyme activities in fibroblasts [167]. Furthermore, a positive association was 
observed between the number of repeat units and post-methionine load plasma tHcy 
concentrations [167].
Genetic association studies are widely used for the identification of candidate genes 
of complex, i.e. non-mendelian traits [171]. In such studies, the association is 
investigated between a phenotype and genomic markers close to or, preferably, 
within the gene of interest. Such a marker in itself is not necessarily functionally 
related to the phenotype but may be in linkage disequilibrium with a functional 
variant.
In the present study, we investigated the potential involvement of genetic variants in 
non-coding regions or of silent mutations in the CBS gene in hyperhomocysteinemia 
and vascular disease, as possible markers which may be in linkage disequilibrium 
with a functional polymorphism. We analyzed two silent single nucleotide 
polymorphisms (699CoT, 1080CoT) and a short tandem repeat (STR) -5697(GT) 
[157] in the CBS gene in 190 vascular disease patients and in 381 population-based 
controls. We report the allele frequencies and genotype distributions of these 
polymorphic variants in both study groups, and describe their association with 
fasting, post-methionine load and delta (i.e. increase upon methionine loading) 
plasma tHcy concentrations. Also, the extent of linkage disequilibrium between the 
several CBS variants are calculated.
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Materials and Methods
Study population
We studied 190 patients with coronary, peripheral or cerebral vascular disease; a 
total of 130 cases were recruited from a cohort of patients who underwent coronary 
angiography in the Zuiderziekenhuis Hospital in Rotterdam, The Netherlands [28]. 
Reasons for angiography were myocardial infarction or angina pectoris and cases 
were defined as those having > 90% occlusion in one and > 40% occlusion in one 
additional coronary artery. The other 60 patients had documented premature 
cardiovascular disease of which 10 patients had suffered from myocardial infarction,
32 from cerebral arterial occlusive disease and 18 from peripheral arterial occlusive 
disease [70].
The control group consisted of 381 controls, of whom 101 were included from the 
general population in Rotterdam and comprised subjects with no history of 
cardiovascular disease [28] and 280 were recruited from a general practice in The 
Hague, The Netherlands to take part in a health survey [94].
Biochemical parameters
After an overnight fast, blood was collected in EDTA tubes for measurement of 
fasting tHcy. The EDTA-blood samples were placed on ice immediately, and 
centrifuged for 10 minutes at 3000 g with minimal delay. All individuals were 
subjected to a standardized methionine loading test [96]. Briefly, L-methionine (0.1 
g/kg body weight) was dissolved in 200 mL orange juice and administered orally. All 
study subjects received a standardized low protein breakfast and luncheon, and were 
asked not to consume any milk-containing beverages. After six hours, another blood 
sample was drawn for assessment of the post-methionine load tHcy concentration. 
tHcy was measured in plasma using a high-performance liquid chromatography 
(HPLC) procedure, with reverse phase separation and fluorescence detection, as 
described by Te Poele-Pothoff et al. [97]. All tHcy measurements were conducted at 
the University Medical Center Nijmegen, the Netherlands, and fasting and post-load 
plasma tHcy levels were obtained from 555 and 525 individuals, respectively.
Detection of CBS polymorphisms
Genomic DNA was isolated from buffy coats of EDTA blood by a standard method 
[113], and stored at 4°C until analysis. Genomic DNA was available of 561 
individuals.
699CoT transition
This polymorphism does not create a restriction enzyme recognition site, and was 
therefore analyzed by Primer Introduced Restriction Analysis. A mutagenic sense 
oligonucleotide (5'-CAGCAACCCCCTGGCTCAGT-3') introduces a RsaI site in the 699C 
allele and together with an antisense oligonucleotide (5'-
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TTATCGTTTGTGTCCCGTACCG-3') a genomic DNA fragment of 287 bp was amplified 
using approximately 100 ng genomic DNA and 100 ng of both oligonucleotides in a 
standard PCR buffer (10 mM Tris-HCl, pH 8.3; 50 mM KCl) containing 2 mM MgCl2 
and 200 —M dNTPs. PCR parameters were as follows: 3 min initial denaturation at 
92°C, followed by 35 cycles of 92°C /60s, 64°C /60s, 72°C /30s, and a final extension 
of 7 min at 72°C. After digestion with RsaI and resolution of the fragments on a 20% 
polyacrylamide gel, the 699 CC genotype results in fragments of 171, 92, 20 and 
4bp, whereas the 699 TT genotype shows fragments of 171, 112 and 4 bp.
1080CoT transition
A genomic DNA fragment of 88 bp was amplified by PCR using both 100 ng forward 
(5'-CTGGCAGCACGGTGGCGG-3') and 100 ng reverse oligonucleotides (5'- 
CGCACTGAGTCGGGCAGAATG-3'), and approximately 100 ng genomic DNA in a 
standard PCR buffer (10 mM Tris-HCl, pH 8.3; 50 mM KCl) containing 2 mM MgCl2 
and 200 —M dNTPs. All samples were cycled thirty-five times: 1 min /92°C 
denaturation, 1 min/55°C annealing, 30 sec/72°C extension, preceded by an initial 
denaturation of 3 min/92°C and followed by a final extension of 7 min/72°C. The 
PCR fragment was analyzed by BstUI restriction enzyme analysis followed by 
separation on a 2% agarose gel. The 1080 TT genotype results in an uncut fragment 
of 88 bp, the 1080 CC genotype in two fragments of 55 bp and 33 bp, whereas the 
heterozygous CT genotype is displayed by three fragments (88, 55, and 33 bp).
-5697 (GT) STR
A PCR was performed with a 5'FAM labeled forward primer (5'- 
GAGCTGAAATCACACCACT-3') and a reverse primer (5'-GTTTTTACTACATTTGCTCCC-
30 in a standard PCR buffer containing 2 mM MgCl2 and using an annealing 
temperature of 58°C. The 193-211 bp fluorescently labeled PCR products were 
separated on a 4% denaturating polyacrylamide gel using the ABI Prism 377, 
according to the manufacturer's recommendations. Data-analysis was performed 
using the Genescan and Genotyper Software (Perkin Elmer).
Statistical analysis
Plasma tHcy concentrations showed positive skewness, therefore log-transformed 
tHcy levels were used in all analyses. Differences in genotype distributions, allele 
frequencies and gender were assessed by Pearson's chi-square analysis. Differences 
in continuous variables between cases and controls were assessed by Student's t- 
test, adjusted for age and gender by means of linear regression analysis. One-way 
analysis of variance (ANOVA) was used to assess the differences of continuous 
variables between different genotypes, followed by Bonferroni-corrected t tests. 
Odds ratios (OR) and 95% confidence intervals (95% CI) as estimates of the relative 
risk for arterial occlusive disease for the different CBS genotypes, were calculated 
with logistic regression analysis. We also investigated the association between these 
three genetic variants and the 31 bp VNTR, of which alleles 19 and 21 were shown
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to be associated with increased post-methionine load tHcy concentrations [167]. The 
haplotype frequencies and linkage disequilibria were estimated by the EH program 
[140]. D' reflects the extent of the linkage disequilibrium, which is reported as the 
ratio between the actual value of D (i.e. the departure from linkage disequilibrium) 
and the maximum value it can have for the given allele frequencies. The sign in front 
of the coefficients indicates whether the rare alleles are associated (+) or the rare 
allele is associated with the frequent allele (-). All P-values reported are two-tailed, 
and statistical significance was accepted at P <0.05.
Table 1. Characteristics and tHcy in cases and controls.
Cases
(n=190)
Controls
(n=381)
P a
Age (years) 49.0 ± 10.2 50.8 ± 11.9 0.11
Gender (% male) 75.3 74.3 0.80b
Fasting tHcy (—mol/L) 14.4 (13.7-15.1) 13.4 (13.0-13.9) 0.011c
Postload tHcy (—mol/L) 41.3 (39.4-43.3) 39.1 (38.0-40.3) 0.045c
Postload increased (—mol/L) 26.1 (24.6-27.7) 24.7 (23.6-25.9) 0.13c
age is expressed as mean ± SD and tHcy as geometric means (95% CI) 
a Student's ftest 
b Pearson j 2 test 
c adjusted for age and gender
d increase upon methionine loading (i.e. postload minus fasting tHcy)
Results
Table 1 depicts age, gender, and tHcy concentrations (i.e. fasting, post methionine 
load, and net increase upon methionine loading) of cases and controls. Age, 
expressed as the geometric mean, and the percentage males did not differ between 
the two groups. A higher fasting tHcy (+7.5%; P=0.011) and post-methionine 
loading tHcy concentration (+5.6%; P=0.045) was seen in cases compared with 
controls. Cases and controls showed a comparable net increase upon methionine 
loading (i.e. post-load minus fasting tHcy concentration).
Both 699CoT, 1080CoT as well as the GT STR genotype distributions were in 
Hardy-Weinberg equilibrium (data not shown). Genotype distributions for each of the 
three CBS polymorphisms were similar in cases and controls (Table 2, left side). The 
allele frequency of the 699T allele was 0.37 and 0.35 in patients and controls, 
respectively ( j 2=0.30, P=0.58); the 1080T allele had an allele frequency of 0.32 in 
patients and of 0.37 in controls ( j 2=2.89, P=0.09). In our study population, we 
identified 10 different alleles defined by the highly polymorphic GT STR (which were 
named after the number of repeat units) that lead to the observation of 22 different 
genotype combinations (Table 2).
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Table 2. CBS genotype distribution in cases and controls and the relationship between tHcy 
and CBS genotypes (patients and controls combined).
CBS
Genotype
Number of 
Patients Controls 
n (%) n (%)
Fasting
tHcy
—mol/L
Postload
tHcy
—mol/L
'  tHcya
699CC 76 (40.0) 156 (42.9) 13.9 40.0 25.1
699CT 87 (45.8) 158 (43.4) 13.5 39.6 25.5
699TT 27 (14.2) 50 (13.7) 14.2 40.0 25.1
j 2=0.41; P=0.81 P=0.60b P=0.92b P=0.91b
1080CC 93 (49.2) 150 (40.4) 14.0 40.6 25.9
1080CT 70 (37.0) 164 (44.2) 13.6 39.1 24.9
1080TT 26 (13.8) 57 (15.4) 13.5 39.7 24.4
j 2=3.98; P=0.14 P=0.58b P=0.38b P=0.44b
GT STR
14-14 1 (0.5) 1 (0.3) 20.1 44.3 24.2
11-16 0 1 (0.3) 11.4 31.8 20.5
12-16 1 (0.5) 0 11.6 - -
13-16 0 1 (0.3) 9.6 24.3 14.8
14-16 9 (4.8) 33 (9.6) 14.3 40.6 26.1
15-16 10 (5.3) 11 (3.2) 15.0 41.7 25.9
16-16 75 (40.1) 146 (42.7) 13.5 39.4 25.2
14-17 2 (1.1) 3 (0.9) 15.4 41.6 25.8
16-17 47 (25.1) 79 (23.1) 13.6 40.3 26.1
17-17 3 (1.6) 4 (1.2) 18.3 46.7 28.1
14-18 1 (0.5) 4 (1.2) 13.1 37.5 23.6
15-18 1 (0.5) 1 (0.3) 13.4 47.6 33.5
16-18 14 (7.5) 25 (7.3) 13.7 38.7 24.7
17-18 2 (1.1) 8 (2.3) 15.3 38.1 22.5
18-18 2 (1.1) 1 (0.3) 11.6 34.3 22.6
14-19 1 (0.5) 2 (0.6) 13.6 45.3 30.5
16-19 11 (5.9) 16 (4.7) 15.1 39.4 20.6
17-19 5 (2.7) 3 (0.9) 13.2 44.8 30.5
18-19 0 1 (0.3) 12.8 38.5 25.8
19-19 0 1 (0.3) 7.8 20.7 12.8
16-20 1 (0.5) 0 18.9 46.1 27.0
17-20 1 (0.5) 1 (0.3) 13.0 38.2 25.0
j 2=17.74; P=0.67 P=0.42b P=0.78b P=0.73b
tHcy expressed as geometric means (95% CI)
a net increase upon methionine loading (i.e. postload minus fasting tHcy) 
b ANOVA on log transformed data
CBS genotypes were investigated as risk factors for arterial occlusive disease. The 
differences in CBS genotype frequencies between the case and control group were 
not statistically significant (Table 2). Odds ratios for the 699TT and 699CT genotype, 
with the 699CC genotype as reference category, were 1.07 (95% CI: 0.81-1.40) and 
1.12 (95% CI: 0.77-1.64) respectively. Odds ratios for the 1080TT and 1080CT 
genotype, with 1080CC as reference category, were 1.07 (95% CI: 0.89-1.52) and
0.94 (95% CI: 0.54-1.62) respectively.
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In addition, the association between CBS genotypes and fasting and post-load 
plasma tHcy concentrations was studied (Table 2, right side). We combined cases 
and controls to increase statistical power, since associations between CBS genotypes 
and plasma tHcy did not differ between cases and controls (all P-values > 0.14). For 
the 699CoT polymorphism no differences in fasting, post-load or delta tHcy 
concentrations were observed between the three genotypes (Table 2). Furthermore, 
none of the genotypes defined by the 1080CoT polymorphism showed an 
association with elevated fasting, post-load or delta tHcy concentration (Table 2). 
The different GT STR genotypes were also not associated with a change in plasma 
tHcy concentrations (Table 2). We also investigated the association between these 
three genetic variants and the 31 bp VNTR, of which alleles 19 and 21 were shown 
to be associated with increased post-methionine load tHcy concentrations.[167] The 
positive association between alleles 19 and 21 and post-load tHcy concentrations was 
however not reflected in one of the genotypes defined by the three variants studied 
here. We examined whether alleles 19 and 21 were located on particular haplotypes, 
but found out that this was not the case; six different haplotypes were observed 
containing allele 19, and three containing allele 21 (Table 3).
Linkage disequilibria were calculated between the 699C o T , 1080CoT and the GT 
STR and all were found to be highly significant ( P<0.001; data not shown). All 
pairwise linkage disequilibria between the different CBS alleles are depicted in Table 
4.
Table 3. Haplotypes of the CBS 31 bp VNTR alleles 19 and 21 
and their relative frequencies
Haplotype Polymorphisms Relative frequency
31 bp VNTR GT STR 699CoT 1080CoT
A 19 15 T C 0.036
B 19 16 C C 0.074
C 19 16 C T 0.036
D 19 16 T C 0.448
E 19 17 C T 0.036
F 19 17 T C 0.085
G 21 16 C C 0.190
H 21 16 T C 0.038
I 21 17 C C 0.058
Discussion
In the present study, we investigated the potential involvement of variants in non­
coding regions or silent mutations in the CBS gene by analyzing the 699C o T  and 
1080CoT variants and a GT STR, which is located in the promotor region, as 
markers of possible genetic CBS defects contributing to hyperhomocysteinemia and 
to the risk of arterial occlusive disease. No differences in genotype distributions or 
allele frequencies were found between cases and controls, indicating that no
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particular CBS genotype is over-represented in arterial occlusive disease patients 
compared with controls. We investigated the associations between CBS genotypes 
and plasma tHcy concentrations, especially after methionine loading. The two silent 
mutations as well as the GT STR did not show an association with tHcy 
concentrations, neither fasting, nor post-load, nor on the increase upon methionine 
loading.
Table 4. Linkage disequilibrium coefficients (D') between different alleles of CBS 
polymorphisms. The sign in front of the coefficients indicates whether the rare alleles are 
associated (+) or whether the rare allele is associated with the frequent allele (-).
Polymorphism
Allele
699CoT 1080CoT
1080CoT -0.75 -
-5697 (GT) STR 14 0.71 -0.80
15 0.25 -0.35
16 0.25 -0.08
17 -0.35 0.52
18 -0.47 0.67
19 -0.32 -0.36
Besides fasting plasma tHcy concentrations [28, 91], also post-methionine load tHcy 
concentrations have been associated with an increased CVD risk [28, 29, 172]. 
Verhoef et al. [28] calculated that the risk of coronary artery disease increased with 
20% for each 12 —mol/L increase in post-load tHcy levels. Graham et al. [30] 
reported a relative risk for vascular disease of 1.5 for a subject with a post-load tHcy 
level above the 80th percentile of controls. Since methionine loading particularly 
provocates the transsulfuration of homocysteine into cysteine, in which CBS is the 
regulating enzyme, it has been postulated that hyperhomocysteinemia after 
methionine loading reflects the involvement of suboptimal CBS function [161]. 
Several studies excluded the involvement of heterozygosity for CBS deficiency in 
hyperhomocysteinemia and premature vascular disease [70, 72, 73], but the results 
of these studies do not exclude an involvement of a mildly impaired CBS function. No 
potentially functional polymorphisms associated with hyperhomocysteinemia after 
methionine loading were detected in the CBS gene in the analyses of the genetic 
basis of homocystinuria. However, most studies performed thus far, only examined 
the coding region of the CBS gene, leaving the non-coding regions unexplored. The 
effect of a potential functional polymorphism may be reflected in other, non­
functional, polymorphisms, in case they are in linkage disequilibrium.
Recently, Kruger et al. [173] calculated odds ratios of the 699TT and 1080CC 
genotypes versus the other two genotypes defined by each variant on the risk of 
coronary artery disease and found decreased risks, i.e. protective effects. However, 
individuals with the 699TT or 1080CC genotype had similar fasting tHcy
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concentrations as the other genotypes and, unfortunately, no post-load tHcy 
concentrations were available. They postulated that the 699T and 1080T alleles, may 
be linked to other yet unidentified functional polymorphisms in the CBS gene. These 
results were similar to those of De Stefano et al. [174], who also did not find an 
effect of both CBS 699CoT and the 1080CoT CBS variants on fasting tHcy 
concentrations. They did not examine the association between the CBS variants and 
post-methionine load tHcy concentrations either. Aras et al. [175] reported 
decreased post-methionine load tHcy concentrations in individuals who were 
heterozygous or homozygous for the 699T allele compared with the 699CC subjects. 
This association became more significant when individuals carrying the 844ins68 and 
the 1080T allele were excluded . With regard to the 1080CoT polymorphism, the 
1080T allele was associated with lower post-methionine load tHcy levels only when 
individuals carrying the 844ins68 and the 699T allele were excluded from the 
analysis. They also speculated that the 699C o T  and 1080CoT CBS variants may be 
in linkage disequilibrium with regulatory elements that upregulate CBS gene 
transcription [175]. In the current study however, the two silent polymorphisms as 
well as the GT STR did not show any association with tHcy concentrations, neither 
fasting, nor post-load, nor on the increase upon methionine loading. Both etiologic 
and genetic heterogeneity may play an important role in genetic association studies. 
Since the populations used in the different studies may have a different background, 
it is possible that the actual range of etiologies vary across samples. Allele 
frequencies of the 699CoT and 1080CoT polymorphisms were comparable between 
the three studies published earlier [173-175] and the present one, ranging from 31.8 
to 39.4 %  for the 699T allele and from 32.4 to 35.5 %  for the 1080T allele.
We also investigated the association between these three genetic variants and the 31 
bp VNTR, of which the alleles containing 19 and 21 repeat units were shown to be 
associated with increased post-methionine load tHcy concentrations [167]. However, 
this positive association between alleles 19 and 21 and post-load tHcy concentrations 
was not reflected in one of the genotypes defined by the three variants studied here. 
One explanation is that alleles 19 and 21 are rare (allele frequencies of 10.5% and 
2.7%, respectively) and are therefore not picked up by a genetic association analysis 
described here. Furthermore, we observed that alleles 19 and 21 were both not 
located on one particular haplotype, but that different haplotypes were observed 
containing allele 19, which was also the case for allele 21 (Table 3).
In the present study, we detected strong linkage disequilibria between the CBS 
variants studied. For each pair of alleles, defined by the three CBS variants, linkage 
disequilibrium coefficients (D') were calculated (Table 4). D' between the 699C o T  
and the 1080CoT polymorphisms of -0.75 in our study is similar to that calculated 
by De Stefano et al. [174] of -0.83 in almost 800 subjects recruited from 11 
European countries.
In conclusion, we did not find any genotype, defined by the three CBS variants 
studied here, associated with elevated tHcy concentrations. Although we observed 
strong linkage between these three polymorphisms, no evidence for a common CBS
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polymorphism leading to elevated tHcy concentrations and increased CVD risk was 
found.
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Discussion
About 30 years ago, McCully postulated the hypothesis that mildly elevated tHcy 
concentrations could increase the risk of cardiovascular disease [14] after observing 
artery wall lesions in two different metabolic disorders of the methionine metabolism 
resulting both in elevated tHcy concentrations [3]. Since then many studies have 
been conducted to investigate whether elevated tHcy concentrations are indeed 
associated with an increased risk of cardiovascular diseases. Most of the studies 
performed were of retrospective nature, of which many actually found that elevated 
tHcy concentrations, either fasting or after methionine loading, are more frequently 
shown in patients with vascular disease than in controls subjects, while only some 
did not [23]. Also many prospective studies were described, of which a number 
reported a positive association [51, 90, 126, 176-181] and some no association [86, 
87, 182, 183].
Several studies calculated to what extent increased tHcy concentrations contributed 
to the risk of CVD and found that a 5 —mol/L increase in tHcy leads up to a 70% 
higher risk on CVD [23, 25, 26]. This positive association between tHcy and risk of 
CVD is of similar strength for fasting and postload tHcy levels [28].
High tHcy concentrations may be caused by nutritional deficiencies of folate, vitamin 
B12 and vitamin B6, by age or gender [37], or by lifestyle factors like coffee 
consumption and smoking [47, 48]. In a study among family members of 21 
postload hyperhomocysteinemic vascular patients, it was shown that, after exclusion 
of individuals with vitamin deficiencies, liver and renal diseases, the number of family 
members with hyperhomocysteinemia was much higher than might be expected in 
the normal population [66]. Furthermore, postload mild hyperhomocysteinemia was 
established in at least one other family member in 71% of the families, indicating a 
strong genetic basis of hyperhomocysteinemia. This conclusion that 
hyperhomocysteinemia is, at least partially, genetically based is in line with previous 
reports [62-65, 184]. So, variation in genes encoding for enzymes involved in the 
regulation of homocysteine metabolism may affect tHcy concentrations. The genes 
coding for the enzymes MTHFR, CBS and MS are comprehensible candidates because 
of their direct catalytic involvement in homocysteine and folate metabolism, but 
other enzymes involved in homocysteine metabolism, such as BHMT, SHMT or 
MTHFD, are also potential candidates. In addition, enzymes involved in the 
metabolism of cofactors, such as vitamin B6 or B12, or involved substrates, like folate, 
could be of great importance in maintaining homocysteine homeostasis.
So far, numerous variations in genes involving homocysteine metabolism have been 
described (Table 1), of which the 677CoT polymorphism in the MTHFR gene is the 
most frequently reported.
CBS
844ins68
In the CBS gene several polymorphisms have been reported. A 68 bp insertion 
(844ins68) was first reported in a patient with classical homocystinuria [185], but 
later appeared to be a common variant [74]. This insertion always segregates in c/s
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with the 833ToC mutation, but both are most likely skipped by alternative splicing of 
the CBS mRNA [74, 75]. The 844ins68 does not seem to affect the CBS enzyme 
activity [75] or tHcy concentrations [75, 76]. Although in 1999, Tsai et al. reported 
that carriers of the 844ins68 insertion have even lower post-methionine load 
increases of tHcy when vitamin B6 concentrations were below the sample median of
38.0 nmol/L [170].
Table 1. Possible genetic determinants of tHcy concentrations.
Gene Polymorphism Amino acid 
substitution
Frequency in %o 
(allele)
Effect on 
tHcy*
MTHFR 677CoT A226V 30-40 (T) +
1298AoC E433A 30-40 (C) +/-
CBS 844ins68 - 5-12 (ins) 0
14037 31 bp VNTR - na ** +
-5707 GT STR - na ** 0
699CoT Y233Y 30-40 (T) 0
1080CoT A360A 30-45 (T) 0
MS 2756AoG D919G 15-20 (G) +/-
MTTR 66AoG I22M 50 (G) +/-
BHMT 595GoA G199S 1 (A) 0
716GoA Q239R 32 (A) 0
1218GoT Q406H < 1 (T) 0
cSHMT 1420CoT L474F 32 (T) +/-
MTHFD 1958GoA R653Q 44 (A) 0
TC 67AoG I23V 13 (G) +/-
280GoA G94S < 1 (G) 0
776CoG P259R 50 (G) +/-
1043CoT S348F 11 (T) 0
1196GoA R399Q 2 (A) 0
GCPII 1561CoT H475Y 5-10 (T) +/-
RFC 80GoA R27H 48 (A) 0
* +: clear association; +/-: possible association; 0: no association 
** not applicable
31 bp VNTR
In 1998, Kraus et al. described the complete nucleotide sequence of the human CBS 
gene and reported a variable number of tandem repeat (VNTR) polymorphism of 31 
bp in intron 13 [157]. However, after closer examination we found that this 31 bp 
VNTR spans the exon 13-intron 13 boundary and could therefore contain multiple 
splice donor sites, with possible repercussions on CBS protein and, consequently, 
function. We found that this 31 bp VNTR is associated with a significant increase in 
post-methionine load tHcy concentrations and showed evidence of alternative 
splicing in individuals with different VNTR genotypes [167; Chapter 7 of this thesis]. 
In addition, we observed a negative correlation between CBS enzyme activity and an 
increasing number of repeat units, which corroborates the positive association 
between the VNTR and postload tHcy concentrations. We later confirmed the positive
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association between post-methionine load tHcy concentrations and number of repeat 
units in more than 1400 subjects of the Framingham Offspring Study (Chapter 8 of 
this thesis). Yang et al. [166] reported lower post-methionine load tHcy 
concentrations in the 17-18 as well as the 18-19 genotype compared with the most 
common 18-18 genotype.
699CoT (Y233Y) and 1080CoT (A360A)
These two silent polymorphisms in the CBS gene have been studied as possible 
determinants of tHcy concentrations and risk of CAD or as markers for possible 
functional variants in the CBS gene [173-175]. De Stefano et al. [174] found no 
association between these CBS variants and tHcy concentrations, while Aras et al. 
[175] reported decreased post-methionine load tHcy concentrations in individuals 
who were heterozygous or homozygous for the 699T allele compared with the 699CC 
subjects. This association became more significant when individuals carrying the 
844ins68 and the 1080T allele were excluded. With regard to the 1080CoT 
polymorphism, the 1080T allele was associated with lower post-methionine load tHcy 
levels only when individuals carrying the 844ins68 and the 699T allele were excluded 
from the analysis. They speculated that the 699CoT and 1080CoT CBS variants 
may be in linkage disequilibrium with regulatory elements that upregulate CBS gene 
transcription [175]. In 2000, Kruger et al. [173] failed to find an association between 
the two silent CBS variants and tHcy concentrations, while in their study population 
of 142 CAD patients and 105 controls, the homozygous 699TT individuals as well as 
the 1080CC subjects were significantly underrepresented in the patients. We 
however, did not observe any association between tHcy concentrations and the 
different genotypes of these two CBS variants [186; Chapter 9 of this thesis].
MS
In the MS gene, a single nucleotide polymorphism was identified at position 2756,
i.e. an A to G transition (D919G) [110]. Harmon et al. [123] reported a relative risk 
of 1.58 (95% CI: 1.14-2.19) of the 2756AA genotype versus the AG and GG 
genotype, for having a tHcy concentration in the top half of the distribution. Several 
years later, Hyndman et al. calculated that the 2756AG heterozygotes were less likely 
to have a recurrent vascular event than the AA individuals [OR: 3.4 (95% CI 1.09­
10.9)]. Furthermore, this 2756AoG polymorphism did not affect tHcy concentrations 
but the red blood cell folate levels were significantly elevated in the 2756AG 
heterozygotes compared with the AA subjects [118]. Chen et al. [116] also 
investigated the association between this MS variant and plasma tHcy 
concentrations, folate levels and risk of myocardial infarction (MI). They found a non­
significant reduction of MI risk of the GG versus the AA individuals and a trend to 
decreased tHcy concentrations. In our study population of CVD patients and healthy 
controls the 2756GG genotype was significantly associated with increased CHD risk, 
whereas the AG genotype was inversely, although not significantly, associated with
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CHD risk. The 2756AoG polymorphism was, in our study population, not associated 
with fasting or post methionine load tHcy levels (Chapter 4 of this thesis).
MTRR
The enzyme methionine synthase reductase (MTRR) is needed to maintain MS in its 
active state. Polymorphisms of MTRR might therefore influence tHcy concentrations. 
Mutation analysis of the MTRR gene in homocystinuric patients belonging to the cblE 
complementation group led to the discovery of a polymorphism, an A to G 
substitution at bp 66 (I22M), that is common in the general population [187]. In a 
subsequent study, the 66GG genotype appeared to increase the risk of NTD 
pregnancy outcome in women with low vitamin B12 levels, while no association 
between the 66AoG polymorphism and tHcy concentrations was reported [187]. 
This polymorphism was also reported to be a risk factor for the development of 
premature CAD with a relative risk of 1.49 (95% CI 1.10-2.03) in 66GG subjects 
compared with 66AA individuals. Again, there was no difference in tHcy, plasma 
folate, and vitamin B12 concentrations between the three 66A o G  genotypes [188]. 
In a study of 601 Northern Irish men, Gaughan et al. [189] established a relative risk 
of 1.59 (95% CI, 1.10-2.25) for the 66AA genotype to be in the upper half of the 
tHcy distribution. This tHcy elevating effect was found independent of serum folate, 
vitamin B12 and B6 levels and the estimated effect of the 66AA genotype on CVD risk 
was an approximately 4% increase compared with the 66GG genotype.
BHMT
BHMT is the enzyme which, along with MS, remethylates homocysteine to 
methionine, but is primarily expressed in liver and kidney. There is only one study 
which reported polymorphisms in the BHMT gene and the influence of three BHMT 
variants on tHcy concentrations and CVD risk [190; Chapter 6 of this thesis]. One 
variant, the 1218GoT (Q406H) substitution, was found in only one patient and one 
control in heterozygous state. The other two, the 595G o A  (G199S) and the 716GoA  
(Q239R) transitions, were found more frequently but showed no associations with 
tHcy concentrations and were not associated with and increased CVD risk.
MTHFR
677CoT (A226V)
Kang et al. described a thermolabile form of MTHFR in 1988 [77] and the 677CoT  
variant turned out to be responsible for this phenomenon [79]. The 677CoT variant 
in the MTHFR gene correlated with reduced enzyme activity and increased 
thermolability of the enzyme in lymphocyte extracts in both heterozygous and 
homozygous state. In addition, 677TT homozygotes had significantly elevated tHcy 
concentrations [79]. This thermolabile MTHFR was identified in different forms of 
premature vascular disease and its incidence was estimated to be 28% in 
hyperhomocysteinemic vascular patients [69]. Since then, numerous studies have 
been reported which investigated this MTHFR variant on its association with tHcy
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concentrations and CVD risk [83]. Although an association between the 677CoT  
variant and elevated tHcy concentrations was universally found [70, 72, 79-82, 98, 
102, 104, 124], an increased risk for CVD was found in only some of these studies 
[70, 72]. The association between the 677CoT variant and elevated tHcy 
concentrations was reported to exist only in individuals with low folate status [81, 
82]. In 1998, the hypothesis that this variant would be associated with altered 
distribution of red blood cell (RBC) folates was tested by a chromatographic method 
in vitro [191]. Probably due to the reduced MTHFR enzyme activity, formylated 
tetrahydrofolate polyglutamates were present at the expense of methylTHF in most 
677TT individuals.
1298AoC (E433A)
In 1998, a second common polymorphism in the MTHFR gene was described, i.e. the 
1298AoC transition, that mandates an amino acid substitution of glutamate by 
alanine [93]. This variant was observed only in trans with the 677CoT variant and 
was associated with decreased MTHFR enzyme activities. In chapter 2 of this thesis 
we described the associations of this 1298AoC variant with MTHFR enzyme activity, 
tHcy concentrations and risk of CVD. We also detected a decrease in enzyme activity, 
both in individuals with the 1298AC and 1298CC genotype, but noted no effect on 
the thermostability of the enzyme nor on tHcy concentrations [192; Chapter 2 of this 
thesis]. Although all studies corroborate that the 1298AoC variant is associated with 
decreased MTHFR activities [93, 99, 100, 192], which was supported by expression 
analysis in E. coli [193], an association with tHcy concentrations was in general not 
detected [99-101, 194-198]. Probably, other factors that affect tHcy concentrations, 
like nutritional status, play a role or the decreased MTHFR enzyme activity must 
reach a certain threshold below which it will result in increased tHcy concentrations.
SHMT
In humans, SHMT is present as two iso-enzymes, one located in the mitochondrion 
and the other in the cytoplasm [199]. In 1999, the genes for both isoforms were 
sequenced and in both genes several variations were found [200]. One 
polymorphism in the cytosolic SHMT, the 1420C o T  (L474F), was associated with 
increased tHcy concentrations and decreased plasma and red blood cell folate levels 
in 1420CC homozygotes. This polymorphism may cause a shift in distribution of the 
different folate derivatives and its repercussions on homocysteine/folate metabolism 
deserve further attention, e.g. by in vitro expression analysis.
MTHFD
In the MTHFD gene, a 1958GoA (R653Q) substitution was detected in NTD patients 
and controls, but no association between this variant and tHcy concentrations was 
found [201].
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TC
Since transcobalamin (TC) is the transporter of vitamin B12 to the cells and vitamin 
B12 is the cofactor for MS, variation in the TC gene could affect tHcy concentrations. 
Several variants have been reported in the TC gene [132, 134, 135], of which the 
779CoG (P259R) polymorphism is the most studied. In 1998, Namour et al. [137] 
reported a lower vitamin B12 level as well as a lower apo-TC (the proportion of TC 
that does not contain vitamin B12) concentration in subjects carrying the 779G allele. 
Several years later, they reported the same results with respect to apo-TC levels, but 
observed no differences in vitamin B12 concentrations between the 779CoG  
genotypes and concluded that the 779C allele might enhance the intracellular vitamin 
B12 availability [138]. McCaddon et al. [202] studied this TC 779CoG variant in 73 
healthy elderly volunteers and in 71 dementia patients and observed no association 
with either vitamin B12 levels nor with tHcy concentrations. Lower holo-TC (the 
proportion that contains vitamin B12) levels of the 779G allele were reported by 
Afman et al. [141] in a population of 46 mothers with a NTD child and 73 controls, 
whereas no association between the 779CoG genotypes and tHcy concentrations 
was observed. Later, in the same study population, this 779G allele was found to be 
associated with a lower total-TC, lower apo-TC as well as a lower holo-TC/total-TC 
ratio, suggesting that the TC 779C o G  variant may result in a disturbance of the 
vitamin B12 binding to TC [139].
Our results [203; Chapter 5 of this thesis] showed an association between the 259PP 
genotype and decreased tHcy concentrations only when the vitamin B12 status 
reached above 299 pmol/L. These data indicate that in particular 259PP individuals 
benefit from high vitamin B12 levels with respect to tHcy lowering, in contrast to their 
259PR and 259RR peers, and suggest a gene-environment interaction between this 
TC variant and vitamin B12 levels. We therefore also investigated whether the P259R 
variant influenced the slope of the curve relating plasma tHcy and vitamin B12 levels 
and we observed a clear negative correlation between vitamin B12 levels and plasma 
tHcy in 259PP individuals as well as in 259PR heterozygotes, while in subjects with 
the 259RR genotype no such association was found. Possibly, the 259P allele affects 
TC transcription or binding and transport of vitamin B12 by TC with positive 
repercussions on intracellular availability of vitamin B12.
Other variants in the TC gene are the M198T, I219L, S376L [134], the Q234R [135], 
the I23V [132] and the G94S, S348F and R399Q [139]. The latter four were also 
examined for their possible role in homocysteine metabolism [203; Chapter 5 of this 
thesis], but only the I23V polymorphism seemed to have an association with tHcy 
concentrations, although this was only observed in the three homozygous 23VV 
individuals. These TC variants were also studied in another study by us, but none of 
these was found to be associated with tHcy concentrations [139].
GCPII
Folate plays an important role in homocysteine metabolism as the substrate for 
MTHFR. Dietary folates are a mixture of polyglutamylated folates and since
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polyglutamates are poorly transported across membranes, they have to be 
hydrolyzed in the digestion system to monoglutamyl folates by the action of 
folylpoly-j-glutamate carboxypeptidase (FGCP). This enzyme is expressed by the 
glutamate carboxypeptidase gene II (GCPII). Variation in this gene could therefore 
affect the intestinal absorption of dietary folates, resulting in altered blood folate 
levels and, consequently, tHcy concentrations. In 2000, Devlin et al. [106] reported a 
C to T substitution at bp 1561 (H475Y) and examined the functional significance of 
this variant in vitro. Compared with FGCP activity in wildtype transfectants, the 
1561CoT variant resulted in a significant reduction in FGCP activity by 53%. In 
addition, among 75 healthy subjects six subjects heterozygous for the 1561CoT 
variant had lower plasma folate levels and higher tHcy concentrations than the 
1561CC individuals. They postulated that the presence of the 1561CoT variant 
impaired the intestinal absorption of dietary folates, resulting in relatively low blood 
folate levels and hyperhomocysteinemia. These results however, were contradicted 
by our results [204; Chapter 3 of this thesis]. We investigated the relationship 
between the 1561CoT variant in the GCPII gene with fasting, post-methionine load 
tHcy, folate and vitamin B12 levels and the risk of cardiovascular disease (CVD) in 190 
vascular disease patients and in 601 apparently healthy controls. Although no clear 
association was seen between the variant and tHcy concentrations and vitamin B12 
levels, the 1561CoT polymorphism significantly increased both red blood cell folate 
and plasma folate concentrations (ANOVA 3=0.013; test for linear trend 3=0.03, 
respectively).
Reduced-Folate Carrier
A polymorphism, the 80GoA (R27H), in the reduced folate carrier gene, the 
candidate gene for 5-MeTHF internalization within cells, was reported by Chango et 
al. [205]. This variant however was not associated with a change in tHcy, plasma 
and red blood cell folate concentrations.
Other
In NTD patients, a polymorphism in the folate receptor-alpha gene has been 
investigated, though its association with tHcy concentrations was not investigated 
[206]. We also explored this folate receptor-alpha gene as well as the folate 
receptor-beta gene for variants in spina bifida patients, mothers of a spina bifida 
child and controls, but no polymorphisms were found [207].
Gene-gene interactions
A combination of multiple variants was studied by Tsai et al. [124]. They studied the 
combined effect of the CBS 844ins68 variant, the 677C o T  MTHFR variant and the 
2756AoG polymorphism in the MS gene, on either fasting of post-methionine load 
tHcy concentrations and found that the effects of these three variants were additive 
and therefore demonstrated a polygenic regulation of tHcy concentrations [124]. 
Another genetic interaction analysis was carried out by Dekou et al. [208] to
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determine whether the effects of three variants, the MTHFR 677CoT , the MS 
2756AoG and the CBS 844ins68, on tHcy levels were independent and additive. 
They observed that the tHcy raising effect of the 677TT genotype was absent in 23 
men who also carried the CBS 844ins68 insertion. In the group of men homozygous 
for the MS 2756AoG variant, those carrying the CBS 844ins68 allele had lower tHcy 
concentrations than those lacking the insertion. A similar analysis for the effects of 
MTHFR and MS genotypes suggested that the tHcy increasing effect of both variants 
was additive. For all of these gene-gene effects the possible involvement of 
nutritional status was explored but were not substantially altered by these 
adjustments. Recently, Feix et al. [209] reported that the 2756AoG transition in the 
MS gene in combination with the MTHFR 677TT/1298AA and 677CT/1298AC is 
associated with high tHcy concentrations. However, when they confined their 
analysis to only the MS variant, they did not observe any association with tHcy 
concentrations whatsoever [209].
So, although the majority of studies on genetic regulation of tHcy concentrations 
have been confined to a single polymorphism, the few studies on gene-gene 
interaction document polygenic influence on tHcy concentrations. Therefore, studies 
which do not confine their analyses to a single polymorphism are probably very 
interesting for studying the genetic basis of hyperhomocysteinemia.
Gene-environment interactions
Many studies have demonstrated the importance of nutritional regulation of tHcy 
concentrations [39]. An interaction between micronutrient deficiencies and defects in 
genes regulating homocysteine metabolism has in particular been demonstrated for 
the 677CoT polymorphism in the MTHFR gene [82]. Since many nutritional factors 
like folate or B-vitamins play an important role in the homocysteine metabolism as 
cofactors or substrate, further research on an interactive role between these factors 
and genetic variation is warranted.
In conclusion, many variants in genes involved in the homocysteine metabolism have 
been studied by now. Besides the 677CoT polymorphism in the MTHFR gene, which 
has a pronounced effect on tHcy concentrations, several other variants have been 
reported to influence homocysteine metabolism by affecting enzyme activity, like the 
MTHFR 1298AoC and CBS 31 bp VNTR, or by showing an association with tHcy 
concentrations, like the MS 2756AoG, cSHMT 1420CoT, the MTRR 66AoG and the 
GCPII 1561CoT variants. Despite the large number of publications on the 
association between elevated tHcy concentrations and various polymorphisms, our 
understanding of the etiology of moderately elevated tHcy concentrations is still 
incomplete. Although there is a wide agreement that both genetic and nutritional 
factors are implicated, all the genetic variations described so far do not seem to 
comprise the genetic component of hyperhomocysteinemia in the general population. 
In a recent, yet unpublished study, Kluijtmans et al. (personal communication) found 
that these known polymorphisms did explain only 9%o of the overall variance in the
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plasma tHcy concentrations, which was almost entirely explained by the MTHFR 
677CoT polymorphism. Probably, more genetic variations in genes involved in 
homocysteine metabolism are present. Genes that could be eligible as candidate are 
genes involved in transport or absorption of folate, such as the folate binding 
protein, or cofactors like vitamin B12 and B6. Also (other) variants, in the genes 
mentioned here, can be further examined on their role and effect on tHcy 
concentrations and/or CVD risk. Besides the genes of key enzymes in the 
homocysteine metabolism, other genes coding for enzymes that might be relevant 
for homocysteine homeostasis could be important. Therefore, a genome-wide 
approach using linkage and association in large family cohorts is a powerful tool to 
discover unknown polymorphisms that influence homocysteine concentration in 
humans.
Genetic determinants and CVD risk
Since the discovery of the thermolabile 677C o T  MTHFR variant, much effort has 
been directed towards determining its clinical significance. Despite its association 
with tHcy concentrations, which is universally reported [84], only a few studies 
reported this MTHFR variant as a risk factor for cardiovascular diseases [70, 72] 
while many others were not able to find such an association. The question raises 
whether this can be ascribed to the lack of power of the individual studies, or 
whether this variant has actually no clinical significance [83]. On the basis of the 
average difference in tHcy concentration between the 677TT and the 677CC 
genotypes of ~2.6 —mol/L [84] and the association of a 1 —mol/L increase in tHcy 
concentration with a 10% increase in risk of vascular disease [23], the expected 
odds ratio for the 677TT genotype compared with the 677CC genotype is 1.26 [210]. 
The odds ratio calculated by Brattstrom et al. in their meta-analysis [84] of 1.12 
(95% CI 0.92-1.37) is well in line with an effect of this magnitude. At the moment, 
the results of the largest meta-analysis with ~12000 cases and ~12000 controls, in 
which data of 25 studies have been pooled, are analyzed [211]. This analysis has the 
power to investigate whether this 677TT genotype is related to increased CVD risk. 
The outcome of this analysis should give a definite answer to the question whether 
the 677TT genotype is related to an increased risk of CVD. If indeed a significant 
odds ratio of coronary heart disease (CHD) for those with the 677TT genotype is 
observed, these results would plea for tHcy being causally related to CVD, since 
having the 677TT genotype can be considered a lifelong exposure to increased tHcy 
concentrations.
Despite the clear association between increased tHcy concentrations and risk of CVD, 
it is still under debate whether elevated tHcy concentrations are the cause of the 
disease or an effect of the vascular event. The main part of the studies, including the 
prospective studies, find increased tHcy concentrations associated with CVD risk. The 
magnitude of these associations however, do differ substantially between the several 
studies. Generally, the risk determined in prospective studies is less strong than 
those calculated in retrospective studies [25] and this can point to bias.
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In addition, the pathogenic mechanism to which tHcy can affect CVD risk, is still not 
clarified. Genetic analysis, as described above in which the association between 
genetic variants and risk of CVD is established, may provide a clarification in the 
question whether tHcy is causally related to CVD.
Intriguing are recent results from a placebo controlled intervention trial, in which a 
combination of folic acid, vitamin B12 and pyridoxine was administered to 205 CVD 
patients, which resulted in a lower rate of restenosis in patients assigned to folate 
treatment compared with the placebo group [212]. Furthermore, in patients treated 
with folate with no response, i.e. no decrease of tHcy concentrations, no 
improvement in the rate of restenosis was observed. These results point to a causal 
involvement of homocysteine in cardiovascular disease, although an involvement of 
other effects of folate treatment cannot be excluded. Moreover, the rate of 
restenosis is a surrogate endpoint of CVD and despite these encouraging data, 
intervention studies on hard clinical endpoints, i.e. the prevention of cardiovascular 
disease, are required before hyperhomocysteinemia will generally be accepted as a 
preventable risk factor for CVD.
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S u m m a ry
Homocysteine is an amino acid that plays a pivotal role in methionine metabolism. 
Moderately elevated plasma tHcy concentrations are considered to be a risk factor 
for cardiovascular diseases (CVD). Plasma tHcy concentrations are influenced by 
environmental factors, such as diet and lifestyle factors, and by genetic factors, like 
an inherited enzyme deficiency due to variation in the genes encoding these 
enzymes. This thesis describes several variants in the genes involved in 
homocysteine/methionine metabolism and their associations with plasma tHcy 
concentrations and risk of CVD.
A general introduction on homocysteine metabolism, its relationship with CVD and 
determinants of hyperhomocysteinemia are described in ch a p te r 1. After this 
general introduction, this thesis is divided in two parts: the first part deals with 
variation in genes involved in the remethylation of homocysteine (P a rt 1, ch a p te rs  
2-6). The second part deals with genetic variation in the degradation of 
homocysteine via the transsulfuration pathway in which CBS is the regulating enzyme 
(P a rt 2, ch a p te rs  7-9).
The most extensively studied genetic determinant of tHcy concentrations is the 
6 7 7 C o T  polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene. 
MTHFR catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5- 
methyltetrahydrofolate, which is the methyl donor in the remethylation of 
homocysteine by methionine synthase (MS). We analyzed two MTHFR variants, i.e. 
6 7 7 C o T  (A226V) and 1298AoC (E433A), and studied their association with MTHFR 
enzyme activity, plasma tHcy concentrations and risk of CVD (ch a p te r 2). We 
observed a significant decrease in MTHFR enzyme activity in both 677CT and 677TT 
subjects as well as increased fasting and post-methionine load tHcy concentrations. 
The 1298AoC variant was also associated with decreased MTHFR enzyme activities, 
in both 1298AC and 1298CC individuals, but showed, in contrast to the 677C o T  
variant, no association with tHcy concentrations.
Dietary folates are a mixture of polyglutamylated folates which need to be 
hydrolyzed to monoglutamyl folates before they can be absorbed from the intestine. 
In ch a p te r 3, we describe a genetic variant, i.e. 1561C oT (H475Y), in the 
glutamate carboxypeptidase II (GCPII) gene and studied its relationship with fasting, 
post-methionine load plasma tHcy, folate and vitamin B12 levels and the risk of 
cardiovascular disease (CVD). The GCPII gene encodes the enzyme folylpoly-j - 
glutamate carboxypeptidase (FGCP), which hydrolyzes polyglutamates to 
monoglutamyl folates in the intestine. No clear association was seen between this 
variant and plasma tHcy concentrations, but the 1561C oT polymorphism was 
associated with significantly increased red blood cell folate and plasma folate 
concentrations. However, this variant was not associated with CVD risk.
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Methionine synthase (MS) catalyzes the remethylation of homocysteine to 
methionine, which requires 5-methyltetrahydrofolate as methyl donor and vitamin B 12 
as a cofactor. In ch a p te r 4, a single nucleotide polymorphism in the MS gene, the 
2756AoG (D919G), is described in 123 CVD patients and 540 healthy controls. In 
this study population, the 2756AoG  polymorphism was found not to be associated 
with fasting or post methionine load tHcy concentrations. However, the 2756GG 
genotype was significantly associated with increased CHD risk of 3.5, whereas the AG 
genotype did not show an association with CHD risk. A meta-analysis was performed 
with available studies so far and results of this meta-analysis indicated that neither 
the AG and GG genotype are significant risk factors for CHD.
Vitamin B12 is the cofactor for MS and transcobalamin (TC) is responsible for vitamin 
B12 transport to the cells. Variation in the TC gene could therefore affect tHcy 
concentrations by influencing intracellular availability of vitamin B 12. In ch a p te r 5, 
we report on the associations between five sequence variants in the TC gene and 
plasma tHcy, vitamin B12 concentrations and risk of CVD. Our results showed an 
association between the 259PP individuals of the 7 7 6 C o G  (P259R) variant and 
decreased tHcy concentrations, only when their vitamin B12 status reached above 
299 pmol/L. These data indicate that in particular 259PP individuals benefit from high 
vitamin B12 levels with respect to homocysteine lowering, in contrast to their 259PR 
and 259RR peers, and suggest a gene-environment interaction between this TC 
variant and vitamin B12 levels. Possibly, the 259P allele affects TC transcription or 
binding and transport of vitamin B12 by TC with positive repercussions on intracellular 
availability of vitamin B12. Also the 6 7 A o G  (I23V) polymorphism seemed to have an 
association with tHcy concentrations, although decreased tHcy concentrations were 
only observed in the three homozygous 23VV individuals.
Betaine-homocysteine methyltransferase (BHMT) is the enzyme which, along with 
MS, remethylates homocysteine to methionine. In C h a p te r 6 the molecular genetic 
analysis of the coding region of BHMT gene is described, in which three variants 
were discovered, i.e. 595G oA , 7 1 6 G oA  and 1218GoT. We subsequently 
investigated the influence of these variants on homocysteine metabolism in a study 
group of vascular cases and healthy controls. One variant, the 1218G o T  (Q406H) 
substitution, was found in heterozygous state in only one patient and in one control 
individual. The other two polymorphisms, the 595G o A  (G199S) and the 7 1 6 G oA  
(Q239R) transitions, were found at a higher frequency but showed no associations 
with tHcy concentrations and were not associated with an increased CVD risk. So, we 
did not find an involvement of genetic variation in the BHMT gene in 
hyperhomocysteinemia.
In p art 2 of this thesis, the role of genetic variation in the degradation of 
homocysteine via the transsulfuration pathway, in which CBS is the regulating 
enzyme, was investigated. CBS deficiency is the most common cause of severe
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hyperhomocysteinemia, and genetic studies excluded heterozygosity for CBS 
deficiency as an important contributor to moderately elevated tHcy levels. However, 
genetic variants causing mild CBS dysfunction, and which lead to 
hyperhomocysteinemia after methionine loading have not been examined as yet.
We investigated the involvement of a 31 bp variable number of tandem repeats 
(VNTR) in the CBS gene in hyperhomocysteinemia, and observed five different 
alleles, i.e. alleles 16, 17, 18, 19 and 21, as described in ch a p te r 7. We found that 
this 31 bp VNTR is associated with a significant increase in post-methionine load tHcy 
concentrations, i.e. a 10-20% increase in tHcy concentrations in individuals with 
genotypes 19-19 and 21-21 compared with the most common 18-18 genotype. We 
also provided evidence of alternative splicing in individuals with different VNTR 
genotypes. In addition, we observed a clear negative correlation between CBS 
enzyme activity and an increasing number of repeat units, which corroborates the 
positive association between the VNTR and post-load tHcy concentrations. We 
confirmed the positive association between post-methionine load tHcy concentrations 
and the number of repeat units in a group of more than 1400 subjects of the 
Framingham Offspring Study, which is described in ch a p te r 8 of this thesis. We 
were also able to investigate possible effect modification, in particular by vitamin B6, 
which is a cofactor of CBS. We however, found no influence of vitamin B6 
concentrations on the observed association between post-methionine load tHcy 
concentrations and the number of repeat units.
Genetic association studies are widely used for the identification of candidate genes 
of complex, i.e. non-mendelian traits. In such studies, the association between a 
phenotype and genomic markers close to or, preferably, within the gene of interest is 
investigated. Such a marker in itself is not necessarily functionally related to the 
phenotype but may be in linkage disequilibrium with a functional variant. In a study, 
described in chap te r 9, we investigated a potential involvement of variants in non­
coding regions or of silent mutations in the CBS gene in hyperhomocysteinemia and 
vascular disease, as possible markers which may be in linkage disequilibrium with a 
functional polymorphism. We analyzed two silent single nucleotide polymorphisms, 
i.e. 699CoT (Y233Y) and 1080CoT (A360A), and a short tandem repeat (STR) -  
5697(GT) in the CBS gene in 190 vascular disease patients and in 381 population- 
based controls. Although we observed strong linkage between these three 
polymorphisms, no evidence for a common CBS polymorphism leading to elevated 
tHcy concentrations and increased CVD risk was found.
In chap te r 10, we described a detailed list of all possible genetic determinants of 
homocysteine and discussed their relevance to CVD risk.
In conclusion, many variants in genes involved in the homocysteine metabolism have 
been studied by now. In this thesis, several genetic variants have been reported to
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influence homocysteine metabolism by affecting enzyme activity, or by showing an 
association with plasma tHcy concentrations. However, our understanding of the 
genetic etiology of moderately elevated plasma tHcy concentrations is still 
incomplete, since all the genetic variations described so far do not seem to comprise 
the genetic component of hyperhomocysteinemia in the general population. 
Probably, more variation in genes involved in homocysteine metabolism are present. 
Genetic analyses, as described in this thesis, in which the association between 
genetic variants and tHcy concentrations and risk of CVD is studied, may provide 
more insight in the genetic basis of hyperhomocysteinemia and possibly give a 
clarification in the question whether homocysteine is causally related to CVD.
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S a m en vattin g
Homocysteine is een aminozuur dat een centrale rol speelt in het methionine 
metabolisme. Verhoogde plasma homocysteine concentraties worden als een 
risicofactor voor hart- en vaatziekten (HVZ) beschouwd. Plasma homocysteine 
concentraties worden beinvloed door omgevingsfactoren, zoals dieet en levensstijl, 
en door genetische factoren, zoals een erfelijke enzymdeficiëntie of als gevolg van 
variatie in de genen die coderen voor deze enzymen. Dit proefschrift beschrijft 
verscheidene genetische varianten in de genen die betrokken zijn bij het 
homocysteïne/methionine metabolisme en hun associatie met plasma homocysteine 
concentraties en het risico op HVZ.
Een algemene introductie over het homocysteïne metabolisme, de relatie tussen 
hyperhomocysteïnemie en HVZ en de determinanten van hyperhomocysteïnemie 
worden beschreven in h o o fd stu k  1. Na deze algemene introductie is het 
proefschrift in twee delen ingedeeld: in het eerste deel worden genetische variaties 
in genen betrokken bij de remethylering van homocysteïne behandeld (D eel 1, 
h oo fd stu kk en  2-6), en in het tweede deel worden de gevonden varianten in de 
degradatie van homocysteïne via de transsulfurerings route, waarin cystathionine ß- 
synthase (CBS) het regulerende enzym is, beschreven (D eel 2, h o o fd stu kk e n  7 ­
9).
De meest bestudeerde genetische determinant van homocysteïne concentraties is 
het 6 7 7 C o T  polymorfisme in het methyleentetrahydrofolaat reductase (MTHFR) gen. 
MTHFR katalyseert de reductie van 5,10-methyleentetrahydrofolaat tot 5- 
methyltetrahydrofolaat, wat de methyldonor is in de remethylering van homocysteïne 
door het enzym methionine synthase (MS). In h o o fd stu k  2 hebben we twee MTHFR 
varianten geanalyseerd, de 677CoT(A226V) en 1298AoC (E433A), en hebben de 
associatie tussen beide varianten en MTHFR enzymactiviteit, plasma homocysteïne 
concentraties en het risico op HVZ bestudeerd. Hierbij vonden we een significante 
verlaging van de MTHFR enzymactiviteit in zowel 677CT als 677TT individuen en een 
verhoogde nuchter en methionine-belaste homocysteïne concentratie. De 1298A o C  
variant was eveneens geassocieerd met verlaagde MTHFR enzymactiviteit, maar 
vertoonde, in tegenstelling tot de 6 7 7 C o T  variant, geen associatie met 
homocysteïne concentraties. Mogelijk spelen andere factoren die de MTHFR 
enzymactiviteit in vivo beïnvloeden een rol, of moet de MTHFR enzymactiviteit een 
bepaalde drempel bereiken waaronder het resulteert in verhoogde plasma 
homocysteïne concentraties.
In het dieet zijn folaten een mengeling van polyglutamaten die gehydrolyseerd 
moeten worden tot monoglutamaten voordat ze inwendig kunnen worden 
opgenomen. In h o o fd stu k  3 hebben we een genetische variant, de 1561C oT  
(H475Y), in het glutamaat carboxypeptidase II (GCPII) gen onderzocht en de relatie 
met nuchtere en methionine-belaste plasma homocysteïne, plasma folaat en vitamine
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B12 spiegels en het risico op HVZ bestudeerd. Het GCPII gen codeert voor het enzym 
folylpoly-j-glutamaat carboxypeptidase (FGCP), dat in de darmen polyglutamaten 
hydrolyseert tot monoglutamaten. We vonden geen associatie tussen deze variant en 
plasma homocysteïne concentraties, maar het 1561CoT polymorfisme was 
geassocieerd met significant verhoogde folaat concentraties in de rode bloedcel en in 
het plasma. Een mogelijke associatie met het risico op HVZ kon niet worden 
aangetoond.
Methionine Synthase (MS) katalyseert de remethylering van homocysteïne tot 
methionine en vereist 5-methyltetrahydrofolaat als methyldonor en vitamine B 12 als 
co-factor. In h o o fd stu k  4  hebben we een nucleotide substitutie in het MS gen, de 
2756AoG (D919G), in 123 HVZ patiënten en 540 gezonde controles bestudeerd. In 
deze populatie was het 2756AoG polymorfisme niet geassocieerd met nuchtere of 
methionine-belaste homocysteïne concentraties. Het 2756GG genotype was echter 
wel significant geassocieerd met een verhoogd HVZ risico van 3,5, terwijl het AG 
genotype niet geassocieerd was met het risico op HVZ. Een meta-analyse van 5 
beschikbare studies wees uit dat noch het AG noch het GG genotype geassocieerd 
waren met een significant verhoogd risico op HVZ.
Vitamine B12, de co-factor voor MS, wordt door transcobalamine (TC) naar de cellen 
getransporteerd. Variaties in het TC gen zouden daardoor een effect kunnen hebben 
op de homocysteïne concentraties door de beschikbaarheid van vitamine B12 in de cel 
te beïnvloeden. In h o o fd stu k  5 rapporteren we over de associaties tussen vijf 
polymorfismen in het TC gen en plasma homocysteïne, vitamine B12 concentraties en 
het risico op HVZ. Onze resultaten laten een associatie zien tussen plasma 
homocysteine concentraties en het TC 776CoG  (P259R) genotype in een subgroep 
van de studiepopulatie: de 259PP individuen hadden een verlaagde plasma 
homocysteïne concentratie, alleen bij een plasma vitamine B12 status boven de 299 
pmol/L. Deze data geven aan dat 259PP individuen mogelijk profiteren van hoge 
vitamine B12 spiegels met betrekking tot het verlagen van homocysteïne 
concentraties en suggereren een gen-omgevingsinteractie tussen dit TC genotype en 
vitamine B12 spiegels. Mogelijk beïnvloedt het 259P allel de TC transcriptie of binding 
en transport van B12 door TC, met mogelijke gevolgen voor de beschikbaarheid van 
vitamine B12 in de cel. Ook het 67AoG  (I23V) polymorfisme leek een associatie te 
vertonen met homocysteïne concentraties, hoewel verlaagde homocysteïne 
concentraties slechts in drie homozygote 23VV individuen werden waargenomen.
Betaine-homocysteïne methyltransferase (BHMT) is het enzym dat, evenals MS, 
homocysteïne remethyleert tot methionine. In h o o fd stu k  6 is de moleculair- 
genetische analyse van de coderende regio van het BHMT gen beschreven, waarbij 
drie varianten werden gevonden: 595GoA, 716GoA en 1218GoT. Vervolgens 
onderzochten we de invloed van deze varianten op het homocysteïne metabolisme in 
een studie groep van HVZ patiënten en gezonde controles. Eén variant, de 1218G o T
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(Q406H) substitutie, werd in heterozygote vorm in één patiënt en in één controle 
gevonden. De twee andere polymorfismen, de 5 9 5 G o A  (G199S) en 7 1 6G oA  
(Q239R) transities, werden in een hogere frequentie aangetroffen, maar vertoonden 
geen associatie met homocysteïne concentraties en waren niet geassocieerd met een 
verhoogd risico op HVZ. Onze studie liet geen betrokkenheid zien van genetische 
variatie in het BHMT gen in hyperhomocysteïnemie.
In dee l 2 van dit proefschrift, wordt de rol van genetische variatie in de degradatie 
van homocysteïne via de transsulfureringsroute, waarin CBS het regulerende enzym 
is, onderzocht. CBS deficiëntie is de meest voorkomende oorzaak van ernstige 
hyperhomocysteïnemie en recente genetische studies hebben heterozygotie voor CBS 
deficiëntie uitgesloten als een belangrijke oorzaak van verhoogde homocysteïne 
spiegels. Echter, genetische varianten als oorzaak van een milde CBS disfunctie, die 
leiden tot hyperhomocysteinemie na een orale methionine belastingtest, zijn 
vooralsnog niet onderzocht.
Wij onderzochten de betrokkenheid van een 31 bp "variable number of tandem 
repeats" (VNTR) in het CBS gen bij hyperhomocysteïnemie, en vonden vijf 
verschillende allelen: allelen 16, 17, 18, 19 en 21, zoals beschreven in h o o fd stu k  7. 
We toonden aan dat deze 31 bp VNTR geassocieerd was met een significante 
verhoging in homocysteïne concentraties na methioninebelasting, namelijk 10-20% 
verhoging in homocysteïne concentraties in individuen met genotypen 19-19 en 21­
21 vergeleken met het meest voorkomende genotype 18-18. Bovendien zagen we 
een duidelijke negatieve correlatie tussen CBS enzymactiviteit en een toenemend 
aantal repeat elementen, wat de positieve associatie tussen de VNTR en methionine­
belaste homocysteïne concentraties bevestigde. Ook lieten wij bewijs zien voor het 
optreden van alternatieve splicing in individuen met verschillende VNTR genotypen. 
Wij toonden de positieve associatie tussen homocysteïne concentraties na 
methioninebelasting en het aantal repeat elementen opnieuw aan in meer dan 1400 
individuen van de Framingham Offspring Study, zoals beschreven in h o o fd stu k  8 
van dit proefschrift. Hierin waren we ook in staat om mogelijk effect-modificatie, met 
name door vitamine B6, een co-factor voor CBS, te bestuderen. Wij vonden echter 
geen invloed van vitamine B6 concentraties op de gevonden associatie tussen 
homocysteïne concentraties na methioninebelasting en het aantal repeat elementen.
Genetische associatie studies worden regelmatig gebruikt voor de identificatie van 
kandidaatgenen in complexe, niet Mendeliaans-overervende, aandoeningen. In zulke 
studies wordt de associatie tussen een fenotype en genomische markers, dicht bij of 
bij voorkeur in het gen, onderzocht. Zo'n marker is op zich niet noodzakelijk 
functioneel gerelateerd aan het fenotype, maar kan in linkage disequilibrium zijn met 
een functionele variant. In een studie beschreven in h o o fd stu k  9 onderzochten wij 
een mogelijke betrokkenheid van varianten in niet-coderende regionen of van 
zogenaamde 'silent' mutaties in het CBS gen bij hyperhomocysteïnemie en HVZ. We
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bestudeerden deze varianten als markers die mogelijk in linkage disequilibrium zijn 
met een functioneel polymorfisme. We analyseerden twee silent nucleotide 
substituties, de 699CoT  (Y233Y) en de 1080CoT (A360A), en een short tandem 
repeat (STR) -5697(GT), in 190 HVZ patiënten en in 381 controles. Hoewel we een 
sterke koppeling detecteerden tussen deze drie polymorfismen, vonden we geen 
aanwijzingen voor een algemeen voorkomend CBS polymorfisme dat geassocieerd is 
met verhoogde homocysteïne concentraties en verhoogd risico op HVZ.
In h o o fd stu k  10 geven we een gedetailleerd overzicht van mogelijke genetische 
determinanten van homocysteïne en bespreken hun relevantie voor het risico op 
HVZ.
Samenvattend, veel varianten in genen die betrokken zijn bij het homocysteïne 
metabolisme zijn inmiddels bestudeerd. In dit proefschrift worden verscheidene 
genetische varianten beschreven die een effect hebben op het homocysteïne 
metabolisme door het beïnvloeden van enzymactiviteit of een associatie laten zien 
met plasma homocysteïne concentraties. Echter, ons inzicht in de genetische 
etiologie van verhoogde plasma homocysteïne spiegels is nog steeds onvolledig, 
aangezien alle genetische variaties die tot nu toe beschreven zijn de genetische 
component van hyperhomocysteïnemie in de algemene populatie niet volledig 
verklaren. Waarschijnlijk zijn meer genetische varianten betrokken bij het ontstaan 
van hyperhomocysteïnemie. Genetische analyses, zoals beschreven in dit 
proefschrift, waarin de associatie tussen genetische varianten en homocysteïne 
concentraties en het risico op HVZ wordt bestudeerd, zouden meer inzicht moeten 
kunnen verschaffen over de genetische oorzaken van hyperhomocysteïnemie en 
mogelijk een opheldering kunnen geven over de vraag of homocysteïne causaal 
gerelateerd is aan HVZ.
136
Chapter 12
References

References
References
[1] Netherlands Heart Foundation. Cardiovascular diseases in the Netherlands 2001. The 
Hague, The Netherlands: 2001.
[2] Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 
1993;362:801-809.
[3] McCully KS. Vascular pathology of homocysteinemia: implications for the 
pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128.
[4] Finkelstein JD, Martin JJ. Methionine metabolism in mammals- Adaptation to 
methionine excess. J Biol Chem 1986;261:1582-1587.
[5] Anonymous. Pyridoxine and pyridoxal 5' phosphate - Monograph. Altern Med Rev 
2001;6:87-92.
[6] Merrill AH, Henderson JM. Vitamin B6 metabolism by human liver. Ann N Y Acad Sci 
1990;585:110-117.
[7] Leklem JE. Vitamin B-6: a status report. J Nutr 1990;120 Suppl 11:1503-1507.
[8] Bender DA. Non-nutritional uses of vitamin B6. Br J Nutr 1999;81:7-20.
[9] Russell-Jones GJ, Alpers DH. Vitamin B12 transporters. Pharm Biotechnol 
1999;12:493-520.
[10] Seetharam B, Bose S, Li N. Cellular import of cobalamin (Vitamin B-12). J Nutr 
1999;129:1761-1764.
[11] Seetharam B, Li N. Transcobalamin II and its cell surface receptor. Vitam Horm 
2000;59:337-366.
[12] Halsted CH. Intestinal absorption and malabsorption of folates. Annu Rev Med 
1980;31:79-87.
[13] Shane B, Stokstad EL. Vitamin B12-folate interrelationships. Annu Rev Nutr 
1985;5:115-141.
[14] McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis 
1975;22:215-227.
[15] Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role 
for methionine metabolism. J Clin Invest 1976;57:1079-1082.
[16] Kang S-S, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine 
A possible risk factor for coronary artery disease. J Clin Invest 1986;77:1482-1486.
[17] Brattstrom LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia--a possible risk 
factor for arteriosclerotic cerebrovascular disease. Stroke 1984;15:1012-1016.
139
Chapter 12
[18] Boers GHJ, Smals AG, Trijbels JMF, et al. Heterozygosity for homocystinuria in 
premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313 
:709-715.
[19] Brattstrom L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in 
early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine 
and folic acid treatment. Atherosclerosis 1990;81:51-60.
[20] Malinow MR, Kang S-S, Taylor LM, et al. Prevalence of hyperhomocyste(e)inemia in 
patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-1188.
[21] Den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for 
deep-vein thrombosis. N Engl J Med 1996;334:759-762.
[22] Den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia 
and venous thrombosis: a meta-analysis. Thromb Haemost 1998;80:874-877.
[23] Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of 
plasma homocysteine as a risk factor for vascular disease. Probable benefits of 
increasing folic acid intakes. JAMA 1995;274:1049-1057.
[24] Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular 
disease. Annu Rev Medicine 1998;49:31-62.
[25] Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic 
review of published epidemiological studies. J Cardiovasc Risk 1998;5:229-232.
[26] Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine 
and cardiovascular risk. Am J Clin Nutr 2000;72:324-332.
[27] Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk 
factor for vascular disease. N Engl J Med 1991;324:1149-1155.
[28] Verhoef P, Kok FJ, Kruyssen DA, et al. Plasma total homocysteine, B vitamins, and 
risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:989-995.
[29] Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post­
methionine load hyperhomocysteinemia in persons with normal fasting total plasma 
homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis 
1995;116:147-151.
[30] Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for 
vascular disease. The European Concerted Action Project. JAMA 1997;277:1775- 
1781.
[31] Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal 
coronary heart disease. JAMA 1996;275:1893-1896.
[32] Silberberg JS, Crooks RL, Wlodarczyk JH, Fryer JL. Association between plasma folate 
and coronary disease independent of homocysteine. Am J Cardiol 2001;87:1003- 
1004.
140
References
[33] Voutilainen S, Rissanen TH, Virtanen J, Lakka TA , Salonen JT. Low dietary folate 
intake is associated with an excess incidence of acute coronary events: The Kuopio 
Ischemic Heart Disease Risk Factor Study. Circulation 2001;103:2674-2680.
[34] Van Guldener C, Robinson K. Homocysteine and renal disease. Semin Thromb 
Hemost 2000;26:313-324.
[35] Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of 
plasma total homocysteine concentration in the Framingham Offspring cohort. Am J 
Clin Nutr 2001;73:613-621.
[36] Andersson A, Brattstrom L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma 
homocysteine before and after methionine loading with regard to age, gender, and 
menopausal status. Eur J Clin Invest 1992;22:79-87.
[37] Nygard O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma 
total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 
1998;67:263-270.
[38] Refsum H, Nygard O, Kvale G, Ueland PM, Vollset SE. The Hordaland homocysteine 
study: the opposite tails odds ratios reveal differential effects of gender and intake of 
vitamin supplements at high and low plasma total homocysteine concentrations. J 
Nutr 1996;126:1244S-1248S.
[39] Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake 
as primary determinants of homocysteinemia in an elderly population. JAMA 
1993;270:2693-2698.
[40] Ueland P.M., Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular 
disease. In: Francis RBJ, ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and 
Endothelial Function, New York: Marcel Dekker, 1992:183-236.
[41] Ueland PM, Nygard O, Vollset SE, Refsum H. The Hordaland Homocysteine Studies. 
Lipids 2001;36 Suppl:S33-S39
[42] De Bree A, Verschuren WM, Blom HJ, Kromhout D. Association between B vitamin 
intake and plasma homocysteine concentration in the general Dutch population aged 
20-65 y. Am J Clin Nutr 2001;73:1027-1033.
[43] Brouwer IA, van Dusseldorp M, West CE, et al. Dietary folate from vegetables and 
citrus fruit decreases plasma homocysteine concentrations in humans in a dietary 
controlled trial. J Nutr 1999;129:1135-1139.
[44] Tucker KL, Selhub J, Wilson PW, Rosenberg IH. Dietary intake pattern relates to 
plasma folate and homocysteine concentrations in the Framingham Heart Study. J 
Nutr 1996;126:3025-3031.
[45] McNulty H, Cuskelly GJ, Ward M. Response of red blood cell folate to intervention: 
implications for folate recommendations for the prevention of neural tube defects.
Am J Clin Nutr 2000;71:1308S-1311S.
141
Chapter 12
[46] Nygard O, Refsum H, Ueland PM, et al. Coffee consumption and plasma total 
homocysteine: The Hordaland Homocysteine Study. Am lin Nutr 1997;65:136-143.
[47] Grubben MJ, Boers GH, Blom HJ, et al. Unfiltered coffee increases plasma 
homocysteine concentrations in healthy volunteers: a randomized trial. Am J Clin 
Nutr 2000;71:480-484.
[48] De Bree A, Verschuren WM, Blom HJ, Kromhout D. Lifestyle factors and plasma 
homocysteine concentrations in a general population sample. Am J Epidemiol 
2001;154:150-154.
[49] Vollset SE, Nygard O, Kvale G, Ueland PM, Refsum H. The Hordaland Homocysteine 
Study: Lifestyle and total plasma homocysteine levels in Western Norway. In:
Graham I, Refsum H, Rosenberg IH, Ueland PM, eds. Homocysteine Metabolism:
From Basic Science to Clinical Medicine, Massachusetts: Kluwer Academic Publishers, 
1997:177-182.
[50] Cravo ML, Gloria LM, Selhub J, et al. Hyperhomocysteinemia in chronic alcoholism: 
correlation with folate, vitamin B-12, and vitamin B-6 status. Am J Clin Nutr 
1996;63:220-224.
[51] Ubbink JB, Fehily AM, Pickering J, Elwood PC, Vermaak WJ. Homocysteine and 
ischaemic heart disease in the Caerphilly cohort. Atherosclerosis 1998;140:349-356.
[52] De Bree A, Verschuren WM, Blom HJ, Kromhout D. Alcohol consumption and plasma 
homocysteine: what's brewing? Int J Epidemiol 2001;30:626-627.
[53] Blom HJ. Diseases and drugs associated with hyperhomocysteinemia. In: Carmel R, 
Jacobsen DW, eds. Homocysteine in health and disease, Cambridge University Press, 
2001:331-340.
[54] Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular 
risk profile. The Hordaland Homocysteine Study. JAMA 1995;274:1526-1533.
[55] Carson NAJ, Neill DW. Metabolic abnormalities detected in a survey of mentally 
backward individuals in Northern Ireland. Arch Dis Child 1962;37:505-513.
[56] Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CS, Beaudet 
AL, Sly WS, Valle D, eds. The metabolic and molecular basis of inherited disease, 7 
ed. New York: McGraw-Hill, 1995:1279-1327.
[57] Kraus JP, Janosik M, Kozich V, et al. Cystathionine beta-synthase mutations in 
homocystinuria. Hum Mutat 1999;13:362-375.
[58] Kluijtmans LA, Boers GH, Kraus JP, et al. The molecular basis of cystathionine beta- 
synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on 
biochemical and clinical phenotype and on response to treatment. Am J Hum Genet 
1999; 65:59-67.
[59] Gallagher PM, Ward P, Tan S, et al. High frequency (71%) of cystathionine beta- 
synthase mutation G307S in Irish homocystinuria patients. Hum Mutat 1995;6:177- 
180.
142
References
[60] Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: Scriver CS, 
Beaudet AL, Slay WS , Valle D, eds. The metabolic basis of inherited disease, 7 ed. 
New York: McGraw-Hill, 1995:3111-3128.
[61] Fenton WA, Rosenberg LE. Inherited disorders of cobalamin transport and 
metabolism. In: Scriver CS, Beaudet AL, Slay WS, Valle D, eds. The metabolic basis of 
inherited disease, 7 ed. New York: McGraw-Hill, 1995:3129-3149.
[62] Berg K, Malinow MR, Kierulf P, Upson B. Population variation and genetics of plasma 
homocyst(e)ine level . Clin Genet 1992;41:315-321.
[63] Reed T, Malinow MR, Christian JC, Upson B. Estimates of heritability of plasma 
homocyst(e)ine levels in aging adult male twins. Clin Genet 1991;39:425-428.
[64] Genest JJ, McNamara JR, Upson B, et al. Prevalence of familial 
hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler 
Thromb 1991;11:1129-1136.
[65] Wu LL, Wu J, Hunt SC, et al. Plasma homocyst(e)ine as a risk factor for early familial 
coronary artery disease. Clin Chem 1994;40:552-561.
[66] Franken DG, Boers GH, Blom HJ, Cruysberg JR, Trijbels FJ, Hamel BC. Prevalence of 
familial mild hyperhomocysteinemia. Atherosclerosis 1996;125:71-80.
[67] Mudd SH, Havlik R, Levy HL, McKusick VA, Feinleib M. A study of cardiovascular risk 
in heterozygotes for homocystinuria. Am J Hum Genet 1981;33:883-893.
[68] Daly L, Robinson K, Tan KS, Graham IM. Hyperhomocysteinaemia: a metabolic risk 
factor for coronary heart disease determined by both genetic and environmental 
influences? QJM 1993;86:685-689.
[69] Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ.
Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild 
hyperhomocysteinemia. Am J Hum Genet 1995;56:142-150.
[70] Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild 
hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate 
reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 
1996;58:35-41.
[71] Kraus JP, Le K, Swaroop M, et al. Human cystathionine beta-synthase cDNA: 
sequence, alternative splicing and expression in cultured cells. Hum Mol Genet 
1993;2:1633-1638.
[72] Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature 
coronary heart disease. Evidence for a common gene mutation. Circulation 
1996;94:2154-2158.
[73] Kozich V, Kraus E, de Franchis R, et al. Hyperhomocysteinemia in premature arterial 
disease: examination of cystathionine beta-synthase alleles at the molecular level. 
Hum Mol Genet 1995;4:623-629.
143
Chapter 12
[74] Sperandeo MP, de Franchis R, Andria G, Sebastio G. A 68-bp insertion found in a 
homocystinuric patient is a common variant and is skipped by alternative splicing of 
the cystathionine beta-synthase mRNA. Am J Hum Genet 1996;59:1391-1393.
[75] Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in 
the cystathionine beta-synthase gene. Am J Hum Genet 1996;59:1262-1267.
[76] Kluijtmans LA, Boers GH, Trijbels FJ, van Lith-Zanders HM, van den Heuvel LP, Blom 
HJ. A common 844INS68 insertion variant in the cystathionine beta-synthase gene. 
Biochem Mol Med 1997;62:23-25.
[77] Kang S-S, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate 
homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase.
Am J Hum Genet 1988;43:414-421.
[78] Kang S-S, Wong PWK, Susmano A, Sora H, Norusis M, Ruggie N. Thermolabile 
methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery 
disease. Am J Hum Genet 1991;48:536-545.
[79] Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: 
a common mutation in methylenetetrahydrofolate reductase. Nat Genet 
1995;10:111-113.
[80] Van der Put NM, van den Heuvel LP, Steegers-Theunissen RP, et al. Decreased 
methylene tetrahydrofolate reductase activity due to the 677CoT mutation in 
families with spina bifida offspring. J Mol Med 1996;74:691-694.
[81] Harmon DL, Woodside JV, Yarnell JW, et al. The common 'thermolabile' variant of 
methylene tetrahydrofolate reductase is a major determinant of mild 
hyperhomocysteinaemia. QJM 1996;89:571-577.
[82] Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common 
mutation in methylenetetrahydrofolate reductase, and plasma homocysteine 
concentrations. Circulation 1996;93:7-9.
[83] Fletcher O, Kessling AM. MTHFR association with arteriosclerotic vascular disease? 
Hum Genet 1998;103:11-21.
[84] Brattstrom L, Wilcken DEL, Ohrvik J, Brudin L. Common methylenetetrahydrofolate 
reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease 
- The result of a meta-analysis. Circulation 1998;98:2520-2526.
[85] Kluijtmans LA, Whitehead AS. Methylenetetrahydrofolate reductase genotypes and 
predisposition to atherothrombotic disease; evidence that all three MTHFR C677T 
genotypes confer different levels of risk. Eur Heart J 2001;22:294-299.
[86] Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A 
prospective study of plasma homocyst(e)ine and risk of ischemic stroke . Stroke 
1994;25:1924-1930.
[87] Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease 
incidence in relation to fasting total homocysteine, related genetic polymorphisms,
144
References
and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 
1998;98:204-210.
[88] Mudd SH, Matorin AI, Levy HL. Homocysteine thiolactone: failure to detect in human 
serum or plasma. Res Commun Chem Pathol Pharmacol 1989;63:297-300.
[89] Rosenblatt DS, Cooper BA. Selective deficiencies of methyl-B12 (cblE and cblG). Clin 
Invest Med 1989;12:270-271.
[90] Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma 
homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 
1992;268:877-881.
[91] Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and 
ischemic heart disease: results of a prospective study with implications regarding 
prevention. Arch Intern Med 1998;158:862-867.
[92] Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect? 
Am J Clin Nutr 2000;72:315-323.
[93] Van der Put NMJ, Gabreels F, Stevens EMB, et al. A second common mutation in the 
methyelenetetrahydrofolate reductase gene: an additional risk factor for neural-tube 
defects? Am J Hum Genet 1998;62:1044-1051.
[94] Den Heijer M, Blom HJ, Gerrits WB, et al. Is hyperhomocysteinaemia a risk factor for 
recurrent venous thrombosis? Lancet 1995;345:882-885.
[95] Van der Put NMJ, Blom HJ. Reply to Donnelly. Am J Hum Genet 2000;66:744-745.
[96] Boers GHJ, Smals AG, Trijbels JMF, Leermakers AI, Kloppenborg PW. Unique 
efficiency of methionine metabolism in premenopausal women may protect against 
vascular disease in the reproductive years. J Clin Invest 1983;72:1971-1976.
[97] Te Poele-Pothoff MT, van den Berg M, Franken DG, et al. Three different methods for 
the determination of total homocysteine in plasma. Ann Clin Biochem 1995;32:218- 
220.
[98] Van der Put NMJ, Steegers-Theunissen RPM, Frosst P, et al. Mutated 
methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 
1995;346:1070-1071.
[99] Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism 
in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme 
activity. Mol Genet Metab 1998;64:169-172.
[100] Chango A, Boisson F, Barbe F, et al. The effect of 677CoT and 1298AoC mutations 
on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in 
healthy subjects. Br J Nutr 2000;83:593-596.
[101] Friedman G, Goldschmidt N, Friedlander Y, et al. A common mutation A1298C in 
human methylenetetrahydrofolate reductase gene: association with plasma total 
homocysteine and folate concentrations. J Nutr 1999;129:1656-1661.
145
Chapter 12
[102] Girelli D, Friso S, Trabetti E, et al. Methylenetetrahydrofolate reductase C677T 
mutation, plasma homocysteine, and folate in subjects from northern Italy with or 
without angiographically documented severe coronary atherosclerotic disease: 
evidence for an important genetic-environmental interaction. Blood 1998;91:4158- 
4163.
[103] Jee SH, Beaty TH, Suh I, Yoon Y, Appel LJ. The methylenetetrahydrofolate reductase 
gene is associated with increased cardiovascular risk in Japan, but not in other 
populations. Atherosclerosis 2000;153:161-168.
[104] Verhoef P, Kok FJ, Kluijtmans LA, et al. The 677CoT mutation in the 
methylenetetrahydrofolate reductase gene: associations with plasma total 
homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 
1997;132:105-113.
[105] Selhub J, Jacques PF, Rosenberg IH, et al. Serum total homocysteine concentrations 
in the third National Health and Nutrition Examination Survey (1991-1994): 
population reference ranges and contribution of vitamin status to high serum 
concentrations. Ann Intern Med 1999;131:331-339.
[106] Devlin AM, Ling EH, Peerson JM, et al. Glutamate carboxypeptidase II: a 
polymorphism associated with lower levels of serum folate and 
hyperhomocysteinemia. Hum Mol Genet 2000;9:2837-2844.
[107] Brancaccio R, Passariello A, Buoninconti A, et al. Multiple genotyping for genes of the 
folate/methionine metabolism in Italian NTD patients. Abstracts Book of 3rd 
International Conference on Homocysteine Metabolism. 2001 (Abstract).
[108] Selhub J, Jacques PF, Bostom AG, Wilson PW, Rosenberg IH. Relationship between 
plasma homocysteine and vitamin status in the Framingham study population. Impact 
of folic acid fortification. Public Health Rev 2000;28:117-145.
[109] Matthews RG, Sheppard C, Goulding C. Methylenetetrahydrofolate reductase and 
methionine synthase: biochemistry and molecular biology. Eur J Pediatr 1998;157 
Suppl 2:S54-S59
[110] Leclerc D, Campeau E, Goyette P, et al. Human methionine synthase: cDNA cloning 
and identification of mutations in patients of the cblG complementation group of 
folate/cobalamin disorders. Hum Mol Genet 1996;5:1867-1874.
[111] Van der Put NMJ, van der Molen EF, Kluijtmans LAJ, et al. Sequence analysis of the 
coding region of human methionine synthase: relevance to hyperhomocysteinaemia 
in neural-tube defects and vascular disease. QJM 1997;90:511-517.
[112] Chen LH, Liu ML, Hwang HY, Chen LS, Korenberg J, Shane B. Human methionine 
synthase. cDNA cloning, gene localization, and expression. J Biol Chem 
1997;272:3628-3634.
[113] Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA 
from human nucleated cells. Nucleic Acids Res 1988;16:1215
146
References
[114] Tsai MY, Welge BG, Hanson NQ, et al. Genetic causes of mild hyperhomocysteinemia 
in patients with premature occlusive coronary artery diseases. Atherosclerosis 
1999;143:163-170.
[115] Morita H, Kurihara H, Sugiyama T, et al. Polymorphism of the methionine synthase 
gene : association with homocysteine metabolism and late-onset vascular diseases in 
the Japanese population. Arterioscler Thromb Vasc Biol 1999;19:298-302.
[116] Chen J, Stampfer MJ, Ma J, et al. Influence of a methionine synthase (D919G) 
polymorphism on plasma homocysteine and folate levels and relation to risk of 
myocardial infarction. Atherosclerosis 2001;154:667-672.
[117] Zhang G, Dai C. Gene polymorphisms of homocysteine metabolism-related enzymes 
in Chinese patients with occlusive coronary artery or cerebral vascular diseases. 
Thromb Res 2001;104:187-195.
[118] Hyndman ME, Bridge PJ, Warnica JW, Fick G, Parsons HG. Effect of heterozygosity for 
the methionine synthase 2756 AoG  mutation on the risk for recurrent cardiovascular 
events. Am J Cardiol 2000;86:1144-6, A9.
[119] D'Angelo A, Coppola A, Madonna P, et al. The role of vitamin B12 in fasting 
hyperhomocysteinemia and its interaction with the homozygous C677T mutation of 
the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of 
patients with early-onset thrombotic events. Thromb Haemost 2000;83:563-570.
[120] Ma J, Stampfer MJ, Christensen B, et al. A polymorphism of the methionine synthase 
gene: association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal 
cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:825-829.
[121] Geisel J, Zimbelmann I, Schorr H, et al. Genetic defects as important factors for 
moderate hyperhomocysteinemia. Clin Chem Lab Med 2001;39:698-704.
[122] Wang XL, Duarte N, Cai H, et al. Relationship between total plasma homocysteine, 
polymorphisms of homocysteine metabolism related enzymes, risk factors and 
coronary artery disease in the Australian hospital-based population. Atherosclerosis 
1999;146:133-140.
[123] Harmon DL, Shields DC, Woodside JV, et al. Methionine synthase D919G 
polymorphism is a significant but modest determinant of circulating homocysteine 
concentrations. Genet Epidemiol 1999;17:298-309.
[124] Tsai MY, Bignell M, Yang F, Welge BG, Graham KJ, Hanson NQ. Polygenic influence 
on plasma homocysteine: association of two prevalent mutations, the 844ins68 of 
cystathionine beta-synthase and A(2756)G of methionine synthase, with lowered 
plasma homocysteine levels. Atherosclerosis 2000;149:131-137.
[125] Siri PW, Verhoef P, Kok FJ. Vitamins B6, B12, and folate: association with plasma 
total homocysteine and risk of coronary atherosclerosis. J Am Coll Nutr 1998;17:435- 
441.
147
Chapter 12
[126] Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of 
myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 
1996;143:845-859.
[127] Robinson K, Arheart K, Refsum H, et al. Low circulating folate and vitamin B6 
concentrations: risk factors for stroke, peripheral vascular disease, and coronary 
artery disease. European COMAC Group. Circulation 1998;97:437-443.
[128] Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and 
vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J 
Clin Nutr 1994;59:940-948.
[129] Zeitlin A, Frishman WH, Chang CJ. The association of vitamin b 12 and folate blood 
levels with mortality and cardiovascular morbidity incidence in the old old: the Bronx 
aging study. Am J Ther 1997;4:275-281.
[130] Lucock M, Daskalakis I, Briggs D, Yates Z, Levene M. Altered folate metabolism and 
disposition in mothers affected by a spina bifida pregnancy: influence of 677CoT 
methylenetetrahydrofolate reductase and 2756AoG methionine synthase genotypes. 
Mol Genet Metab 2000;70:27-44.
[131] Wang XL, Cai H, Cranney G, Wilcken DE. The frequency of a common mutation of the 
methionine synthase gene in the Australian population and its relation to smoking 
and coronary artery disease. J Cardiovasc Risk 1998;5:289-295.
[132] Li N, Seetharam S, Seetharam B. Genomic structure of human transcobalamin II: 
comparison to human intrinsic factor and transcobalamin I. Biochem Biophys Res 
Commun 1995;208:756-764.
[133] Quadros EV, Rothenberg SP, Pan YC, Stein S. Purification and molecular 
characterization of human transcobalamin II. J Biol Chem 1986;261:15455-15460.
[134] Li N, Seetharam S, Lindemans J, Alpers DH, Arwert F, Seetharam B. Isolation and 
sequence analysis of variant forms of human transcobalamin II. Biochim Biophys 
Acta 1993;1172:21-30.
[135] Li N, Sood GK, Seetharam S, Seetharam B. Polymorphism of human transcobalamin 
II: substitution of proline and/or glutamine residues by arginine. Biochim Biophys 
Acta 1994;1219:515-520.
[136] Regec A, Quadros EV, Platica O, Rothenberg SP. The cloning and characterization of 
the human transcobalamin II gene. Blood 1995;85:2711-2719.
[137] Namour F, Guy M, Aimone-Gastin I, de Nonancourt M, Mrabet N, Gueant JL. 
Isoelectrofocusing phenotype and relative concentration of transcobalamin II 
isoproteins related to the codon 259 Arg/Pro polymorphism. Biochem Biophys Res 
Commun 1998;251:769-774.
[138] Namour F, Olivier J, Abdelmouttaleb I, et al. Transcobalamin codon 259 
polymorphism in HT-29 and Caco-2 cells and in Caucasians: relation to 
transcobalamin and homocysteine concentration in blood. Blood 2001;97:1092-1098.
148
References
[139] Afman LA, Lievers KJA, van der Put NMJ, Trijbels JMF, Blom HJ. New Single­
Nucleotide Polymorphisms in the transcobalamin gene: relation to transcobalamin 
concentration and NTD risk. Eur J Hum Genet 2002;10:433-438.
[140] Xie X., Ott J. Testing linkage disequilibrium between a disease gene and marker loci. 
Am J Hum Genet 1993;53:1107 (Abstract).
[141] Afman LA, van der Put NMJ, Thomas CM, Trijbels JMF, Blom HJ. Reduced vitamin B12 
binding by transcobalamin II increases the risk of neural tube defects. QJM 
2001;94:159-166.
[142] Barak AJ, Tuma DJ. Betaine, metabolic by-product or vital methylating agent? Life 
Sci 1983;32:771-774.
[143] Boers GHJ, Van den Berg M, Franken DG. Treatment of mild hyperhomocysteinemia. 
In: Graham I, Refsum H, Rosenberg IH, Ueland PM, eds. Homocysteine Metabolism: 
From Basis Science to Clinical Medicine, Dordrecht: Kluwer Academic, 1997:111-116.
[144] Garrow TA. Purification, kinetic properties, and cDNA cloning of mammalian betaine- 
homocysteine methyltransferase. J Biol Chem 1996;271:22831-22838.
[145] Breksa AP, Garrow TA. Recombinant human liver betaine-homocysteine S- 
methyltransferase: identification of three cysteine residues critical for zinc binding. 
Biochemistry 1999;38:13991-13998.
[146] Millian NS, Garrow TA. Human betaine-homocysteine methyltransferase is a zinc 
metalloenzyme. Arch Biochem Biophys 1998;356:93-98.
[147] Park EI, Garrow TA. Interaction between dietary methionine and methyl donor intake 
on rat liver betaine-homocysteine methyltransferase gene expression and 
organization of the human gene. J Biol Chem 1999;274:7816-7824.
[148] Sunden SL, Renduchintala MS, Park EI, Miklasz SD, Garrow TA. Betaine-homocysteine 
methyltransferase expression in porcine and human tissues and chromosomal 
localization of the human gene. Arch Biochem Biophys 1997;345:171-174.
[149] Tyagi S, Kramer FR. Molecular beacons: probes that fluoresce upon hybridization.
Nat Biotechnol 1996;14:303-308.
[150] Giesendorf BA, Vet JA, Tyagi S, Mensink EJ, Trijbels FJ, Blom HJ. Molecular beacons: 
a new approach for semiautomated mutation analysis. Clin Chem 1998;44:482-486.
[151] Canty DJ. Determinants of plasma homocysteine. Am J Clin Nutr 1998;68:919-921.
[152] Van der Put NM, Thomas CM, Eskes TK, et al. Altered folate and vitamin B12 
metabolism in families with spina bifida offspring. QJM 1997;90:505-510.
[153] Nelen WL, Blom HJ, Steegers EA, den Heijer M, Thomas CM, Eskes TK. Homocysteine 
and folate levels as risk factors for recurrent early pregnancy loss. Obstet Gynecol 
2000;95:519-524.
[154] Keating MT, Sanguinetti MC. Molecular genetic insights into cardiovascular disease. 
Science 1996;272:681-685.
149
Chapter 12
[155] Suzuki K, Kuriyama M, Saito T, Ichinose A. Plasma lipoprotein(a) levels and 
expression of the apolipoprotein(a) gene are dependent on the nucleotide 
polymorphisms in its 5'-flanking region. J Clin Invest 1997;99:1361-1366.
[156] Inoue I, Nakajima T, Williams CS, et al. A nucleotide substitution in the promoter of 
human angiotensinogen is associated with essential hypertension and affects basal 
transcription in vitro. J Clin Invest 1997;99:1786-1797.
[157] Kraus JP, Oliveriusova J, Sokolova J, et al. The human cystathionine beta-synthase 
(CBS) gene: complete sequence, alternative splicing, and polymorphisms. Genomics 
1998;52:312-324.
[158] Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium 
thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
[159] Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective 
study of serum total homocysteine concentration and risk of stroke in middle-aged 
British men. Lancet 1995;346:1395-1398.
[160] Kang SS, Wong PW. Genetic and nongenetic factors for moderate 
hyperhomocyst(e)inemia. Atherosclerosis 1996;119:135-138.
[161] Finkelstein JD, Martin JJ. Methionine metabolism in mammals. Distribution of 
homocysteine between competing pathways. J Biol Chem 1984;259:9508-9513.
[162] Shapiro MB, Senapathy P. RNA splice junctions of different classes of eukaryotes: 
sequence statistics and functional implications in gene expression. Nucleic Acids Res 
1987;15:7155-7174.
[163] Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair 
substitutions in mRNA splice junctions of human genes: causes and consequences. 
Hum Genet 1992;90:41-54.
[164] Guo M, Lo PC, Mount SM. Species-specific signals for the splicing of a short 
Drosophila intron in vitro. Mol Cell Biol 1993;13:1104-1118.
[165] Turri MG, Cuin KA, Porter AC. Characterisation of a novel minisatellite that provides 
multiple splice donor sites in an interferon-induced transcript. Nucleic Acids Res 
1995;23:1854-1861.
[166] Yang F, Hanson NQ, Schwichtenberg K, Tsai MY. Variable number tandem repeat in 
exon/intron border of the cystathionine beta-synthase gene: a single nucleotide 
substitution in the second repeat prevents multiple alternate splicing. Am J Med 
Genet 2000;95:385-390.
[167] Lievers KJ, Kluijtmans LA, Heil SG, et al. A 31 bp VNTR in the cystathionine beta- 
synthase (CBS) gene is associated with reduced CBS activity and elevated post-load 
homocysteine levels. Eur J Hum Genet 2001;9:583-589.
[168] Feinleib M, Kannel WB, Garrison RJ, McNamara PM , Castelli WP. The Framingham 
Offspring Study. Design and preliminary data. Prev Med 1975;4:518-525.
150
References
[169] Kannel WB, Feinleib M, McNamara PM, Garrison RJ , Castelli WP. An investigation of 
coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 
1979;110:281-290.
[170] Tsai MY, Yang F, Bignell M, Aras O, Hanson NQ. Relation between plasma 
homocysteine concentration, the 844ins68 variant of the cystathionine beta-synthase 
gene, and pyridoxal-5'-phosphate concentration. Mol Genet Metab 1999;67:352-356.
[171] Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994;265:2037- 
2048.
[172] Verhoef P, Meleady R, Daly LE, Graham IM, Robinson K, Boers GH. Homocysteine, 
vitamin status and risk of vascular disease; effects of gender and menopausal status. 
European COMAC Group. Eur Heart J 1999;20:1234-1244.
[173] Kruger WD, Evans AA, Wang L, et al. Polymorphisms in the CBS gene associated with 
decreased risk of coronary artery disease and increased responsiveness to total 
homocysteine lowering by folic acid. Mol Genet Metab 2000;70:53-60.
[174] De Stefano V, Dekou V, Nicaud V, et al. Linkage disequilibrium at the cystathionine 
beta synthase (CBS) locus and the association between genetic variation at the CBS 
locus and plasma levels of homocysteine. Ann Hum Genet 1998;62:481-490.
[175] Aras O, Hanson NQ, Yang F, Tsai MY. Influence of 699CoT and 1080CoT 
polymorphisms of the cystathionine beta-synthase gene on plasma homocysteine 
levels. Clin Genet 2000;58:455-459.
[176] Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. 
Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous 
thromboembolism. Circulation 1997;95:1777-1782.
[177] Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total 
homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-709.
[178] Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine 
levels and all-cause and cardiovascular disease mortality in elderly Framingham men 
and women. Arch Intern Med 1999;159:1077-1080.
[179] Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma 
homocysteine levels and mortality in patients with coronary artery disease. N Engl J 
Med 1997;337:230-236.
[180] Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. 
Serum homocysteine and risk of coronary heart disease and cerebrovascular disease 
in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 1998;18:1895- 
1901.
[181] Whincup PH, Refsum H, Perry IJ, et al. Serum total homocysteine and coronary heart 
disease: prospective study in middle aged men. Heart 1999;82:448-454.
151
Chapter 12
[182] Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and 
lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish 
population based study. Atherosclerosis 1994;106:9-19.
[183] Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of 
cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler 
Thromb Vasc Biol 1997;17:1947-1953.
[184] Williams RR, Malinow MR, Hunt SC, et al. Hyperhomocyst(e)inemia in Utah siblings 
with early coronary disease. Coronary Artery Disease 2002;1:681-685.
[185] Sebastio G, Sperandeo MP, Panico M, de Franchis R, Kraus JP, Andria G. The 
molecular basis of homocystinuria due to cystathionine beta-synthase deficiency in 
Italian families, and report of four novel mutations. Am J Hum Genet 1995;56:1324- 
1333.
[186] Lievers KJA, Kluijtmans LAJ, Heil SG, Boers GHJ , Verhoef P, den Heijer M, Trijbels 
JMF, Blom HJ. Cystathionine B-synthase (CBS) polymorphisms and 
hyperhomocysteinemia: an association study. Eur J Hum Genet 2002; in press.
[187] Wilson A, Platt R, Wu Q, et al. A common variant in methionine synthase reductase 
combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet 
Metab 1999;67:317-323.
[188] Brown CA, McKinney KQ, Kaufman JS, Gravel RA, Rozen R. A common polymorphism 
in methionine synthase reductase increases risk of premature coronary artery 
disease. J Cardiovasc Risk 2000;7:197-200.
[189] Gaughan DJ, Kluijtmans LA, Barbaux S, et al. The methionine synthase reductase 
(MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine 
concentrations. Atherosclerosis 2001;157:451-456.
[190] Heil SG, Lievers KJ, Boers GH, et al. Betaine-homocysteine methyltransferase 
(BHMT): genomic sequencing and relevance to hyperhomocysteinemia and vascular 
disease in humans. Mol Genet Metab 2000;71:511-519.
[191] Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase 
gene is associated with an accumulation of formylated tetrahydrofolates in red blood 
cells. Proc Natl Acad Sci U.S.A. 1998;95:13217-13220.
[192] Lievers KJ, Boers GH, Verhoef P, et al. A second common variant in the 
methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR 
enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med 
2001;79:522-528.
[193] Weisberg IS, Jacques PF, Selhub J, et al. The 1298AoC polymorphism in 
methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association 
with homocysteine. Atherosclerosis 2001;156:409-415.
[194] Hanson NQ, Aras O, Yang F, Tsai MY. C677T and A1298C polymorphisms of the 
methylenetetrahydrofolate reductase gene: incidence and effect of combined
152
References
genotypes on plasma fasting and post-methionine load homocysteine in vascular 
disease. Clin Chem 2001;47:661-666.
[195] Dekou V, Whincup P, Papacosta O, et al. The effect of the C677T and A1298C 
polymorphisms in the methylenetetrahydrofolate reductase gene on homocysteine 
levels in elderly men and women from the British regional heart study. 
Atherosclerosis 1998;154:659-666.
[196] Fodinger M, Buchmayer H, Heinz G, et al. Association of two MTHFR polymorphisms 
with total homocysteine plasma levels in dialysis patients. Am J Kidney Dis 
2001;38:77-84.
[197] Meisel C, Cascorbi I, Gerloff T, et al. Identification of six methylenetetrahydrofolate 
reductase (MTHFR) genotypes resulting from common polymorphisms: impact on 
plasma homocysteine levels and development of coronary artery disease. 
Atherosclerosis 2001;154:651-658.
[198] Szczeklik A, Sanak M, Jankowski M, et al. Mutation A1298C of 
methylenetetrahydrofolate reductase: risk for early coronary disease not associated 
with hyperhomocysteinemia. Am J Med Genet 2001;101:36-39.
[199] Shane B. Folylpolyglutamate synthesis and role in the regulation of one-carbon 
metabolism. Vitam Horm 1989;45:263-335.
[200] Heil SG, van der Put NM, Waas ET, den Heijer M, Trijbels FJ, Blom HJ. Is mutated 
serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube 
defects? Mol Genet Metab 2001;73:164-172.
[201] Hol FA, van der Put NM, Geurds MP, et al. Molecular genetic analysis of the gene 
encoding the trifunctional enzyme MTHFD (methylenetetrahydrofolate- 
dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate 
synthetase) in patients with neural tube defects. Clin Genet 1998;53:119-125.
[202] McCaddon A, Blennow K, Hudson P, Regland B, Hill D. Transcobalamin polymorphism 
and homocysteine. Blood 2001;98:3497-3499.
[203] Lievers KJA, Afman LA, Kluijtmans LAJ, et al. Polymorphisms in the transcobalamin 
gene: associations with plasma homocysteine in healthy subjects and vascular 
disease patients. Clin Chem 2002;48:1383-1389.
[204] Lievers KJA, Kluijtmans LAJ, Boers GHJ, et al. Influence of a glutamate 
carboxypeptidase II (GCPII) polymorphism (1561CoT) on plasma homocysteine, 
folate and vitamin Bi2 levels and its relationship to cardiovascular disease risk. 
Atherosclerosis 2002;164:269-273.
[205] Chango A, Emery-Fillon N, de Courcy GP, et al. A polymorphism (80GoA) in the 
reduced folate carrier gene and its associations with folate status and 
homocysteinemia. Mol Genet Metab 2000;70:310-315.
[206] Barber R, Shalat S, Hendricks K, et al. Investigation of folate pathway gene 
polymorphisms and the incidence of neural tube defects in a Texas hispanic 
population. Mol Genet Metab 2000;70:45-52.
153
Chapter 12
[207] Heil SG, van der Put NM, Trijbels FJ, Gabreels FJ, Blom HJ. Molecular genetic analysis 
of human folate receptors in neural tube defects. Eur J Hum Genet 1999;7:393-396.
[208] Dekou V, Gudnason V, Hawe E, Miller GJ, Stansbie D, Humphries SE. Gene­
environment and gene-gene interaction in the determination of plasma homocysteine 
levels in healthy middle-aged men. Thromb Haemost 2001;85:67-74.
[209] Feix A, Fritsche-Polanz R, Kletzmayr J, et al. Increased prevalence of combined MTR 
and MTHFR genotypes among individuals with severely elevated total homocysteine 
plasma levels. Am J Kidney Dis 2001;38:956-964.
[210] Blom HJ, Verhoef DP. Hyperhomocysteinemia, MTHFR, and risk of vascular disease. 
Circulation 2000;101:E171.
[211] Klerk M, Schouten EG, Blom HJ, Kok FJ, Verhoef P. A pooled analysis on MTHFR 
C677T polymorphism and risk of coronary heart disease. 3rd International 
Conference on Homocysteine Metabolism. 2001;(Abstract).
[212] Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after 
lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593-1600.
154
Publications
L ist o f  p u b lica tio n s
Rattink AP, Hennis BC, L ieve rs KJA, de Maat MPM, Bertina R, Mennen LI and 
Rosendaal FR. Deep-vein thrombosis is not associated with the P/S186 polymorphism 
of histidine-rich glycoprotein. Fibrinolysis Proteolysis 1999;13:35-38.
L ieve rs KJA, Mennen LI, Rattink AP, Zwinderman AH, Jukema JW, Schouten EG and 
de Maat MPM. The -323Ins10 polymorphism for factor VII is not associated with 
coronary atherosclerosis in symptomatic men. The REGRESS study group. Thromb 
Res 2000;97:275-280.
Hedrick PW, Parker KM, Gutierrez-Espeleta GA, Rattink AP and L ieve rs KJA. Major 
histocompatibility complex variation in the Arabian oryx. Evolution Int J Org Evolution 
2000;54:2145-2151.
Heil SG, L ievers KJA, Boers GHJ, Verhoef P, den Heijer M, Trijbels JMF and Blom 
HJ. Betaine-homocysteine methyltransferase (BHMT): genomic sequencing and 
relevance to hyperhomocysteinemia and vascular disease in humans. Mol Genet 
Metab 2000;71:511-519.
L ieve rs KJA, Kluijtmans LAJ, Heil SG, Boers GHJ, Verhoef P, van Oppenraay- 
Emmerzaal D, den Heijer M, Trijbels JMF and Blom HJ. A 31 bp VNTR in the 
cystathionine ß-synthase (CBS) gene is associated with reduced CBS activity and 
elevated post-load homocysteine levels. Eur J Hum Genet 2001;9:583-589.
L ieve rs KJA, Boers GHJ, Verhoef P, den Heijer M, Kluijtmans LAJ, van der Put NMJ, 
Trijbels JMF and Blom HJ. A second common variant in the 
methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR 
enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med 
2001;79:522-528.
Afman LA, L ieve rs KJA, van der Put NMJ, Trijbels JMF and Blom HJ. Single 
nucleotide polymorphisms in the transcobalamin gene: relationship with 
transcobalamin concentrations and risk for neural tube defects. Eur J Hum Genet 
2002;10:433-438.
L ieve rs KJA, Afman LA, Kluijtmans LAJ, Boers GHJ, Verhoef P, den Heijer M, Trijbels 
JMF and Blom HJ. Polymorphisms in the transcobalamin gene: associations with 
plasma homocysteine in healthy subjects and vascular disease patients. Clin Chem 
2002;48:1383-1389.
155
Publications
L ieve rs KJA, Kluijtmans LAJ, Boers GHJ, Verhoef P, den Heijer M, Trijbels JMF and 
Blom HJ. Influence of a glutamate carboxypeptidase II (GCPII) polymorphism 
(1561CoT) on plasma homocysteine, folate and vitamin B i2 levels and its 
relationship to cardiovascular disease risk. Atherosclerosis 2002;164:269-273.
L ieve rs KJA, Kluijtmans LAJ, Heil SG, Boers GHJ, Verhoef P, den Heijer M, Trijbels 
JMF and Blom HJ. Cystathionine ß-Synthase (CBS) polymorphisms and 
hyperhomocysteinemia: an association study. Eur J Hum Genet 2002; in press.
L ieve rs KJA, Kluijtmans LAJ and Blom HJ. Genetics of hyperhomocysteinemia in 
cardiovascular disease. Ann Clin Biochem 2002; in press.
156
Dankwoord
D ankw oord
Uiteraard ben ik niet alleen verantwoordelijk voor de inhoud van dit boekje, want 
zonder de hulp en steun van een hele groep mensen had ik dit nooit voor elkaar 
kunnen krijgen. Ik wil al deze mensen (en natuurlijk iedereen die hier niet met name 
genoemd is) heel hartelijk bedanken voor alles wat zij voor mij gedaan en betekend 
hebben en voor de leuke tijd die ik de afgelopen vier jaar heb gehad.
Mijn promotor Prof. Dr. Ir. J.M.F. Trijbels.
Beste Frans, ondanks je overvolle agenda en inmiddels ook overvolle lab, probeer je 
toch zoveel mogelijk betrokken te zijn bij alles wat er op het lab gebeurt. Niet alleen 
jouw interesse in mijn onderzoek, al heb je er naar eigen zeggen 'natuurlijk niet 
zoveel verstand van', maar ook je uitgebreide kennis op velerlei gebieden vind ik 
bewonderenswaardig. Jouw correcties op mijn manuscripten vond ik altijd zeer 
waardevol, evenals de maandelijkse besprekingen. Bedankt voor alles!
Mijn co-promotores Dr. H.J. Blom, Dr. L.A.J. Kluijtmans en Dr. G.H.J. Boers.
Beste Henk, niet alleen jouw enthousiasme en zeer uitgebreide kennis en interesse 
voor de wetenschap, maar ook je grote persoonlijke betrokkenheid bij iedereen heb 
ik altijd erg gewaardeerd. Ik heb respect voor de manier waarop jij je groep 
begeleidt. Een goede sfeer binnen de groep is even zo belangrijk en dat probeer jij 
altijd na te streven, met succes! Het duurde even voor ik het door had, maar ik kon 
altijd bij je aankloppen met een vraag of probleem, zowel wetenschappelijk als privé. 
Bedankt voor de leerzame èn leuke tijd!
Beste Leo, jij hebt een belangrijke rol gespeeld. Ten eerste natuurlijk als mijn 
'voorganger' heb jij een hele sterke basis gelegd voor mijn onderzoek. Vervolgens 
kwam je als postdoc terug op het lab, waarna je een deel van mijn begeleiding op je 
nam. Artikelen corrigeren kan je als de beste (nadat jij je met mijn artikelen ging 
'bemoeien' werden ze ineens allemaal geaccepteerd!) en van jouw manier van 
schrijven heb ik dan ook ontzettend veel geleerd. Daarnaast bewonder ik de manier 
waarop jij mensen begeleidt. Ik vind je co-promotorschap bij mijn promotie dan ook 
zeker verdiend!
Beste Frits, jouw bijdrage aan mijn onderzoek stamt natuurlijk al vanaf je eigen 
promotie-onderzoek, waarmee je de basis legde voor het homocysteine onderzoek. 
Ik ben blij dat ik toch nog een rol van CBS in milde hyperhomocysteinemie heb 
kunnen aantonen! Jouw kritische opmerkingen over mijn manuscripten maar ook 
tijdens de besprekingen kon ik altijd erg waarderen. Regelmatig vroeg je je echter af 
of alles wel op tijd af was en of het wel genoeg zou zijn, maar ik ga er vanuit dat je 
hier tevreden mee bent. Hartelijk dank!
Homocysteine groep: Naast de wekelijkse donderdagochtend koffie/thee (evt. met 
gebak) waren de jaarlijkse BBQ en alle andere uitjes een ontzettend leuke manier om 
elkaar eens wat beter te leren kennen, die ik dan ook zeker zal gaan missen! Addy, 
Alexandra, Anita, Brenda, Dinny, Erik, Henriette, Jacqueline, John, Maria, Nathalie en 
Suzanne; hartelijk dank voor alle hulp, steun en gezelligheid. Hetzelfde geldt voor
157
Dankwoord
Gerly, Henkjan, Maarten, Lydia en Sandra, die ik bovendien veel succes wil wensen 
bij hun promotie-onderzoek.
Alle onderzoekers/DNA groep LKN: Carin, Connie, Eric, Iwan, Jan, Karin A, Marieke, 
Marije, Maroeska, Lambert, Ralf, Rikke, Roel, Rolf en Sandy wil ik niet alleen hartelijk 
bedanken voor alle hulp maar ook alle gezellige etentjes, verjaardagen en andere 
uitjes en alle discussies over aio- c.q. lab-perikelen, verhuizingen etc.
Alle andere medewerkers van het lab wil ik bedanken voor de leuke sfeer op het lab 
waardoor ik altijd met veel plezier op het lab heb gewerkt en voor alles waarmee ze 
me geholpen hebben.
Jose Ordovas and Jacob Selhub: Jacob, thank you for inviting me and showing me 
some of Boston! Jose, thank you for giving me the opportunity to work in your lab. 
Thanks to you two I could confirm my own results and write another chapter of my 
thesis. I also would like to thank all the people in their labs for helping me and 
enjoying me during my short stay.
Petra Verhoef, Mariska Klerk en 'de rest' uit Wageningen; bedankt voor het geven 
van alle (statistische) adviezen en de gezelligheid tijdens alle bijeenkomsten en 
congressen.
Alle meiden van FVV wil ik bedanken voor alle leuke uitstapjes die voor de nodige 
ontspanning zorgden, ik hoop dat er nog vele zullen volgen!
Mijn (schoon)familie wil ik bedanken voor de gezelligheid en ontspanning tijdens de 
regelmatige 'Twente-weekenden' en voor het mij niet laten verleren van m'n 
moedertaal. Pa en ma, hartelijk dank voor jullie steun en interesse, ook tijdens mijn 
studie. Ik hoop dat ik jullie nu allemaal een idee heb gegeven wat promoveren 
eigenlijk is; nu ben ik dus eindelijk 'geslaagd'!
Patrick, bedankt voor al je steun, je relativeringsvermogen, kookkunsten, gebruik van 
je computer en alle andere dingen, die ik je zelf allemaal nog wel een keer vertel!
Bedankt allemaal!
Karin
158
Notes
Notes
